{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "name": "preprint server project.ipynb",
      "provenance": [],
      "collapsed_sections": [],
      "include_colab_link": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/gauthammudunuru/Course-Certified-Solutions-Architect-Associate/blob/master/preprint_server_project.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "gmail account is called:\n",
        "pteam8576@gmail.com\n",
        "Password: Engineering1!"
      ],
      "metadata": {
        "id": "YOmKcNzC8-jp"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from google.colab import drive #hello world\n",
        "drive.mount('/content/drive')"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "EaQxiaOMIUd3",
        "outputId": "d62e40f2-4aca-4985-fe6f-cc23eebcb610"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Mounted at /content/drive\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 3,
      "metadata": {
        "id": "Qbb1D3CvR_BB"
      },
      "outputs": [],
      "source": [
        "import requests\n",
        "import numpy as np\n",
        "import pandas as pd\n",
        "import seaborn as sns"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# test = requests.get('https://api.medrxiv.org/details/biorxiv/2013-11-15/2021-12-29/198000')       #this gets data from Biorxiv starting with the first upload to today, the index is set as the max retrievable in this dataset, notice the 'count' is less than 100 below\n",
        "test = requests.get('https://api.medrxiv.org/details/medrxiv/2019-07-19/2021-12-29/35500')       #this gets data from Medrxiv starting with the first upload to today"
      ],
      "metadata": {
        "id": "Zgjpje_-SDrz"
      },
      "execution_count": 59,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "print(test.text)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "-Wq9kB6pSsYx",
        "outputId": "3ba6195a-b492-4473-fc66-08a6f60544a5"
      },
      "execution_count": 60,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "{\"messages\":[{\"status\":\"ok\",\"interval\":\"2019-07-19:2021-12-29\",\"cursor\":\"35500\",\"count\":100,\"count_new_papers\":27524,\"total\":35672}], \"collection\":[{\"doi\":\"10.1101\\/2021.12.24.21268317\",\"title\":\"COMPARATIVE ANALYSIS OF ANTIBODY RESPONSES FROM COVID-19 CONVALESCENTS RECEIVING VARIOUS VACCINES REVEALS CONSISTENT HIGH NEUTRALIZING ACTIVITY FOR SARS-CoV-2 VARIANT OF CONCERN OMICRON.\",\"authors\":\"Focosi, D.; Franchini, M.; Joyner, M. J.; Casadevall, A.\",\"author_corresponding\":\"Daniele Franchini Focosi\",\"author_corresponding_institution\":\"Pisa University Hospital\",\"date\":\"2021-12-26\",\"version\":\"2\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/26\\/2021.12.24.21268317.source.xml\",\"abstract\":\"The novel SARS-CoV-2 Omicron variant of concern (VOCs), with its escape from unboosted vaccines and monoclonal antibodies, demonstrates the continued relevance of COVID19 convalescent plasma therapies. Lessons learnt from previous usage of CCP suggests focusing on outpatients and using high nAb-titer units in early disease stages. In this systematic analysis, we show that CCP from unvaccinated donors is not effective against Omicron, while CCP from vaccinees convalescents from previous VOCs or third-dose uninfected vaccinees is likely to remain effective against Omicron. CCP remains the only antibody-based therapy that keeps up with the variants and provides an effective tool to combat the emergence of variants that defeat monoclonal antibodies. Consequently, there is a need for continue study of the variables that determine CCP efficacy.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.23.21268338\",\"title\":\"Unsuspected clonal spread of Methicillin-resistant Staphylococcus aureus causing bloodstream infections in hospitalized adults detected using whole genome sequencing\",\"authors\":\"Talbot, B. M.; Jacko, N. F.; Petit, R. A.; Pegues, D. A.; Shumaker, M. J.; Read, T. D.; David, M. Z.\",\"author_corresponding\":\"Michael Z David\",\"author_corresponding_institution\":\"Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA\",\"date\":\"2021-12-25\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/25\\/2021.12.23.21268338.source.xml\",\"abstract\":\"BackgroundThough detection of transmission clusters of methicillin-resistant Staphylococcus aureus (MRSA) infections is a priority for infection control personnel in hospitals, the transmission dynamics of MRSA among hospitalized patients with bloodstream infections (BSIs) has not been thoroughly studied. Whole genome sequencing (WGS) of MRSA isolates for surveillance is valuable for detecting outbreaks in hospitals, but the bioinformatic approaches used are diverse and difficult to compare.\\n\\nMethodsWe combined short-read WGS with genotypic, phenotypic, and epidemiological characteristics of 106 MRSA BSI isolates collected for routine microbiological diagnosis from inpatients in two hospitals over 12 months. Clinical data and hospitalization history were abstracted from electronic medical records. We compared three genome sequence alignment strategies to assess similarity in cluster ascertainment. We conducted logistic regression to measure the probability of predicting prior hospital overlap between clustered patient isolates by the genetic distance of their isolates.\\n\\nResultsWhile the three alignment approaches detected similar results, they showed some variation. A pangenome-based alignment method was most consistent across MRSA clonal complexes. We identified nine unique clusters of closely-related BSI isolates. Most BSI were healthcare-associated and community-onset. Our logistic model showed that with 13 single nucleotide polymorphisms the likelihood that any two patients in a cluster overlapped in a hospital was 50 percent.\\n\\nConclusionsMultiple clusters of closely related MRSA isolates can be identified using WGS among strains cultured from BSI in two hospitals. Genomic clustering of these infections suggest that transmission resulted from a mix of community spread and healthcare exposures long before BSI diagnosis.\\n\\nSummaryMultiple clusters of closely related MRSA bloodstream infections were identified using WGS in two hospitals using three bioinformatic workflows. Genomic epidemiology suggests that transmission resulted from a mix of community spread and healthcare exposures long before symptom onset.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.23.21268305\",\"title\":\"The HUNT Study: a population-based cohort for genetic research\",\"authors\":\"Brumpton, B. M.; Graham, S.; Surakka, I.; Skogholt, A. H.; Loset, M.; Fritsche, L. G.; Wolford, B.; Zhou, W.; Nielsen, J.; Holmen, O. L.; Gabrielsen, M. E.; Thomas, L.; Bhatta, L.; Rasheed, H.; Zhang, H.; Kang, H. M.; Hornsby, W. E.; Moksnes, M. R.; Coward, E.; Melbye, M.; Giskeodegard, G.; Fenstad, J.; Krokstad, S.; Naess, M.; Langhammer, A.; Boehnke, M.; Abecasis, G.; Asvold, B. O.; Hveem, K.; Willer, C. J.\",\"author_corresponding\":\"Ben M. Brumpton\",\"author_corresponding_institution\":\"Norwegian University of Science and Technology\",\"date\":\"2021-12-25\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"epidemiology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/25\\/2021.12.23.21268305.source.xml\",\"abstract\":\"The Trondelag Health Study (HUNT) is a population-based cohort of [~]229,000 individuals recruited in four waves beginning in 1984 in Trondelag County, Norway. [~]88,000 of these individuals have available genetic data from array genotyping. HUNT participants were recruited during 4 community-based recruitment waves and provided information on health-related behaviors, self-reported diagnoses, family history of disease, and underwent physical examinations. Linkage via the Norwegian personal identification number integrates digitized health care information from doctor visits and national health registries including death, cancer and prescription registries. Genome-wide association studies of HUNT participants have provided insights into the mechanism of cardiovascular, metabolic, osteoporotic and liver-related diseases, among others. Unique features of this cohort that facilitate research include nearly 40 years of longitudinal follow-up in a motivated and well-educated population, family data, comprehensive phenotyping, and broad availability of DNA, RNA, urine, fecal, plasma, and serum samples.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.24.21268367\",\"title\":\"Genomic surveillance reveals the emergence of SARS-CoV-2 Lineage A from Islamabad Pakistan\",\"authors\":\"Umair, M.; Ikram, A.; Rehman, Z.; Haider, S. A.; Badar, N.; Ammar, M.; Ali, Q.; Ahad, A.; Suleman, R.; Salman, M.\",\"author_corresponding\":\"Massab Umair\",\"author_corresponding_institution\":\"National Institute of Health\",\"date\":\"2021-12-25\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nd\",\"category\":\"epidemiology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/25\\/2021.12.24.21268367.source.xml\",\"abstract\":\"The lineage A of SARS-CoV-2 has been around the world since the start of the pandemic. In Pakistan the last case of lineage A was reported in April, 2021 since then no case has been reported. In November, 2021 during routine genomic surveillance at National Institute of Health we have found 07 cases of lineage A from Islamabad, Pakistan. The study reports two novel deletions in the spike glycoprotein. One 09 amino acid deletion (68-76 a.a) is found in the S1 subunit while another 10 amino acid deletion (679-688 a.a) observed at the junction of S1\\/S2 referred as furin cleavage site. The removal of furin cleavage site may result in impaired virus replication thus decreasing its pathogenesis. The actual impact of these two deletions on the virus replication and disease dynamics needs to be studied in detail. Moreover, the enhanced genomic surveillance will be required to track the spread of this lineage in other parts of the country.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.24.21268373\",\"title\":\"Are COVID-19 data reliable? The case of the European Union\",\"authors\":\"Kolias, P.\",\"author_corresponding\":\"Pavlos Kolias\",\"author_corresponding_institution\":\"Aristotle University of Thessaloniki\",\"date\":\"2021-12-25\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by\",\"category\":\"public and global health\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/25\\/2021.12.24.21268373.source.xml\",\"abstract\":\"Previous studies have used Benfords distribution to assess whether there is misreporting of COVID-19 cases and deaths. Data inaccuracies provide false information to the media, undermine global response and hinder the preventive measures taken by countries worldwide. In this study, we analyze daily new cases and deaths from all the countries of the European Union and estimate the conformance to Benfords distribution. For each country, two statistical tests and two measures of deviations are calculated to determine whether the reported statistics comply with the expected distribution. Four country-level developmental indexes are also included, the GDP per capita, health expenditures, the Universal Health Coverage index, and full vaccination rate. Regression analysis is implemented to show whether the deviation from Benfords distribution is affected by the aforementioned indexes. The findings indicate that only three countries were in line with the expected distribution, Bulgaria, Croatia, and Romania. For daily cases, Denmark, Greece, and Ireland, showed the greatest deviation from Benfords distribution and for deaths, Malta, Cyprus, Greece, Italy, and Luxemburg had the highest deviation from Benfords law. Furthermore, it was found that the vaccination rate is positively associated with deviation from Benfords distribution. These results suggest that overall official data provided by authorities are not confirming Benfords law, yet this approach acts as a preliminary tool for data verification. More extensive studies should be made with a more thorough investigation of countries that showed the greatest deviation.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.24.21268373\",\"title\":\"Are COVID-19 data reliable? The case of the European Union\",\"authors\":\"Kolias, P.\",\"author_corresponding\":\"Pavlos Kolias\",\"author_corresponding_institution\":\"Aristotle University of Thessaloniki\",\"date\":\"2021-12-26\",\"version\":\"2\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by\",\"category\":\"public and global health\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/26\\/2021.12.24.21268373.source.xml\",\"abstract\":\"Previous studies have used Benfords distribution to assess whether there is misreporting of COVID-19 cases and deaths. Data inaccuracies provide false information to the media, undermine global response and hinder the preventive measures taken by countries worldwide. In this study, we analyze daily new cases and deaths from all the countries of the European Union and estimate the conformance to Benfords distribution. For each country, two statistical tests and two measures of deviations are calculated to determine whether the reported statistics comply with the expected distribution. Four country-level developmental indexes are also included, the GDP per capita, health expenditures, the Universal Health Coverage index, and full vaccination rate. Regression analysis is implemented to show whether the deviation from Benfords distribution is affected by the aforementioned indexes. The findings indicate that only three countries were in line with the expected distribution, Bulgaria, Croatia, and Romania. For daily cases, Denmark, Greece, and Ireland, showed the greatest deviation from Benfords distribution and for deaths, Malta, Cyprus, Greece, Italy, and Luxemburg had the highest deviation from Benfords law. Furthermore, it was found that the vaccination rate is positively associated with deviation from Benfords distribution. These results suggest that overall official data provided by authorities are not confirming Benfords law, yet this approach acts as a preliminary tool for data verification. More extensive studies should be made with a more thorough investigation of countries that showed the greatest deviation.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.24.21268373\",\"title\":\"Are COVID-19 data reliable? The case of the European Union\",\"authors\":\"Kolias, P.\",\"author_corresponding\":\"Pavlos Kolias\",\"author_corresponding_institution\":\"Aristotle University of Thessaloniki\",\"date\":\"2021-12-29\",\"version\":\"3\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by\",\"category\":\"public and global health\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/29\\/2021.12.24.21268373.source.xml\",\"abstract\":\"Previous studies have used Benfords distribution to assess whether there is misreporting of COVID-19 cases and deaths. Data inaccuracies provide false information to the media, undermine global response and hinder the preventive measures taken by countries worldwide. In this study, we analyze daily new cases and deaths from all the countries of the European Union and estimate the conformance to Benfords distribution. For each country, two statistical tests and two measures of deviations are calculated to determine whether the reported statistics comply with the expected distribution. Four country-level developmental indexes are also included, the GDP per capita, health expenditures, the Universal Health Coverage index, and full vaccination rate. Regression analysis is implemented to show whether the deviation from Benfords distribution is affected by the aforementioned indexes. The findings indicate that only three countries were in line with the expected distribution, Bulgaria, Croatia, and Romania. For daily cases, Denmark, Greece, and Ireland, showed the greatest deviation from Benfords distribution and for deaths, Malta, Cyprus, Greece, Italy, and Luxemburg had the highest deviation from Benfords law. Furthermore, it was found that the vaccination rate is positively associated with deviation from Benfords distribution. These results suggest that overall official data provided by authorities are not confirming Benfords law, yet this approach acts as a preliminary tool for data verification. More extensive studies should be made with a more thorough investigation of countries that showed the greatest deviation.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.25.21268301\",\"title\":\"Serial interval and basic reproduction number of SARS-CoV-2 Omicron variant in South Korea\",\"authors\":\"Kim, D.; Jo, J.; Lim, J.-S.; Ryu, S.\",\"author_corresponding\":\"Sukhyun Ryu\",\"author_corresponding_institution\":\"Department of Preventive Medicine, Konyang University College of Medicine, Daejeon, South Korea\",\"date\":\"2021-12-25\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"public and global health\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/25\\/2021.12.25.21268301.source.xml\",\"abstract\":\"South Korea is experiencing the community transmission of the SARS-CoV-2 Omicron variant (B.1.1.529). We estimated that the mean ({+\\/-} standard deviation) serial interval was 2.22 ({+\\/-} 1.62) days, and the basic reproduction number was 1.90 (95% Credible Interval, 1.50-2.43) for the Omicron variant outbreak in South Korea.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.24.21268337\",\"title\":\"Pathological slow-wave activity and impaired working memory binding in post-traumatic amnesia\",\"authors\":\"Mallas, E.-J.; Gorgoraptis, N.; Dautricourt, S.; Pertzov, Y.; Scott, G.; Sharp, D. J.\",\"author_corresponding\":\"Emma-Jane Mallas\",\"author_corresponding_institution\":\"Imperial College London\",\"date\":\"2021-12-25\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nd\",\"category\":\"neurology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/25\\/2021.12.24.21268337.source.xml\",\"abstract\":\"The mechanism by which information is bound together in working memory is a central question for cognitive neuroscience. This binding is transiently disrupted during periods of post-traumatic amnesia following significant head injuries. The reason for this impairment is unclear but may be due to electrophysiological changes produced by head impacts. These are common and include pathological low frequency activity, which is associated with poorer neurological outcomes and may disrupt cortical communication. Here, we investigate associative memory binding during post-traumatic amnesia and test the hypothesis that misbinding is caused by a disruption in cortical communication produced by the pathological slowing of brain activity. Thirty acute moderate-severe traumatic brain injury patients (mean time since injury = 10 days) and 26 healthy controls were tested with a precision working memory paradigm that required the association of object and location information. A novel entropy ratio measure was calculated from behavioural performance. This provided a continuous measure of the degree of misbinding and the influence of distracting information. Resting state EEG was used to assess the electrophysiological effects of traumatic brain injury. Patients in post-traumatic amnesia showed abnormalities in working memory function and made significantly more misbinding errors than patients who were not in post-traumatic amnesia and controls. Patients showed a higher entropy ratio in the distribution of spatial responses, indicating that working memory recall was abnormally biased by the locations of non-target items suggesting a specific impairment of object and location binding. Slow wave activity was increased following traumatic brain injury. Increases in the delta-alpha ratio indicative of an increase in low frequency power specifically correlated with binding impairment in working memory. In contrast, although connectivity was increased in the theta band and decreased in the alpha band after traumatic brain injury, this did not correlate with working memory impairment. Working memory and electrophysiological abnormalities both normalised at six-month follow-up, in keeping with a transient increase in slow-wave activity causing post-traumatic amnesia that impaired working memory function. These results show that patients in post-traumatic amnesia show high rates of working memory misbinding that are associated with a pathological shift towards lower frequency oscillations.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.24.21268371\",\"title\":\"Relative Importance of Various Inflammatory Markers and Their Critical Thresholds for COVID-19 Mortality\",\"authors\":\"budhiraja, s.; Indrayan, A.; das, p.; dewan, a.; singh, o.; nangia, v.; singh, y. p.; pandey, r.; gupta, a. k.; gupta, m.; bhasin, d.; uniyal, b.; mathur, m.; pawar, m.\",\"author_corresponding\":\"sandeep budhiraja\",\"author_corresponding_institution\":\"Clinical Directorate and Dept of Internal Medicine, Max Healthcare\",\"date\":\"2021-12-25\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/25\\/2021.12.24.21268371.source.xml\",\"abstract\":\"BackgroundVarious inflammatory markers are commonly assessed in many patients to help in the management of COVID-19 patients. It is not clear, though, how much risk of mortality their different levels of elevations entail, and which marker signifies more risk than others and how much. This study was undertaken to describe their levels and to answer these questions regarding eight inflammatory markers, namely, CRP, D-dimer, ferritin, IL-6, LDH, CPK, troponin-I.\\n\\nMethodsThe data were retrieved from the electronic records of 19852 CoViD-19 patients admitted to a chain of hospitals in north India from March 2020 to July 2021. Levels for most markers were available for more than 10,000 patients. In view of widely different ranges of values of different markers, we divided their values into quintiles (Qs) and studied the pattern of mortality and for running the logistic regression. In addition, logarithm transformation was also tried. The statistical distribution of the values was compared by Mann-Whitney test. Relative importance was judged by the mortality rates, area under the ROC curves (AUROCs), and the odds ratios.\\n\\nResultsAlthough the mortality increased with decreasing ALC and increasing level of all the other markers, more than 70% survived even with levels in the extreme quintile. The adjusted odds ratio was the highest (7.62) for the Q5 levels of IL-6, closely followed by D-dimer (OR = 6.04). The AUROC was the highest (0.817) for LDH and the least (0.612) for CPK. However, the optimal cut-off for any marker could correctly classify not more than 80% deaths and the multivariable logistic regression could correctly classify patients with mortality in less than 24% cases.\\n\\nConclusionAlthough elevated levels of all the markers and low values of ALC were significant risk factor but no firm evidence was available for any of the eight markers to be a major indicator of the mortality in COVID-19 unless they reach to a critical threshold. Among those studied, D-Dimer (>192 ng\\/mL) followed by IL-6 (>4.5 pg\\/mL) had stronger association with mortality even with moderate and higher end of the normal levels and LDH (>433 U\\/L) and troponin-I (>0.002ng\\/mL) with only steeply increased levels. Ferritin had modest association, and CPK, CRP and ALC were a relatively poor risk of mortality.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.23.21268321\",\"title\":\"Influenza A H1N1 mediated pre-existing immunity to SARS-CoV-2 predicts COVID-19 outbreak dynamics\",\"authors\":\"Martin Almazan, N.; Rahbar, A.; Carlsson, M.; Hoffman, T.; Kolstad, L.; Ronnberg, B.; Russel Pantalone, M.; Lewensohn Fuchs, I.; Naucler, A.; Ohlin, M.; Sacharczuk, M.; Religa, P.; Amer, S.; Molnar, C.; Lundkvist, A.; Susrud, A.; Sorensen, B.; Soderberg-Naucler, C.\",\"author_corresponding\":\"Cecilia Soderberg-Naucler\",\"author_corresponding_institution\":\"Department of Medicine, Unit for Microbial Pathogenesis, Karolinska Institutet, Stockholm, Sweden. Department of Neurology, Karolinska University Hospital, Stoc\",\"date\":\"2021-12-25\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/25\\/2021.12.23.21268321.source.xml\",\"abstract\":\"Susceptibility to SARS-CoV-2 infections is highly variable, ranging from asymptomatic and mild infections in most, to deadly outcome in few. Here, we present evidence that antibodies induced by currently circulating influenza A H1N1 (flu) strains cross react with the most critical receptor binding motif of the SARS-CoV-2 spike protein that interacts with the ACE2 receptor. About 58- 68% of blood donors in Stockholm had detectable antibodies to this cross-reactive peptide, NGVEGF, and seasonal flu vaccination trended to enhance binding of inhibitory antibodies to SARS-CoV-2. This peptide also activated CD8 T cells in 20% of healthy subjects. Eleven additional CD8 T-cell peptides that cross-react with flu and SARS-CoV-2 were identified that potentially protect against SARS-CoV-2 in 40-71% of individuals, depending on their HLA type.\\n\\nOne-Sentence SummaryFlu-mediated pre-immunity to SARS-CoV-2 may protect against COVID-19 and likely affects herd immunity thresholds.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.23.21268315\",\"title\":\"Genomic diversification of long polynucleotide fragments is a signature of emerging SARS-CoV-2 variants of concern\",\"authors\":\"Murugadoss, K.; Niesen, M. J.; Raghunathan, B.; Lenehan, P. J.; Ghosh, P.; Feener, T.; Anand, P.; Simsek, S.; Suratekar, R.; Hughes, T. K.; Soundararajan, V.\",\"author_corresponding\":\"Venky Soundararajan\",\"author_corresponding_institution\":\"nference\",\"date\":\"2021-12-25\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/25\\/2021.12.23.21268315.source.xml\",\"abstract\":\"Highly transmissible or immuno-evasive SARS-CoV-2 variants have intermittently emerged and outcompeted previously circulating strains, resulting in repeated COVID-19 surges, reinfections, and breakthrough infections in vaccinated individuals. With over 5 million SARS-CoV-2 genomes sequenced globally over the last 2 years, there is unprecedented data to decipher how competitive viral evolution results in the emergence of fitter SARS-CoV-2 variants. Much attention has been directed to studying how specific mutations in the Spike protein impact its binding to the ACE2 receptor or viral neutralization by antibodies, but there is limited knowledge of a genomic signature that is shared primarily by the sequential dominant variants. Here we introduce a methodology to quantify the genome-wide distinctiveness of polynucleotide fragments of various lengths (3-to 240-mers) that constitute SARS-CoV-2 sequences (freely available at https:\\/\\/academia.nferx.com\\/GENI). Compared to standard phylogenetic distance metrics and overall mutational load, the quantification of distinctive 9-mer polynucleotides provides a higher resolution of separation between VOCs (Reference = 89, IQR: 65-108; Alpha = 166, IQR: 150-182; Beta 130, IQR: 113-147; Gamma = 165, IQR: 152-180; Delta = 234, IQR: 216-253; and Omicron = 294, IQR: 287-315). Omicrons exceptionally high genomic distinctiveness may confer a competitive advantage over both prior VOCs (including Delta) and the recently emerged and highly mutated B.1.640.2 (IHU) lineage. Expanding on this analysis, evaluation of genomic distinctiveness weighted by intra-lineage 9-mer conservation for 1,363 lineages annotated in GISAID highlights that genomic distinctiveness has increased over time (R2=0.37) and that VOCs score significantly higher than contemporary non-VOC lineages, with Omicron among the most distinctive lineages observed till date. This study demonstrates the value of characterizing new SARS-CoV-2 variants by their genome-wide polynucleotide distinctiveness and emphasizes the need to go beyond a narrow set of mutations at known functionally or antigenically salient sites on the Spike protein. The consistently higher distinctiveness of each emerging VOC compared to prior VOCs suggests that real-time monitoring of genomic distinctiveness would aid in more rapid assessment of viral fitness.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.24.21268370\",\"title\":\"A novel methodology for the synchronous collection and multimodal visualisation of continuous neurocardiovascular and neuromuscular physiological data in adults with long COVID\",\"authors\":\"Xue, F.; Monaghan, A.; Jennings, G.; Byrne, L.; Foran, T.; Duggan, E.; Romero-Ortuno, R.\",\"author_corresponding\":\"Feng Xue\",\"author_corresponding_institution\":\"Trinity College Dublin\",\"date\":\"2021-12-25\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc\",\"category\":\"cardiovascular medicine\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/25\\/2021.12.24.21268370.source.xml\",\"abstract\":\"Reports suggest that adults with post-COVID-19 syndrome or long COVID may be affected by orthostatic intolerance syndromes, with autonomic nervous system dysfunction as a possible causal factor of neurocardiovascular instability (NCVI). Long COVID can also manifest as prolonged fatigue, which may be linked to neuromuscular function impairment (NMFI). The current clinical assessment for NCVI monitors neurocardiovascular performance upon the application of orthostatic stressors such as an active (i.e. self-induced) stand or a passive (tilt table) standing test. Lower limb muscle contractions may be important in orthostatic recovery via the skeletal muscle pump. In this study, adults with long COVID were assessed with a protocol that, in addition to the standard NCVI tests, incorporated simultaneous lower limb muscle monitoring for NMFI assessment. To accomplish such an investigation, a wide range of continuous non-invasive biomedical technologies were employed, including digital artery photoplethysmography for the extraction of cardiovascular signals, near-infrared spectroscopy for the extraction of regional tissue oxygenation in brain and muscle, and electromyography for assessment of timed muscle contractions in the lower limbs. With the novel technique described and exemplified in this paper, we were able to integrate signals from all instruments used in the assessment in a precisely synchronized fashion. We demonstrate that it is possible to visualize the interactions between all different physiological signals during the combined NCVI\\/NMFI assessment. Multiple counts of evidence were collected, which can capture the dynamics between skeletal muscle contractions and neurocardiovascular responses. The proposed multimodal data visualization can offer an overview of the functioning of the muscle pump during both supine rest and orthostatic recovery and can conduct comparison studies with signals from multiple participants at any given time in the assessment. This could help researchers and clinicians generate and test hypotheses based on the multimodal inspection of raw data, in long COVID and other clinical cohorts.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.23.21268341\",\"title\":\"Identifying Mitral Valve Prolapse at Risk for Ventricular Arrhythmias and Myocardial Fibrosis from 12-lead Electrocardiograms using Deep Learning\",\"authors\":\"Tison, G. H.; Abreau, S.; Lim, L.; Crudo, V.; Barrios, J.; Nguyen, T.; Hu, G.; Dixit, S.; Nah, G.; Lee, Y.; Deling, F.\",\"author_corresponding\":\"Geoffrey H Tison\",\"author_corresponding_institution\":\"UCSF\",\"date\":\"2021-12-25\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"cardiovascular medicine\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/25\\/2021.12.23.21268341.source.xml\",\"abstract\":\"BackgroundMitral valve prolapse (MVP) is a common valvulopathy, with a subset of MVP patients developing sudden cardiac death or cardiac arrest. Complex ventricular ectopy (ComVE) represents a marker of arrhythmic risk that is associated with myocardial fibrosis and increased mortality in MVP. We hypothesize that an ECG-based machine-learning model can identify MVP with ComVE and\\/or myocardial fibrosis on cardiac magnetic resonance (CMR) imaging.\\n\\nMethodsA deep convolutional neural network (CNN) was trained to detect ComVE using 6,916 12-lead ECGs from 569 MVP patients evaluated at the University of California San Francisco (UCSF) between 2012 and 2020. A separate CNN was also trained to detect late gadolinium enhancement (LGE) using 87 ECGs from MVP patients with contrast CMR. Results: The prevalence of ComVE was 160\\/569 or 28% (20 patients or 3% had cardiac arrest or sudden cardiac death). The area under the curve (AUC) of the CNN to detect ComVE was 0.81 (95% CI, 0.78-0.84). AUC remained high even after excluding patients with moderate-severe mitral regurgitation (MR) [0.80 (95% CI, 0.77-0.83)], or with bileaflet MVP [0.81 (95% CI, 0.76-0.85)]. The top ECG segments able to discriminate ComVE vs no ComVE were related to ventricular depolarization and repolarization (early-mid ST and QRS fromV1, V3, and III). LGE in the papillary muscles or basal inferolateral wall was present in 21 (24%) of 87 patients with available CMR. The AUC for detection of LGE was 0.75 (95% CI, 0.68-0.82).\\n\\nConclusionsStandard 12-lead ECGs analyzed with machine learning can detect MVP at risk for ventricular arrhythmias and fibrosis and can identify novel ECG correlates of arrhythmic risk regardless of leaflet involvement or mitral regurgitation severity. ECG-based CNNs may help select those MVP patients requiring closer follow-up and\\/or a CMR.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.23.21268276\",\"title\":\"Risk of myocarditis following sequential COVID-19 vaccinations by age and sex\",\"authors\":\"Patone, M.; Mei, W. X.; Handunnetthi, L.; Dixon, S.; Zaccardi, F.; Shankar-Hari, M.; Watkinson, P.; Khunti, K.; Harnden, A.; Coupland, C. A.; Channon, K. M.; Mills, N. L.; Sheikh, A.; Hippisley-Cox, J.\",\"author_corresponding\":\"Julia Hippisley-Cox\",\"author_corresponding_institution\":\"University of Oxford\",\"date\":\"2021-12-25\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"epidemiology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/25\\/2021.12.23.21268276.source.xml\",\"abstract\":\"In an updated self-controlled case series analysis of 42,200,614 people aged 13 years or more, we evaluate the association between COVID-19 vaccination and myocarditis, stratified by age and sex, including 10,978,507 people receiving a third vaccine dose. Myocarditis risk was increased during 1-28 days following a third dose of BNT162b2 (IRR 2.02, 95%CI 1.40, 2.91). Associations were strongest in males younger than 40 years for all vaccine types with an additional 3 (95%CI 1, 5) and 12 (95% CI 1,17) events per million estimated in the 1-28 days following a first dose of BNT162b2 and mRNA-1273, respectively; 14 (95%CI 8, 17), 12 (95%CI 1, 7) and 101 (95%CI 95, 104) additional events following a second dose of ChAdOx1, BNT162b2 and mRNA-1273, respectively; and 13 (95%CI 7, 15) additional events following a third dose of BNT162b2, compared with 7 (95%CI 2, 11) additional events following COVID-19 infection. An association between COVID-19 infection and myocarditis was observed in all ages for both sexes but was substantially higher in those older than 40 years. These findings have important implications for public health and vaccination policy.\\n\\nFundingHealth Data Research UK.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.24.21268368\",\"title\":\"Causal attribution fractions for epidemiological studies, applied to a UK Biobank study of smoking and BMI\",\"authors\":\"Webster, A.\",\"author_corresponding\":\"Anthony Webster\",\"author_corresponding_institution\":\"University of Oxford\",\"date\":\"2021-12-25\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"epidemiology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/25\\/2021.12.24.21268368.source.xml\",\"abstract\":\"Epidemiological studies often use proportional hazard models to estimate associations between potential risk factors and disease risk. It is emphasised that when the \\\"backdoor criteria\\\" from causal-inference applies, if diseases are sufficiently rare, then the proportional hazard model can be used to estimate causal associations. When the \\\"frontdoor criteria\\\" applies (allowing causal estimates with unmeasured confounders), similar estimates are found to mediation analyses with measured confounders. Reasons for this are discussed. An attribution fraction is constructed using the average causal effects (ACE) of exposures on the population, and simple methods for its evaluation are suggested. It differs from the attribution fraction used by the World Health Organisation (WHO), except for specific circumstances where the latter can agree or provide a bound. A counterfactual argument determines an individuals attribution fraction Af in terms of proportional hazard estimates, as Af = 1- 1\\/R, where R is an individuals relative risk. Causally meaningful attribution fractions cannot be constructed for all known risk factors or confounders, but there are important cases where they can. As an example, systematic proportional hazards studies with UK Biobank data estimate the attribution fractions of smoking and BMI for 226 diseases. The attribution of risk is characterised in terms of disease chapters from the International Classification of Diseases (ICD-10), and the diseases most strongly attributed to smoking and BMI are identified. The result is a quantitative characterisation of the causal influence of smoking and BMI on the landscape of disease incidence in the UK Biobank population.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.24.21268331\",\"title\":\"Traditional Chinese medicine: A Bayesian network model of public awareness, usage determinants, and perception of scientific support in Austria\",\"authors\":\"Eigenschink, M.; Bellach, L.; Leonard, S. R.; Dablander, T. E.; Maier, J.; Dablander, F.; Sitte, H. H.\",\"author_corresponding\":\"Harald H Sitte\",\"author_corresponding_institution\":\"Institute of Pharmacology, Medical University of Vienna, Austria\",\"date\":\"2021-12-25\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by\",\"category\":\"public and global health\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/25\\/2021.12.24.21268331.source.xml\",\"abstract\":\"IntroductionDespite the paucity of evidence verifying its efficacy and safety, traditional Chinese medicine (TCM) is expanding in popularity and political support. Decisions to include TCM diagnoses in the International Classification of Diseases 11th Revision (ICD-11) by the World Health Organization (WHO) and campaigns to integrate TCM into national healthcare systems have occurred whilst the public perception and usage of TCM, especially in Europe, remains undetermined. Accordingly, this study investigates the popularity, usage patterns, perception of scientific support for TCM, and its relationship to homeopathy.\\n\\nMethodsA cross-sectional survey was performed in Austria and data from 1382 participants were analysed. A Bayesian network model retrieved partial correlations indicating distinct associations between sociodemographic determinants, complementary and alternative medicine (CAM) usage patterns, readiness to vaccinate, and TCM related variables.\\n\\nResultsTCM was broadly known by the Austrian population (89.9% of women, 90.6% of men), with 58.9% of women and 39.5% of men using TCM between 2016 and 2019. 66.4% of women and 49.7% of men agreed with TCM being supported by science. We found a strong positive relationship between the perceived scientific support for TCM and trust in TCM-certified medical doctors. Moreover, perceived scientific support for TCM was negatively correlated with the proclivity to get vaccinated. Additionally, our Bayesian network model yielded distinct associations between TCM-, homeopathy-, and vaccination-related variables.\\n\\nConclusionTCM is widely known within the Austrian general population and actively used by a substantial proportion. However, a crucial disparity exists between the commonly held public perception that TCM is scientific and findings from evidence-based studies. As public opinion towards TCM, and the proclivity to use it, are promoted through institutionalisation and official acknowledgement, it would be critical to sustain and support the distribution of unbiased, science-driven information by governmental institutions and policymakers to encourage informed patient-driven decision-making.\\n\\nStrengths and limitations of this studyO_LIThis is the first study to comprehensively explore the usage patterns and sociodemographic associations of TCM in a European population, not based on data deriving from the seventh round of the European Social Survey.\\nC_LIO_LIWe are the first study on CAM usage patterns to graphically explore and report data using a Bayesian Gaussian copula graphical model--thereby, retrieving distinct partial correlations.\\nC_LIO_LIWe provide an up-to-date summary of TCM, set forth our findings at a geopolitical scale and highlight that the discrepancy between the paucity of evidence underpinning most TCM modalities and the international promotion of TCM is also reflected in the widely-held public perception that TCM is supported by science.\\nC_LIO_LIDue to the retrospective character of our cross-sectional survey, answers are naturally prone to recall and response bias.\\nC_LIO_LIOur sample is skewed towards the young, people with higher levels of education, and shows a relative underrepresentation of males. Therefore, we post-stratified our sample using representative data from Austrias federal statistical office \\\"Statistik Austria\\\" as a robustness check.\\nC_LI\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.24.21268331\",\"title\":\"Traditional Chinese medicine: A Bayesian network model of public awareness, usage determinants, and perception of scientific support in Austria\",\"authors\":\"Eigenschink, M.; Bellach, L.; Leonard, S. R.; Dablander, T. E.; Maier, J.; Dablander, F.; Sitte, H. H.\",\"author_corresponding\":\"Harald H Sitte\",\"author_corresponding_institution\":\"Institute of Pharmacology, Medical University of Vienna, Austria\",\"date\":\"2021-12-26\",\"version\":\"2\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by\",\"category\":\"public and global health\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/26\\/2021.12.24.21268331.source.xml\",\"abstract\":\"IntroductionDespite the paucity of evidence verifying its efficacy and safety, traditional Chinese medicine (TCM) is expanding in popularity and political support. Decisions to include TCM diagnoses in the International Classification of Diseases 11th Revision (ICD-11) by the World Health Organization (WHO) and campaigns to integrate TCM into national healthcare systems have occurred whilst the public perception and usage of TCM, especially in Europe, remains undetermined. Accordingly, this study investigates the popularity, usage patterns, perception of scientific support for TCM, and its relationship to homeopathy.\\n\\nMethodsA cross-sectional survey was performed in Austria and data from 1382 participants were analysed. A Bayesian network model retrieved partial correlations indicating distinct associations between sociodemographic determinants, complementary and alternative medicine (CAM) usage patterns, readiness to vaccinate, and TCM related variables.\\n\\nResultsTCM was broadly known by the Austrian population (89.9% of women, 90.6% of men), with 58.9% of women and 39.5% of men using TCM between 2016 and 2019. 66.4% of women and 49.7% of men agreed with TCM being supported by science. We found a strong positive relationship between the perceived scientific support for TCM and trust in TCM-certified medical doctors. Moreover, perceived scientific support for TCM was negatively correlated with the proclivity to get vaccinated. Additionally, our Bayesian network model yielded distinct associations between TCM-, homeopathy-, and vaccination-related variables.\\n\\nConclusionTCM is widely known within the Austrian general population and actively used by a substantial proportion. However, a crucial disparity exists between the commonly held public perception that TCM is scientific and findings from evidence-based studies. As public opinion towards TCM, and the proclivity to use it, are promoted through institutionalisation and official acknowledgement, it would be critical to sustain and support the distribution of unbiased, science-driven information by governmental institutions and policymakers to encourage informed patient-driven decision-making.\\n\\nStrengths and limitations of this studyO_LIThis is the first study to comprehensively explore the usage patterns and sociodemographic associations of TCM in a European population, not based on data deriving from the seventh round of the European Social Survey.\\nC_LIO_LIWe are the first study on CAM usage patterns to graphically explore and report data using a Bayesian Gaussian copula graphical model--thereby, retrieving distinct partial correlations.\\nC_LIO_LIWe provide an up-to-date summary of TCM, set forth our findings at a geopolitical scale and highlight that the discrepancy between the paucity of evidence underpinning most TCM modalities and the international promotion of TCM is also reflected in the widely-held public perception that TCM is supported by science.\\nC_LIO_LIDue to the retrospective character of our cross-sectional survey, answers are naturally prone to recall and response bias.\\nC_LIO_LIOur sample is skewed towards the young, people with higher levels of education, and shows a relative underrepresentation of males. Therefore, we post-stratified our sample using representative data from Austrias federal statistical office \\\"Statistik Austria\\\" as a robustness check.\\nC_LI\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.23.21268347\",\"title\":\"Ex-vivo mucolytic and anti-inflammatory activity of BromAc in tracheal aspirates from COVID-19\",\"authors\":\"Coelho dos Reis, J. G. A.; Marques Ferreira, G.; Aparecida Lourenco, A.; Lopes Ribeiro, A.; Pacheco da Silveira Martins da Mata, C.; de Melo Oliveira, P.; de Almeida Marques, D. P.; Lopes Ferreira, L.; Alves Clarindo, F.; Ferreira da Silva, M.; Portella Povoas Filho, H.; Ribeiro Oliveira, N. R.; Meyhr D Carmo Sodre, M.; Rocha Gadelha, S.; Albuquerque, G. R.; Mendes Maciel, B.; Melo Mariano, A. P.; de Melo Silva, M.; Fontana, R.; Marin, L. J.; Santiago Alberto Carlos, R.; Teixeira Sampaio Lopes, A.; Barbosa Ferreira, F.; Ribeiro dos Santos, U.; Santos de Santana, I. T.; Ferraz Fehlberg, H.; Pas\",\"author_corresponding\":\"David L Morris\",\"author_corresponding_institution\":\"Mucpharm Pty Ltd, Sydney NSW Australia; University of New South Wales, St George & Sutherland Hospital Clinical School, Sydney NSW Australia; Department of Surg\",\"date\":\"2021-12-25\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nd\",\"category\":\"respiratory medicine\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/25\\/2021.12.23.21268347.source.xml\",\"abstract\":\"COVID-19 is a lethal disease caused by the pandemic SARS-CoV-2, which continues to be a public health threat. COVID-19 is principally a respiratory disease and is often associated with sputum retention, for which there are limited therapeutic options. In this regard, we evaluated the use of BromAc(R), a combination of Bromelain and Acetylcysteine (NAC). Both drugs present mucolytic effect and have been studied to treat COVID-19. Therefore, we sought to examine the mucolytic, antiviral, and anti-inflammatory effect of BromAc(R) in tracheal aspirate samples from critically ill COVID-19 patients requiring mechanical ventilation.\\n\\nMethodTracheal aspirate samples from COVID-19 patients were collected following next of kin consent and mucolysis, rheometry and cytokine storm analysis was performed.\\n\\nResultsBromAc(R) displayed a robust mucolytic effect in a dose dependent manner. BromAc(R) showed anti-inflammatory activity, reducing the action of cytokine storm, chemokines including MIP-1alpha, CXCL8, MIP-1b, MCP-1 and IP-10, and regulatory cytokines IL-5, IL-10, IL-13 IL-1RA and total reduction for IL-9 compared to NAC alone and control. BromAc(R) acted on IL-6, demonstrating a reduction in G-CSF and VEGF-D at concentrations of 125 and 250{micro}g.\\n\\nConclusionThese results indicate robust mucolytic and anti-inflammatory effect of BromAc(R) in tracheal aspirates from critically ill COVID-19 patients, indicating its potential as a therapeutic strategy to COVID-19.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.21.21267745\",\"title\":\"Development of reference equations for the six-minute walk distance of school-aged Nigerian children\",\"authors\":\"Ubuane, P. O.; Ajiboye, O. A.; Adekunle, M. O.; Akinola, A. O.; Akinyosoye, G.; Kayode-Awe, M. O.; Ajayi, O. A.; Ohagwu, C. I.; Animasahun, B. A.; Njokanma, F. O.\",\"author_corresponding\":\"Peter Odion Ubuane\",\"author_corresponding_institution\":\"Lagos State University Teaching Hospital\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"pediatrics\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.21.21267745.source.xml\",\"abstract\":\"BackgroundThe six-minute walk test (6MWT), a simple, reliable and valid test that uses the distance walked in six minutes (six-minute walk distance, 6MWD) to quantify functional capacity, is widely used in chronic cardiopulmonary and non-cardiopulmonary disorders. However, absence of reference standards for Nigerian school-age children limits its use in this age group.\\n\\nObjectivesTo develop normative values and equations for the 6MWT of school-aged Nigerian children.\\n\\nMethodsIn a cross-sectional study, healthy children aged 6-11 years in Lagos, Nigeria, completed 6MWT on 20-meter straight outdoor courses in their schools following standardized guidelines. Potential predictors: demographic (age, sex), anthropometric (height, weight, chest circumference, leg length) and physiologic data [pre-walk, immediate post-walk and 5th minute-post-walk heart rate (HR), oxygen saturation (SpO2), systolic pressure (SBP), diastolic blood pressure (DBP) and rating of perceived exertion (RPE)] and difference between pre-walk and post-walk HR ({Delta}HR), SpO2 (({Delta}SpO2), SBP ({Delta}SBP), DBP ({Delta}DBP) and RPE ({Delta}RPE). Primary outcome: six-minute walk distance (6MWD) in metres.\\n\\nResultsOverall, 627 pupils (52.1% girls) walked 504.6 {+\\/-} 66.6 m (95% CI: 499.4, 509.8), ranging from 326.6 m to 673.0 m; 16 m longer in boys (p=0.002). Stepwise linear regression yielded: 6MWD (m) = 347.9 + 14 (Age) + 1.6 ({Delta}HR) + 17.6 (Sex) + 1.2 ({Delta}SBP); R2 =0.25. Previously published reference equations over-estimated Nigerian childrens 6MWD.\\n\\nConclusionThe reference values and prediction equations, after validation in other Nigerian populations, may be useful for functional evaluation of Nigerian children aged 6-11 years with chronic childhood disorders.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.22.21268168\",\"title\":\"Genome-wide association study of Alzheimer's disease brain imaging biomarkers and neuropsychological phenotypes in the EMIF-AD Multimodal Biomarker Discovery dataset\",\"authors\":\"Homann, J.; Osburg, T.; Ohlei, O.; Dobricic, V.; Deecke, L.; Bos, I.; Vandenberghe, R.; Gabel, S.; Scheltens, P.; Teunissen, C. E.; Engelborghs, S.; Frisoni, G.; Blin, O.; Richardson, J. C.; Bordet, R.; Lleo, A.; Alcolea, D.; Popp, J.; Clark, C.; Peyratout, G.; Martinez-Lage, P.; Tainta, M.; Dobson, R. J. B.; Legido-Quigley, C.; Sleegers, K.; Van Broeckhoven, C.; Wittig, M.; Franke, A.; Lill, C. M.; Blennow, K.; Zetterberg, H.; Lovestone, S.; Streffer, J.; ten Kate, M.; Vos, S. J. B.; Barkhof, F.; Visser, P. J.; Bertram, L.\",\"author_corresponding\":\"Lars Bertram\",\"author_corresponding_institution\":\"Luebeck Interdisciplinary Platform for Genome Analytics (LIGA), University of Luebeck, Luebeck, Germany\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"genetic and genomic medicine\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.22.21268168.source.xml\",\"abstract\":\"Alzheimers disease (AD) is the most frequent neurodegenerative disease with an increasing prevalence in industrialized, ageing populations. AD susceptibility has an established genetic basis which has been the focus of a large number of genome-wide association studies (GWAS) published over the last decade. Most of these GWAS used dichotomized clinical diagnostic status, i.e. case vs. control classification, as outcome phenotypes, without the use of biomarkers. An alternative and potentially more powerful study design is afforded by using quantitative AD-related phenotypes as GWAS outcome traits, an analysis paradigm that we followed in this work. Specifically, we utilized genotype and phenotype data from n=931 individuals collected under the auspices of the European Medical Information Framework for Alzheimers Disease Multimodal Biomarker Discovery (EMIF-AD MBD) study to perform a total of 19 separate GWAS analyses. As outcomes we used five magnetic resonance imaging (MRI) traits and seven cognitive performance traits. For the latter, longitudinal data from at least two timepoints were available in addition to cross-sectional assessments at baseline. Our GWAS analyses revealed several genome-wide significant associations for the neuropsychological performance measures, in particular those assayed longitudinally. Among the most noteworthy signals were associations in or near EHBP1 (EH domain binding protein 1; on chromosome 2p15) and CEP112 (centrosomal protein 112; 17q24.1) with delayed recall in a memory performance test. On the X chromosome, which is often excluded in other GWAS, we identified a genome-wide significant signal near IL1RAPL1 (interleukin 1 receptor accessory protein like 1; Xp21.3). While polygenic score (PGS) analyses showed the expected strong associations with SNPs highlighted in relevant previous GWAS on hippocampal volume and cognitive function, they did not show noteworthy associations with recent AD risk GWAS findings. In summary, our study highlights the power of using quantitative endophenotypes as outcome traits in AD-related GWAS analyses and nominates several new loci not previously implicated in cognitive decline.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.24.21268381\",\"title\":\"Assessing the contribution of rare-to-common protein-coding variants to circulating metabolic biomarker levels via 412,394 UK Biobank exome sequences\",\"authors\":\"Nag, A.; Middleton, L.; Dhindsa, R. S.; Vitsios, D.; Wigmore, E. M.; Allman, E.; Reznichenko, A.; Carss, K.; Smith, K. R.; Wang, Q.; Challis, B.; Paul, D. S.; Harper, A. R.; Petrovski, S.\",\"author_corresponding\":\"Slave Petrovski\",\"author_corresponding_institution\":\"AstraZeneca\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"genetic and genomic medicine\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.24.21268381.source.xml\",\"abstract\":\"Genome-wide association studies have established the contribution of common and low frequency variants to metabolic biomarkers in the UK Biobank (UKB); however, the role of rare variants remains to be assessed systematically. We evaluated rare coding variants for 198 metabolic biomarkers, including metabolites assayed by Nightingale Health, using exome sequencing in participants from four genetically diverse ancestries in the UKB (N=412,394). Gene-level collapsing analysis - that evaluated a range of genetic architectures - identified a total of 1,303 significant relationships between genes and metabolic biomarkers (p<1x10-8), encompassing 207 distinct genes. These include associations between rare non-synonymous variants in GIGYF1 and glucose and lipid biomarkers, SYT7 and creatinine, and others, which may provide insights into novel disease biology. Comparing to a previous microarray-based genotyping study in the same cohort, we observed that 40% of gene-biomarker relationships identified in the collapsing analysis were novel. Finally, we applied Gene-SCOUT, a novel tool that utilises the gene-biomarker association statistics from the collapsing analysis to identify genes having similar biomarker fingerprints and thus expand our understanding of gene networks.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.22.21268237\",\"title\":\"Temporal trends in hospitalizations and 30-day mortality in older patients during the COVID pandemic from March 2020 to July 2021\",\"authors\":\"Garcia-Ptacek, S.; Xu, H.; Annetorp, M.; Back Jerlardtz, V.; Cederholm, T.; Engstrom, M.; Kivipelto, M.; Lundberg, L. G.; Metzner, C.; Olsson, M.; Skogo Nyvang, J.; Suhl Oberg, C.; Akesson, E.; Religa, D.; Eriksdotter, M.\",\"author_corresponding\":\"Sara Garcia-Ptacek\",\"author_corresponding_institution\":\"Karolinska\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"geriatric medicine\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.22.21268237.source.xml\",\"abstract\":\"ImportancePrevious reports have suggested reductions in mortality risk from COVID-19 throughout the first wave of the COVID-19 pandemic. Mortality changes later in the pandemic and pandemic effects on other types of geriatric hospitalizations are less studied.\\n\\nObjectivesTo describe the changes in hospitalizations and 30-day mortality in Stockholm for patients 70+ receiving inpatient geriatric care for COVID-19 and other causes.\\n\\nDesignObservational study. For patients 70 or older, we present the incidence of 30-day mortality from COVID-19 in the Stockholm region, in relationship to geriatric hospitalizations and 30-day mortality after admission for COVID-19 and other causes.\\n\\nSettingHospitalizations for patients 70+ from geriatric clinics in Stockholm, Sweden hospitalized for COVID-19 or other causes between March 2020 and July 31, 2021, were included.\\n\\nParticipantsThe total number of geriatric hospitalizations for patients 70+ was 5,320 for COVID-19 and 32,243 for non-COVID-19 causes, corresponding to 4,565 individual COVID-19 patients and 19,308 non-COVID-19 patients.\\n\\nExposure(s)The date of hospital admission to a geriatric clinic. Main Outcome(s) and Measure(s): 30-day mortality after admission.\\n\\nResultsIn patients with COVID-19, the 30-day mortality rate was highest at the beginning of the first wave (29% in March-April 2020), decreased as the first wave subsided (7% July-August), increased again in the second wave (17% November-December), but failed to increase as much in the third wave (11-13% March-July 2021). In non-COVID-19 geriatric patients during the same period, the 30-day mortality presented a similar trend, but with a smaller magnitude of variation (5 to 10%). The number of persons 70 or older testing positive for COVID-19 in Stockholm reached two peaks in 2020 (April and December), fell in January 2021 and then increased again in March-April 2021.\\n\\nConclusions and RelevanceDuring the first and second waves, hospital admissions and 30-day mortality after geriatric hospitalization for COVID-19 increased in periods of high community transmission, although the mortality peak was lower in wave 2 than in wave 1. The mortality for non-COVID geriatric cases was lower and more stable but also showed an increase with the pandemic peaks.\\n\\nKEY POINTSO_ST_ABSQuestionC_ST_ABSMultiple previous reports in different countries and settings have shown higher case fatality ratio or hospitalized case fatality ratio for COVID-19 in the first wave compared to the second wave of the pandemic. However, less is known about how the COVID-19 waves specifically affected the care of geriatric patients, including those with conditions other than COVID.\\n\\nFindingsThe total number of hospitalizations was 5,320 for COVID-19 and 32,243 for non-COVID-cases. In COVID-patients, the 30-day mortality rate was highest at the beginning of the first wave (29% in March-April 2020), reached 17% at the second wave peak (November-December) followed by 11-13% in the third wave (March-July 2021). The mortality in non-COVID geriatric patients showed a similar trend, but of lower magnitude (5-10%). During the incidence peaks, COVID-19 hospitalizations displaced non-COVID geriatric patients.\\n\\nMeaningHospital admissions and 30-day mortality after hospitalizations for COVID-19 increased in periods of high community transmission, albeit with decreasing mortality rates from wave 1 to 3, with a possible vaccination effect in wave 3. Thus, the healthcare system could not compensate for the high community spread of COVID-19 during the pandemic peaks, which also led to displacing care for non-COVID geriatric patients. These results are important for planning healthcare resources in future health emergencies.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.23.21268061\",\"title\":\"Identifying Medication-related Intents from a Bidirectional Text Messaging Platform for Hypertension Management: An Unsupervised Learning Approach\",\"authors\":\"Davoudi, A.; Lee, N.; Luong, T.; Delaney, T.; Asch, E.; Chaiyachati, K.; Mowery, D.\",\"author_corresponding\":\"Danielle Mowery\",\"author_corresponding_institution\":\"University of Pennsylvania\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"health informatics\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.23.21268061.source.xml\",\"abstract\":\"BackgroundFree-text communication between patients and providers is playing an increasing role in chronic disease management, through platforms varying from traditional healthcare portals to more novel mobile messaging applications. These text data are rich resources for clinical and research purposes, but their sheer volume render them difficult to manage. Even automated approaches such as natural language processing require labor-intensive manual classification for developing training datasets, which is a rate-limiting step. Automated approaches to organizing free-text data are necessary to facilitate the use of free-text communication for clinical care and research.\\n\\nObjectiveWe applied unsupervised learning approaches to 1) understand the types of topics discussed and 2) to learn medication-related intents from messages sent between patients and providers through a bidirectional text messaging system for managing participant blood pressure.\\n\\nMethodsThis study was a secondary analysis of de-identified messages from a remote mobile text-based employee hypertension management program at an academic institution. In experiment 1, we trained a Latent Dirichlet Allocation (LDA) model for each message type (inbound-patient and outbound-provider) and identified the distribution of major topics and significant topics (probability >0.20) across message types. In experiment 2, we annotated all medication-related messages with a single medication intent. Then, we trained a second LDA model (medLDA) to assess how well the unsupervised method could identify more fine-grained medication intents. We encoded each medication message with n-grams (n-1-3 words) using spaCy, clinical named entities using STANZA, and medication categories using MedEx, and then applied Chi-square feature selection to learn the most informative features associated with each medication intent.\\n\\nResultsA total of 253 participants and 5 providers engaged in the program generating 12,131 total messages: 47% patient messages and 53% provider messages. Most patient messages correspond to blood pressure (BP) reporting, BP encouragement, and appointment scheduling. In contrast, most provider messages correspond to BP reporting, medication adherence, and confirmatory statements. In experiment 1, for both patient and provider messages, most messages contained 1 topic and few with more than 3 topics identified using LDA. However, manual review of some messages within topics revealed significant heterogeneity even within single-topic messages as identified by LDA. In experiment 2, among the 534 medication messages annotated with a single medication intent, most of the 282 patient medication messages referred to medication request (48%; n=134) and medication taking (28%; n=79); most of the 252 provider medication messages referred to medication question (69%; n=173). Although medLDA could identify a majority intent within each topic, the model could not distinguish medication intents with low prevalence within either patient or provider messages. Richer feature engineering identified informative lexical-semantic patterns associated with each medication intent class.\\n\\nConclusionLDA can be an effective method for generating subgroups of messages with similar term usage and facilitate the review of topics to inform annotations. However, few training cases and shared vocabulary between intents precludes the use of LDA for fully automated deep medication intent classification.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.22.21268288\",\"title\":\"Elevation of cell-associated HIV-1 RNA transcripts in CSF CD4+ T cells, despite suppressive antiretroviral therapy, is linked to in vivo brain injury\",\"authors\":\"Suzuki, K.; Zaunders, J.; Gates, T. M.; Levert, A.; Butterly, S.; Liu, Z.; Ishida, T.; Huang, C.-S.; Palmer, S.; Rae, C. D.; Juge, L.; Cysique, L. A.; Brew, B. J.\",\"author_corresponding\":\"John Zaunders\",\"author_corresponding_institution\":\"Centre for Applied Medical Research, St Vincent\\\\'s Hospital, Sydney, NSW, Australia\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"hiv aids\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.22.21268288.source.xml\",\"abstract\":\"ObjectiveDespite effective antiretroviral therapy (ART), brain injury remains prevalent in people living with HIV-1 infection (PLHIV) possibly due to ARTs lack of direct inhibition of transcription with continued local production of viral transcripts and neurotoxic proteins, such as Tat, rather than cell-free whole virion toxicity. We quantified cell-associated (CA) HIV-1 RNA-transcripts in CSF and blood, in relation to proton Magnetic Resonance Spectroscopy (1H MRS) of major brain metabolites, in well characterised PLHIV.\\n\\nMethodsRNA was extracted from cells in 16 paired samples of CSF and blood, from PLHIV on fully suppressive ART. HIV-1 CA-RNA copies were measured using the highly sensitive Double-R assay and normalized \\/106 CD4+ T cells. 18-colour flow cytometry was used to count and analyse CD4+ T cells and monocytes in CSF and blood. The concentrations of major brain metabolites from 1H MRS in frontal white matter (FWM), posterior cingulate cortex (PCC), and caudate areas were measured. Brain injury in each voxel was defined using a composite score derived by principal component analysis.\\n\\nResults14\\/16 CSF cell samples had quantifiable HIV-1 CA-RNA transcripts, at levels significantly higher than in their PBMCs (median 9,266 vs 185 copies \\/106 CD4+ T cells; p<0.0001). Higher levels of CSF transcripts were associated with greater brain injury in the FWM (Std {beta}=-0.73; p=0.007) and PCC (Std {beta}=-0.61; p=0.03). CSF cells were 91% memory T cells, equally CD4+ (median 3,605) cells and CD8+ T cells (3,632), but contained much fewer B cells (0.4 %), NK cells (2.0%) and monocytes (3.1%; 378 cells; >90% CD14+CD16+ phenotype). CXCR3+CD49d+integrin {beta}7-negative, CCR5+ CD4+ T cells were significantly enriched in CSF, compared with PBMC (p <0.001). Transcriptional activity in CSF cells was highly correlated with levels of transcriptional activity in CD4+ T cells in PBMC (r=0.76; p=0.002). In contrast, HIV-1 RNA in highly purified monocytes from PBMC was detected in only 6\\/16 samples.\\n\\nConclusionsElevated HIV-1 transcripts in CSF cells were associated with in vivo brain injury, despite suppressive ART. The cellular source is most likely the predominant CXCR3+ CD49d+ integrin{beta}7-CCR5+ memory CD4+ T cells, not monocytes. Inhibitors of transcription to reduce local production of potentially neurotoxic proteins, should be developed.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.21.21268166\",\"title\":\"SARS-CoV-2 seroprevalence in Kaduna State, Nigeria during October\\/November 2021, following three waves of infection and immediately prior to detection of the Omicron variant\",\"authors\":\"Chechet, G. D.; Kwaga, J. K.; Yahaya, J.; MacLeod, A.; Adamson, W. E.\",\"author_corresponding\":\"Walt E Adamson\",\"author_corresponding_institution\":\"University of Glasgow\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nd\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.21.21268166.source.xml\",\"abstract\":\"Nigeria is the most populated country in Africa with an estimated [~]213 million inhabitants. As of November 2021 there have been three waves of SARS-CoV-2 infection in Nigeria but there has been only one seroprevalence survey conducted to assess the proportion of a population that have been infected, which was performed in December 2020 after the first wave of infection. To provide an update on seroprevalence in Nigeria, we conducted survey at one urban site (n=400) and one rural site (n=402) in Kaduna State, Nigeria during October and November 2021 following the third wave of infection. Seroprevalence for the urban and rural sites was 42.5% and 53.5% respectively (mean 48.0%). Symptoms associated with seropositivity were identified for each site. The overall seroprevalence among unvaccinated individuals was 45.4%. The data indicates an infection rate in Kaduna State at least 387 times greater than that derived from cases confirmed by PCR. Extrapolating to the whole of Nigeria, it would suggest there has been at least 96.7 million infections (compared to 206,138 confirmed cases at the time of surveillance). The work presented here will inform public health policy and deployment strategies for testing, treatment, and vaccination in Nigeria, and provide a baseline for SARS-CoV-2 seroprevalence in Nigeria immediately prior to the spread of the Omicron variant.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.23.21268281\",\"title\":\"Strong off-target antibody reactivity to malarial antigens induced by RTS,S\\/AS01E vaccination is associated with increased protection\",\"authors\":\"Macia, D.; Campo, J. J.; Moncunill, G.; Jairoce, C.; Nhabomba, A. J.; Mpina, M.; Sorgho, H.; Dosoo, D.; Traore, O.; Kusi, K. A.; Williams, N. A.; Randall, A.; Sanz, H.; Valim, C.; Asante, K. P.; Owusu-Agyei, S.; Tinto, H.; Agnandji, S. T.; Kariuki, S.; Gyan, B.; Daubenberger, C.; Mordmu\\u0308ller, B.; Petrone, P.; Dobano, C.\",\"author_corresponding\":\"Carlota Dobano\",\"author_corresponding_institution\":\"ISGlobal, Hospital Cl\\u00ednic - Universitat de Barcelona, Spain\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nd\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.23.21268281.source.xml\",\"abstract\":\"The RTS,S\\/AS01E vaccine targets the circumsporozoite protein (CSP) of the Plasmodium falciparum parasite. Using protein microarrays, levels of IgG to 1,000 P. falciparum antigens were measured in 2,138 infants (age 6-12 weeks) and children (age 5-17 months) from 6 African sites of the phase 3 trial, sampled before and at four longitudinal visits after vaccination. One month post-vaccination, IgG responses to 17% of all probed antigens showed differences between RTS,S\\/AS01E and comparator vaccination groups, whereas no pre-vaccination differences were found. A small subset of antigens presented IgG levels reaching 4- to 8-fold increases in the RTS,S\\/AS01E group, comparable in magnitude to anti-CSP IgG levels ([~]11-fold increase). They were strongly cross-correlated and correlated with anti-CSP levels, waning similarly over time and re-increasing with the booster dose. Such an intriguing phenomenon may be due to cross-reactivity of anti-CSP antibodies with these antigens. RTS,S\\/AS01E vaccinees with strong off-target IgG responses had an estimated lower clinical malaria incidence after adjusting for age group, site and post-vaccination anti-CSP levels. RTS,S\\/AS01E-induced IgG may bind strongly not only to CSP, but to unrelated malaria antigens, and this seems to either confer, or at least be a marker of, increased protection from clinical malaria.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.24.21267950\",\"title\":\"Smoking, race, ancestry and prospective abstinence\",\"authors\":\"Bergen, A. W.; Ervin, C. M.; McMahan, C. S.; Baurley, J. W.; Javitz, H. S.; Hall, S.\",\"author_corresponding\":\"Andrew W Bergen\",\"author_corresponding_institution\":\"Oregon Research Institute\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"addiction medicine\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.24.21267950.source.xml\",\"abstract\":\"BackgroundFactors influencing cessation include biopsychosocial characteristics, treatments and responses to treatment. The first cessation trial designed to assess cessation disparities between African American and White cigarette smokers demonstrated that socioeconomic, treatment, psychosocial and smoking characteristics explained cessation disparities. Ongoing translational efforts in precision cessation treatment grounded in genetically informed biomarkers have identified cessation differences by genotype, metabolism, ancestry and treatment.\\n\\nMethodsIn planned analyses, we evaluated six smoking-related measures, demographic and socioeconomic covariates, and prospective abstinence (7-day point prevalence at 12 weeks with bupropion, nicotine replacement and counseling treatments). We assessed concurrent and predictive validity in two covariate models differing by inclusion of Office of Management and Budget (OMB) race\\/ethnicity or genomic ancestry.\\n\\nResultsWe studied Pharmacogenetic Study participants (N=456, mean age 49.5 years, 41.5% female, 7.4% African American, 9.4% Multiracial, 6.5% Other, and 6.7% Hispanic). Cigarettes per day (OR=0.95, P<.001), Fagerstrom score (OR=0.89, P<=.014), Time-To-First-Cigarette (OR=0.75, P<=.005) and predicted urinary nicotine metabolite ratio (OR=0.57, P<=.039) were associated with abstinence. OMB African American race (ORs from 0.31 and 0.35, p-values<=.007) and African genomic ancestry (ORs from 0.21 and 0.26, p-values<=.004) were associated in all abstinence models.\\n\\nConclusionsFour smoking-related measures exhibited association with abstinence, including predicted nicotine metabolism based on a novel genomic model. African genomic ancestry was independently associated with reduced abstinence. Treatment research that includes social, psychological, treatment and biological factors is needed to reduce cessation disparities.\\n\\nImplicationsO_LIThis is the first application of a statistical learning model of the urinary nicotine metabolite ratio to cessation. Results are concordant with biochemical and genetic models of the plasma nicotine metabolite ratio in multiethnic samples.\\nC_LIO_LIThe urinary ratio exhibits the largest standardized effect size of four smoking-related measures associated with cessation (time-to-first cigarette, total Fagerstrom score and cigarettes per day were the others).\\nC_LIO_LIThe social construct of African American race and genomic African ancestry are significant covariates in all cessation models.\\nC_LIO_LIResults point to social and biological mechanisms requiring investigation in larger samples to understand and reduce cessation health disparities.\\nC_LI\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.22.21268059\",\"title\":\"A model based on a high-resolution flux matrix explains the spread of diseases in a spatial network and the effect of mitigation strategies\",\"authors\":\"Le Treut, G.; Huber, G.; Kamb, M.; Kawagoe, K.; McGeever, A.; Miller, J.; Pnini, R.; Veytsman, B.; Yllanes, D.\",\"author_corresponding\":\"Guillaume Le Treut\",\"author_corresponding_institution\":\"Chan-Zuckerberg Biohub\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by\",\"category\":\"epidemiology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.22.21268059.source.xml\",\"abstract\":\"Propagation of an epidemic across a spatial network of communities is described by a variant of the SIR model accompanied by an intercommunity infectivity matrix. This matrix is estimated from fluxes between communities, obtained from cell-phone tracking data recorded in the USA between March 2020 and February 2021. We have applied this model to the 2020 dynamics of the SARS-CoV-2 pandemic. We find that the numbers of susceptible and infected individuals predicted by the model agree with the reported cases in each community by fitting just one global parameter representing the frequency of interaction between individuals. The effect of \\\"shelter-in-place\\\" policies introduced across the USA at the onset of the pandemic is clearly seen in our results. We then consider the effect that alternative policies would have had, namely restricting long-range travel. We find that this policy is successful in decreasing the epidemic size and slowing down the spread, at the expense of a substantial restriction on mobility as a function of distance. When long-distance mobility is suppressed, this policy results in a traveling wave of infections, which we characterize analytically. In particular, we show the dependence of the wave velocity and profile on the transmission parameters. Finally, we discuss a policy of selectively constraining travel based on an edge-betweenness criterion.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.24.21268333\",\"title\":\"Testing the phenotypic decanalization hypothesis: social determinants of hyperglycemia and type 2 diabetes in adult urban Argentinian population\",\"authors\":\"Petino Zappala, M. A.; Folguera, G.; Benitez Vieyra, S.\",\"author_corresponding\":\"Maria Alejandra Petino Zappala\",\"author_corresponding_institution\":\"Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc\",\"category\":\"epidemiology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.24.21268333.source.xml\",\"abstract\":\"Type 2 diabetes, one of the major causes of death and disability worldwide, is characterized by problems in the homeostasis of blood glucose. Current preventive policies focus mainly on individual behaviors (diet, exercise, salt and alcohol consumption). Recent hypotheses state that the higher incidence of metabolic disease in some human populations may be related to phenotypic decanalization causing a heightened phenotypic variance in response to unusual or stressful environmental conditions, although the nature of these conditions is under debate. Our aim was to explore variability patterns of fasting blood glucose to test phenotypic decanalization as a possible explanation of heightened prevalence for type 2 diabetes in some groups and to detect variables associated with its variance using a nation-wide survey of Argentinian adult population. We found patterns of higher local variance for fasting glycemia associated with lower income and educational attainment. We detected no meaningful association of glycemia or its variability with covariates related to individual behaviors (diet, physical activity, salt or alcohol consumption). Our results were consistent with the decanalization hypothesis for fasting glycemia, which appears associated to socioeconomic disadvantage. We therefore propose changes in public policy and discuss the implications for data gathering and further analyses.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.24.21268375\",\"title\":\"The use of Cohort Size Shrinkage Index (CSSI) to quantify regional famine intensity during the Chinese famine of 1959-61\",\"authors\":\"Liu, C.; Li, C.; Zhou, Z.; Xu, H.; Lumey, L. H.\",\"author_corresponding\":\"L. H. Lumey\",\"author_corresponding_institution\":\"Department of Epidemiology, Mailman School of Public Health, Columbia University\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"epidemiology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.24.21268375.source.xml\",\"abstract\":\"There has been a growing interest in studying the causes and impact of the Great Chinese Famine of 1959-61. The Cohort Size Shrinkage Index (CSSI) is the most widely used measure to examine famine intensity and was used in at least 28 Chinese famine studies to date. We examined the potential impact of violations of three requirements for a valid CSSI measure: reliable information on cohort size by year of birth; a stable trend of cohort size by year of birth; and the absence of significant regional migration. We used data from the 1% China 2000 Census to examine the trend of cohort size over time and concentrated on the time window between 1950-70 to exclude policies and events with a large impact on birth trends other than the famine itself.\\n\\nAcross China we established a significant difference in cohort size trends between pre-famine births and post-famine births, violating one of the main requirements for a valid CSSI measure. This leads to systematic differences in CSSI depending on what non-famine years are selected for comparison. At the province level, CSSIs estimated based on pre- & post-famine births tend to overestimate famine intensity at higher exposure levels and underestimate intensity at lower levels compared to CSSIs based on pre-famine births alone. This is problematic and demonstrates that the CSSI is not as robust an estimator of famine intensity as had been assumed previously. We recommend therefore that all CSSI should be based on pre-famine birth trends.\\n\\nUsing data from Sichuan province, we demonstrate a less pronounced dose-response relation between famine intensity and tuberculosis outcomes using pre-famine based CSSI as compared to reported patterns based on pre- & post-famine based CSSI. We encourage researchers to re-examine their results of Chinese famine studies as local differences in cohort size of pre-famine and post-famine births may lead to significant discrepancies of CSSI estimation and change the interpretation of their findings.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.24.21268382\",\"title\":\"Early estimates of SARS-CoV-2 Omicron variant severity based on a matched cohort study, Ontario, Canada\",\"authors\":\"Ulloa, A. C.; Buchan, S. A.; Daneman, N.; Brown, K. A.\",\"author_corresponding\":\"Kevin Antoine Brown\",\"author_corresponding_institution\":\"Public Health Ontario\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by\",\"category\":\"epidemiology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.24.21268382.source.xml\",\"abstract\":\"While it is now evident that Omicron is rapidly replacing Delta, largely due to immune escape, it is less clear how the severity of Omicron compares to Delta. In Ontario, we sought to examine hospitalization and death associated with Omicron, as compared to cases infected with Delta. We conducted a matched cohort study, considering time to hospitalization or death as the outcome. Cases were matched on gender, age, vaccination status, health region and onset date. We identified 29,594 Omicron cases that met eligibility criteria, of which 11,622 could be matched with at least one Delta case (N=14,181). There were 59 (0.51%) hospitalizations and 3 (0.03%) deaths among matched Omicron cases, compared to 221 (1.6%) hospitalizations and 17 (0.12%) deaths among matched Delta cases. The risk of hospitalization or death was 65% lower (hazard ratio, HR=0.35, 95%CI: 0.26, 0.46) among Omicron cases compared to Delta cases, while risk of intensive care unit admission or death was 83% lower (HR=0.17, 95%CI: 0.08, 0.37). While severity is likely to be reduced, the absolute number of hospitalizations and impact on the healthcare system may nevertheless be significant due to the increased transmissibility of Omicron.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.25.21268394\",\"title\":\"SIR model for assessing the impact of the advent of Omicron and mitigating measures on infection pressure and hospitalization needs\",\"authors\":\"van wees, j.-d.; van der Kuip, M.; Osinga, S.; Keijser, B.; Van Westerloo, D.; Hanegraaf, M.; Pluymaekers, M.; Leeuwenburgh, O.; Brunner, L.; Tutu-van Furth, M.\",\"author_corresponding\":\"jan-diederik van wees\",\"author_corresponding_institution\":\"TNO\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"epidemiology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.25.21268394.source.xml\",\"abstract\":\"BackgroundOn 26 November 2021, the world health organization (WHO) designated the coronavirus SARS-CoV-2 B.1.1.529 a variant of concern, named Omicron (WHO, 2021a). As of December 16, Omicron has been detected in 89 countries (WHO, 2021b). The thread posed by Omicron is highly uncertain.\\n\\nMethods and findingsFor the analysis of the impact of Omicron on infection pressure and hospitalization needs we developed an open-source stochastic SIR (Susceptible-Infectious-Removed) fast-model for simulating the transmission in the transition stage from the prevailing variant (most often Delta) to Omicron. The model is capable to predict trajectories of infection pressure and hospitalization needs, considering (a) uncertainties for the (Omicron) parametrization, (b) pre-existing vaccination and\\/or partial immunity status of the population, and demographic specific aspects regarding reference hospitalization needs, (c) effects of mitigating measures including social distancing and accelerated vaccination (booster) campaigns.\\n\\nConclusionsThe SIR model approach yields results in fair agreement with Omicron transmission characteristics observed in South Africa and prognosis results in Europe (UK and Netherlands). The equations underlying the SIR formulation allows to effectively explore the effect of Omicron parametrization on anticipated infection growth rates and hospitalization rates relative to the prevailing variant. The models are online available as open source on GitHub.\\n\\nOne Sentence Summaryfast-model for the impact of Omicron\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.24.21268384\",\"title\":\"Estimating the impact of implementation and timing of COVID-19 vaccination program in Brazil: a counterfactual analysis\",\"authors\":\"Ferreira, L. S.; Marquitti, F. M. D.; da Silva, R. L. P.; Borges, M. E.; Gomes, M. F. C.; Cruz, O. G.; Kraenkel, R. A.; Coutinho, R. M.; Prado, P. I.; Bastos, L. S.\",\"author_corresponding\":\"Leonardo Souto Ferreira\",\"author_corresponding_institution\":\"Universidade Estadual Paulista, S\\u00e3o Paulo, SP, Brazil\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nd\",\"category\":\"epidemiology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.24.21268384.source.xml\",\"abstract\":\"The vaccines developed in 2020-2021 against the SARS-CoV-2 virus were designed to prevent severity and deaths due to COVID-19. However, how effective this vaccination campaign was at saving lives remains a methodological challenge. In this work, we developed a Bayesian statistical model to estimate the number of deaths and hospitalizations in individuals above 60 years old in Brazil. Using the actual number of hospitalized and deaths from the Brazilian database, and also the coverage of second dose according to the National Immunization Program, we rebuilt the realized scenario as well as the hypothetical scenario without vaccination in Brazil in order to perform a counterfactual analysis. By computing the difference between the hypothetical and realized scenarios, we were able to estimate the direct effect of COVID-19 vaccination in Brazil. We also evaluated two other hypothetical, but not impossible, scenarios considering earlier vaccination roll-outs. We estimated that more than 165 thousand of 60+ years old individuals were not hospitalized due to COVID-19 until August 28, 2021, and other approximately 100 thousand individuals could not have been hospitalized if the immunization started as soon it was approved in Brazil. We also estimate that more than 75 thousand lives were saved in the period analysed for the same age group, and additional 48 thousand lives could have been saved if the Brazilian Government started the immunization 8 weeks earlier.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.22.21268217\",\"title\":\"Humoral Immunogenicity of Three COVID-19 mRNA Vaccine Doses in Patients with Inflammatory Bowel Disease\",\"authors\":\"Schell, T. L.; Knutson, K. L.; Saha, S.; Wald, A.; Phan, H. S.; Almasry, M.; Chun, K.; Grimes, I.; Lutz, M.; Hayney, M. S.; Farraye, F. A.; Caldera, F.\",\"author_corresponding\":\"Freddy Caldera\",\"author_corresponding_institution\":\"Department of Medicine, Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, United Stat\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nd\",\"category\":\"gastroenterology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.22.21268217.source.xml\",\"abstract\":\"Herein, we evaluated the humoral immunogenicity of a third COVID-19 mRNA vaccine dose in patients with IBD. All patients were seropositive and had higher antibody concentrations after the third dose than after completion of the two-dose primary series.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.21.21268133\",\"title\":\"Gestational age and infection are greater predictors of placental histopathology than maternal prepregnancy BMI.\",\"authors\":\"Duffley, E.; Grynspan, D.; Scott, H.; Lafreniere, A.; Borba Vieira de Andrade, C.; Bloise, E.; Connor, K. L.\",\"author_corresponding\":\"Kristin L Connor\",\"author_corresponding_institution\":\"Carleton University\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"pathology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.21.21268133.source.xml\",\"abstract\":\"The placenta undergoes morphological and functional adaptions to adverse exposures during pregnancy. The effects of suboptimal maternal body mass index (BMI), preterm birth, and infection on placental histopathological phenotypes remain unclear, despite the association between these conditions and poor offspring outcomes. We hypothesized that suboptimal maternal prepregnancy BMI and preterm birth (with and without infection) would associate with altered placental maturity and morphometry, and that altered placental maturity would associate with poor birth outcomes. Clinical data and human placentae were collected from 96 pregnancies where mothers were underweight, normal weight, overweight, or obese, without other major complications. Placental histopathological characteristics were scored with an anatomical pathologist. Associations between maternal BMI, placental pathology (immaturity and hypermaturity), placental morphometry, and infant outcomes were investigated at term and preterm, with and without infection. Fetal vascular endothelium volumetric proportion was decreased, whereas syncytial knot volumetric proportion was increased, in placentae from preterm pregnancies with chorioamnionitis compared to term placentae. At term and preterm, pregnancies with overweight and obesity had a high percentage increase in proportion of immature placentae compared to normal weight. Placental maturity did not associate with infant birth outcomes. We observed placental hypermaturity and altered placental morphometry among preterm pregnancies with chorioamnionitis, suggestive of altered placental development, which may inform about pregnancies susceptible to preterm birth and infection. Our data increase our understanding of how common metabolic exposures and preterm birth, in the absence of other comorbidities or perinatal events, potentially contribute to poor pregnancy outcomes and the programming of offspring development.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.22.21268195\",\"title\":\"Utilization of a SARS-CoV-2 Variant Assay for the Rapid Differentiation of Omicron and Delta\",\"authors\":\"Barasch, N. J.; Iqbal, J.; Coombs, M.; Kazi, S.; Wang-Rodriguez, J.; Holodniy, M.; Gelman, M.\",\"author_corresponding\":\"Nicholas Jacob Barasch\",\"author_corresponding_institution\":\"James J. Peters Veterans Affairs Medical Center, Bronx, NY\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc0\",\"category\":\"pathology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.22.21268195.source.xml\",\"abstract\":\"The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529), creates a diagnostic vacuum, since differentiation of Omicron from Delta relies on relatively slow next generation sequencing (NGS) technology delaying epidemiologic understanding and therapeutic intervention. The RUO SARS-CoV-2 Variant Set 1 Test (RSCov2V1) RT-PCR for detection of spike gene N501Y, E484K and del69-70 was designed to differentiate Alpha from Beta and Gamma variants. While Delta lacks these three variants, Omicron has the N501Y and del69-70 mutation. We submitted 88 samples for RSCov2V1 identifying 9 samples with the N501Y and del69-70 mutations while all other samples (79) were negative for all three variants. 9\\/9 samples with the del69-70 and N501Y were identified by NGS to be Omicron while 47\\/47 other samples assessed by NGS were confirmed to be Delta family variants. We demonstrate here that an immediately available RT-PCR assay for detection of spike gene N501Y and del69-70 can be utilized to rapidly differentiate Omicron from Delta variants in the proper epidemiologic context\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.22.21268161\",\"title\":\"Predicting risk of pancreatic cancer in individuals with new-onset type-2 diabetes in primary care: protocol for the development and validation of a clinical prediction model (QPancreasD)\",\"authors\":\"Tan, P. S.; Clift, A. K.; Liao, W.; Patone, M.; Coupland, C.; Bashford-Rogers, R.; Sivakumar, S.; Clifton, D.; Pereira, S. P.; Hippisley-Cox, J.\",\"author_corresponding\":\"Julia Hippisley-Cox\",\"author_corresponding_institution\":\"University of Oxford\",\"date\":\"2021-12-28\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"primary care research\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/28\\/2021.12.22.21268161.source.xml\",\"abstract\":\"BackgroundPancreatic cancer continues to have an extremely poor prognosis in part due to late diagnosis. 25% of pancreatic cancer patients have a prior diagnosis of diabetes, and hence identifying individuals at risk of pancreatic cancer in those with recently diagnosed type 2 diabetes may be a useful opportunity to identify candidates for screening and early detection. In this study, we will comparatively evaluate regression and machine learning-based clinical prediction models for estimating individual risk of developing pancreatic cancer two years after type 2 diabetes diagnosis.\\n\\nMethodsIn the development dataset, we will include adults aged 30-84 years with incident type-2 diabetes registered with QResearch primary care database. Patients will be followed up from type-2 diabetes diagnosis to first diagnosis of pancreatic cancer as recorded in any one of primary care records, hospital episode statistics, cancer registry data, or death records. Cox-proportional hazards models will be used to develop a risk prediction model for estimating individual risk of developing pancreatic cancer during up to 2 years of follow-up. We will perform variable selection using a combination of clinical and statistical significance approach i.e. HR <0.9 or >1.1 and p<0.01. Linear predictors and baseline survivor function at 2 years will be used to compute absolute risk predictions.\\n\\nInternal-external cross-validation (IECV) framework across geographical regions within England will be used to assess performance and pooled using random effects meta-analysis using: (i) model fit in terms of variation explained by the model Royston & Sauerbreis R2D, (ii) calibration slope and calibration-in-the-large, and (iii) discrimination measured in terms of Harrells C and Royston & Sauerbreis D-statistic.\\n\\nFurther, we will evaluate machine learning (ML) approaches for the clinical prediction model using neural networks (NN) and XGBoost. The model predictors and performance of these will be compared with the results of those derived from the regression-based strategy.\\n\\nDiscussionThe proposed study will develop and validate a novel risk prediction model to aid early diagnosis of pancreatic cancer in patients with new-onset diabetes in primary care. With an enhanced decision-risk tool for use at point-of care by general practitioners to assess pancreatic cancer risk, it may improve decision-making so that at-risk patients are rapidly prioritised to aid early diagnosis of pancreatic cancer in patients with newly diagnosed diabetes.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.20.21268053\",\"title\":\"A simple and quick PCR based method for detection of Omicron variant of SARS-CoV-2\",\"authors\":\"Puvar, A.; Pandit, R.; Chaudhari, A. M.; Travadi, T.; Shukla, N.; Joshi, C.; Joshi, M.\",\"author_corresponding\":\"Madhvi Joshi\",\"author_corresponding_institution\":\"Gujarat Biotechnology Research Centre\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by\",\"category\":\"public and global health\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.20.21268053.source.xml\",\"abstract\":\"SARS-CoV-2 pandemic has changed the global landscape since last two years. Against many challenges posed by the COVID-19 pandemic to the humanity, the pace of solutions created by mankind is exemplary; diagnostics, vaccines, alternate therapies, to name a few. With a rapidly changing virus strain, its early identification in the community can be a quick solution to trace the individuals and thus control its spread. This paper describes PCR based quick method for differentiation of Omicron variant of SARS-CoV-2 from other variants. Timely identification of this new variant will enable better management of pandemic control in the population.\\n\\nGraphical Abstract\\n\\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=104 SRC=\\\"FIGDIR\\/small\\/21268053v1_ufig1.gif\\\" ALT=\\\"Figure 1\\\">\\nView larger version (24K):\\norg.highwire.dtl.DTLVardef@435bf0org.highwire.dtl.DTLVardef@490357org.highwire.dtl.DTLVardef@17a7830org.highwire.dtl.DTLVardef@168d391_HPS_FORMAT_FIGEXP  M_FIG C_FIG\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.24.21268369\",\"title\":\"Towards environmental detection of Chagas disease vectors and pathogen\",\"authors\":\"Gysin, G.; Urbano, P.; Brandner-Garrod, L.; Begum, S.; Kristan, M.; Walker, T.; Hernandez, C.; Ramirez, J. D.; Messenger, L. A.\",\"author_corresponding\":\"Louisa  Alexandra Messenger\",\"author_corresponding_institution\":\"London School of Hygiene & Tropical Medicine\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by\",\"category\":\"public and global health\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.24.21268369.source.xml\",\"abstract\":\"BackgroundAccurate surveillance of triatomine household infestation is crucial for Chagas disease vector control. However, no gold standard detection method with high levels of sensitivity or specificity is currently available. Several intrinsic features of triatomine bug behaviour and the lifecycle of Trypanosoma (T.) cruzi lead to deposition of environmental DNA (eDNA) in infested houses. This study evaluated the use of FTA cards and cotton-tipped swabs as low-technology, cost-effective tools for simultaneous detection of T. cruzi and vector eDNA in the laboratory and field.\\n\\nMethods\\/Principal FindingsThis study had two components: (1) laboratory evaluation and optimisation of QIAcard(R) FTA(R) classic cards to detect Rhodnius (R.) prolixus eDNA by altering five different environmental variables (darkness, triatomine number, temperature, feeding status and degradation at ambient temperature); (2) detection of R. prolixus and T. cruzi eDNA from cotton-tipped house wall swabs from an endemic region in Casanare Department, Colombia. eDNA was extracted from all specimens and amplified using a multiplex TaqMan qPCR assay targeting the R. prolixus 12S rRNA gene and T. cruzi satellite DNA region. R. prolixus eDNA from five 3rd\\/4th instar nymphs was successfully amplified from FTA cards after as little as 15 minutes of contact time under standard insectary conditions. Factors significantly increasing eDNA detection from FTA cards were increasing temperature from 21{degrees}C to 27-32{degrees}C, triatomine bug density from 1-25 bugs and recent blood-feeding. eDNA was detectable from FTA cards stored at room temperature for at least two weeks. In cotton-tipped swabs from the field, the sensitivity and specificity of R. prolixus eDNA detection was 60.6% (n=20\\/33) and 100% (n=33\\/33), respectively. T. cruzi eDNA was amplified from 93.9% (n=31\\/33) of infested houses.\\n\\nConclusions\\/SignificanceFTA cards are a highly sensitive tool for entomological surveillance of R. prolixus and exhibit little variability under different environmental conditions. Additionally, cotton-tipped swabs are a relatively sensitive tool for entomological and parasitological surveillance of R. prolixus and T. cruzi in situ, but more feasible due to low cost. Both methods could be utilised by citizen science initiatives to contribute to the control of Chagas disease in endemic communities.\\n\\nAuthor SummaryChagas disease vector control relies on prompt, accurate identification of houses infested with triatomine bugs for targeted insecticide spraying. However, most current detection methods are laborious, lack standardization, have substantial operational costs and limited sensitivity, especially when triatomine bug densities are low or highly focal. We evaluated the use of FTA cards or cotton-tipped swabs to develop a low-technology, non-invasive method of detecting environmental DNA (eDNA) from both triatomine bugs and Trypanosoma cruzi for use in household surveillance in eastern Colombia, an endemic region for Chagas disease. Study findings demonstrated that FTA cards are a sensitive tool for detection of Rhodnius prolixus eDNA at temperatures between 21-32{degrees}C, deposited by individual, recently blood-fed nymphs. Additionally, cotton-tipped swabs are a relatively sensitive tool for field sampling of both T. cruzi and R. prolixus eDNA in infested households and are arguably more feasible due to their lower cost. eDNA detection should not yet replace current surveillance tools, but instead be evaluated in parallel as a more sensitive, higher-throughput, lower cost alternative. eDNA collection requires virtually no skills or resources in situ and therefore has the potential to be implemented in local endemic communities as part of citizen science initiatives to control Chagas disease transmission.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.21.21268075\",\"title\":\"Assessing Immunity by Quantitative Measurement of SARS-CoV-2 IgG Antibodies in Fingerstick Samples\",\"authors\":\"Garza, J. T.; Quick, J.; Chatterjee, D.; Garr, R. P.; Varadhachary, A.; Linbeck, L.\",\"author_corresponding\":\"Javier T. Garza\",\"author_corresponding_institution\":\"Brevitest Technologies, Inc.\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"public and global health\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.21.21268075.source.xml\",\"abstract\":\"COVID-19 has affected billions of people around the world directly or indirectly. The response to the pandemic has focused on preventing the spread of the disease and improving treatment options. Diagnostic technologies have played a key role in this response since the beginning of the pandemic. As vaccines and other treatments have been developed and deployed, interest in understanding and measuring the individual level of immune protection has increased. Historically, use of antibody titers to measure systemic immunity has been constrained by an incomplete understanding of the relationship between antibodies and immunity, the lack of international standards for antibody concentration to enable cross-study comparisons, and insufficient clinical data to allow for the development of robust antibody-immunity models.\\n\\nHowever, these constraints have recently shifted. With a deeper understanding of antibodies, the promulgation of WHO antibody standards, and the development of immunity models using datasets from multiple COVID-19 vaccine trials, certain types of quantitative antibody tests may now provide a way to monitor individual or community immunity against COVID-19. Specifically, tests that quantitate the concentration of anti-RBD IgG -antibodies that target the receptor binding domain of the S1 spike protein component of the SARS-CoV-2 virus - show promise as a useful and scalable measure of the COVID-19 immunity of both individuals and communities. However, to fulfill this promise, a rapid and easy-to-administer test is needed.\\n\\nTo address this important clinical need, Brevitest deployed its point-of-care-capable technology platform that can run a rapid (<15 minute), quantitative antibody test with a sample of 10 l of whole blood from a fingerstick. The test we validated on this platform measures the concentration of anti-RBD IgG in Binding Antibody Units per milliliter (BAU\\/mL) per WHO Reference Standard NIBSC 20\\/136.\\n\\nIn this paper, we present studies used to characterize the Brevitest anti-RBD IgG assay and evaluate its clinical performance, lower limits of measurement, precision, linearity, interference, and cross-reactivity. The results demonstrate the ability of this assay to measure a patients anti-RBD IgG concentration. This information, together with models developed from recent COVID-19 vaccine clinical trials, can provide a means of assessing the current level of immune protection of an individual or community against COVID-19 infection.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.23.21268177\",\"title\":\"Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies\",\"authors\":\"Sormani, M. P.; Schiavetti, I.; Inglese, M.; Carmisciano, L.; Laroni, A.; Lapucci, C.; Visconti, V.; Serrati, C.; Gandoglia, I.; Tassinari, T.; Perego, G.; Brichetto, G.; Gazzola, P.; Mannironi, A.; Stromillo, M. L.; Cordioli, C.; Landi, D.; Clerico, M.; Signoriello, E.; Frau, J.; Ferro, M. T.; Di Sapio, A.; Pasquali, L.; Ulivelli, M.; Marinelli, F.; Manzino, M.; Callari, G.; Iodice, R.; Liberatore, G.; Caleri, F.; Repice, A. M.; Cordera, S.; Battaglia, M. A.; Salvetti, M.; Franciotta, D.; Uccelli, A.\",\"author_corresponding\":\"Maria Pia Sormani\",\"author_corresponding_institution\":\"Department of Health Sciences, Section of Biostatistics, University of Genova, ItalyIRCCS Ospedale Policlinico San Martino, Genova, Italy\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"neurology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.23.21268177.source.xml\",\"abstract\":\"BackgroundPatients with Multiple Sclerosis (pwMS) treated with anti-CD20 or fingolimod showed a reduced humoral response to mRNA-based SARS-CoV-2 vaccines, while the degree of such responses is unimpaired and similar in pwMS treated with other disease modifying therapies (DMTs), or untreated. However, the nature of the SARS-CoV-2 vaccine-induced immune response is based also on cellular immunity and there is emerging evidence that anti-SARS-CoV-2 specific CD4 and CD8 T cell responses can be detected after vaccination also in patients with low antibody levels. In this study we aimed to monitor the risk of breakthrough SARS-CoV-2 infection and to identify correlates of reduced protection in frail vaccinated pwMS on different DMTs.\\n\\nMethodsWe designed a long term clinical follow-up of the CovaXiMS (Covid-19 vaccine in Multiple Sclerosis), a prospective multicenter cohort study enrolling pwMS scheduled for SARS-CoV-2 vaccination with mRNA vaccines and tested for SARS-CoV-2 antibodies before and after the second vaccine dose. These patients were followed with periodic phone calls up to a mean time of 6 months, and all the SARS-CoV-2 breakthrough infections were registered. The impact of DMTs on cumulative incidence of breakthrough Covid-19 cases was presented by Kaplan-Meier curves. A multivariable logistic model was run to assess factors associated to a higher risk of breakthrough infections.\\n\\nFindings1705 pwMS (81.6% BNT162b2 and 18.4% mRNA-1273) had a full vaccination cycle (2 vaccine doses, 21\\/28 days apart). Of them, 1509 (88.5%) had blood assessment 4 weeks after the second vaccine dose. During follow-up, 23 breakthrough Covid-19 infections (cumulative incidence: 1.5%, SE=0.3%) were detected after a mean of 108 days after the second dose (range, 18-230). Of them, 9 were on ocrelizumab, one on rituximab, 4 on fingolimod, 6 on dimethyl-fumarate, one on teriflunomide, and 2 were untreated. Just two cases (a woman on ocrelizumab and a man on teriflunomide) required hospitalization. The probability to be infected was associated only with SARS-CoV-2 antibody levels measured after 4 weeks from the second vaccine dose (HR=0.63, p=0.007); an antibody level of 660 U\\/mL was calculated as the cutoff for higher risk of infection.\\n\\nInterpretationOur data show that the risk of breakthrough SARS-CoV-2 infections is mainly associated with reduced levels of the virus-specific humoral immune response.\\n\\nFundingFISM [2021\\/Special-Multi\\/001]; the Italian Ministry of Health grant  Progetto Z844A 5x1000. Italian Ministry of Health: Ricerca Corrente to IRCCS Ospedale Policlinico San Martino.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.22.21268127\",\"title\":\"Humoral and cellular immune responses to SARS CoV-2 vaccination in Persons with Multiple Sclerosis and NMOSD patients receiving immunomodulatory treatments\",\"authors\":\"Bock, H.; Juretzek, T.; Handreka, R.; Ruhnau, J.; Reuner, K.; Peltroche, H.; Dressel, A.\",\"author_corresponding\":\"Alexander Dressel\",\"author_corresponding_institution\":\"Carl Thiem Klinikum\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"neurology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.22.21268127.source.xml\",\"abstract\":\"BackgroundVaccination against SARS CoV-2 results in excellent personal protection against a severe course of COVID19. In persons with Multiple Sclerosis (PwMS) vaccination efficacy may be reduced by immunomodulatory medications.\\n\\nObjectiveTo assess the vaccination induced cellular and humoral immune response in PwMS receiving disease modifiying therapies.\\n\\nMethodsIn a monocentric observational study on PwMS and patients with Neuromyelitis optica we quantified the cellular and humoral immune responses to SARS CoV-2.\\n\\nResultsPwMS receiving Glatirameracetate, Interferon-{beta}, Dimethylfumarate, Cladribine or Natalalizumab had intact humoral and cellular immune responses following vaccination against SARS CoV-2. B-cell depleting therapies reduced B-cell responses but did not affect T cell responses. S1P inhibitors strongly reduced humoral and cellular immune responses.\\n\\nThere was a good agreement between the Interferon gamma release assay and the T-SPOT assay used to measure viral antigen induced T-cell responses.\\n\\nConclusionThis study demonstrates that S1P inhibitors impair the cellular and humoral immune response in SARS CoV-2 vaccination, whereas patients receiving B-cell depleting therapies mount an intact cellular immune response. These data can support clinicians in counselling their PwMS and NMOSD patients during the COVID 19 pandemic.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.26.21268282\",\"title\":\"Identification of a novel proteomic Biomarker in Parkinson's Disease: Discovery and Replication in Blood, brain and CSF\",\"authors\":\"Winchester, L.; Lawton, M.; Barber, I.; Ash, J.; Liu, B.; Evetts, S.; Vingill, S.; Belen Malpartida, A.; Hopkins-Jones, L.; Lewis, S.; Bresner, C.; Williams, N.; Gentlemen, S.; Wade-Martins, R.; Ryan, B.; Holgado-Nevado, A.; Hu, M.; Ben-Shlomo, Y.; Grosset, D.; Lovestone, S.\",\"author_corresponding\":\"Laura Winchester\",\"author_corresponding_institution\":\"University of Oxford\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"neurology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.26.21268282.source.xml\",\"abstract\":\"Biomarkers to aid diagnosis and delineate progression of Parkinsons Disease (PD) are vital for targeting treatment in the early phases of disease. Here, we aim to discover a multi-protein panel representative of PD and make mechanistic inferences from protein expression profiles within the broader objective of finding novel biomarkers.\\n\\nWe used aptamer-based technology (SomaLogic(R)) to measure proteins in 1,599 serum samples, 85 CSF samples and 37 brain tissue samples collected from two observational longitudinal cohorts (Oxford Parkinsons Disease Centre and Tracking Parkinsons) and the PD Brain Bank, respectively. Random forest machine learning was performed to discover new proteins related to disease status and generate multi-protein expression signatures with potential novel biomarkers. Differential regulation analysis and pathway analysis was performed to identify functional and mechanistic disease associations.\\n\\nThe most consistent diagnostic classifier signature was tested across modalities (CSF AUC = 0.74, p-value = 0.0009; brain AUC = 0.75, p-value = 0.006; serum AUC = 0.66, p-value = 0.0002). In the validation dataset we showed that the same classifiers were significantly related to disease status (p-values < 0.001). Differential expression analysis and Weighted Gene Correlation Network Analysis (WGCNA) highlighted key proteins and pathways with known relationships to PD. Proteins from the complement and coagulation cascades suggest a disease relationship to immune response.\\n\\nThe combined analytical approaches in a relatively large number of samples, across tissue types, with replication and validation, provides mechanistic insights into the disease as well as nominating a protein signature classifier that deserves further biomarker evaluation.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.25.21268402\",\"title\":\"Arachnoid granulations may be protective against the development of shunt dependent chronic hydrocephalus after aneurysm subarachnoid hemorrhage\",\"authors\":\"Almohaimede, K.; Zaccagna, F.; Kumar, A.; da Costa, L.; Wong, E.; Heyn, C.; Kapadia, A.\",\"author_corresponding\":\"Anish Kapadia\",\"author_corresponding_institution\":\"University of Toronto\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"neurology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.25.21268402.source.xml\",\"abstract\":\"Background and PurposeChronic hydrocephalus may develop as a sequela of aneurysmal subarachnoid hemorrhage, requiring long-term cerebrospinal fluid shunting. Several clinical predictors of chronic hydrocephalus and shunt dependence have been proposed. However, no anatomical predictors have been identified.\\n\\nMaterials and MethodsA retrospective cohort study was performed including 61 patients with aneurysmal subarachnoid hemorrhage. Clinical characteristics were noted for each patient including presentation World Federation of Neurosurgical Societies grade, modified Fischer grade, aneurysm characteristics, requirement for acute and chronic cerebrospinal fluid diversion, and 3-month modified Rankin scale. CT images were evaluated to determine the Evans index and to enumerate the number of arachnoid granulations. Association between the clinical characteristics with ventriculoperitoneal shunt insertion and the 3-month modified Rankin scale were assessed.\\n\\nResultsThe initial Evans index was positively associated with mFisher grade and age, but not the number of arachnoid granulations. 16.4 % patients required insertion of a ventriculoperitoneal shunt. The number of arachnoid granulations were a significant negative predictor of ventriculoperitoneal shunt insertion [OR: 0.251 (95% CI:0.073-0.862; P=0.028)]. There was significant difference in the number of arachnoid granulations between those with and without ventriculoperitoneal shunt (p=0.002). No patient with greater than 4 arachnoid granulations required a ventriculoperitoneal shunt, irrespective of severity of initial grade.\\n\\nConclusionArachnoid granulations may be protective against the development of shunt dependent chronic hydrocephalus after aneurysmal subarachnoid hemorrhage. This is irrespective of presenting hemorrhage severity. This is a potentially novel radiologic biomarker and anatomic predictor of shunt dependence.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.24.21267786\",\"title\":\"Vascular burden and cognition: Mediating roles of neurodegeneration and amyloid-PET\",\"authors\":\"Ottoy, J.; Ozzoude, M.; Zukotynski, K.; Adamo, S.; Scott, C.; Gaudet, V.; Ramirez, J.; Swardfager, W.; Cogo-Moreira, H.; Lam, B.; Bhan, A.; Mojiri, P.; Kang, M. S.; Rabin, J. S.; Kiss, A.; Strother, S.; Bocti, C.; Borrie, M.; Chertkow, H.; Frayne, R.; Hsiung, R.; Laforce, R. J.; Noseworthy, M. D.; Prato, F. S.; Sahlas, D. J.; Smith, E. E.; Kuo, P. H.; Sossi, V.; Thiel, A.; Soucy, J.-P.; Tardif, J.-C.; Black, S. E.; Goubran, M.\",\"author_corresponding\":\"Maged Goubran\",\"author_corresponding_institution\":\"Sunnybrook Research Institute\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"neurology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.24.21267786.source.xml\",\"abstract\":\"INTRODUCTIONIt remains unclear to which extent vascular burden promotes neurodegeneration and cognitive dysfunction in a cohort spanning low-to-severe small vessel disease (SVD) and amyloid-beta pathology.\\n\\nMETHODSIn 120 subjects, we investigated 1) whether vascular burden, quantified as total or lobar white matter hyperintensity (WMH) volumes, is associated with different cognitive domains; and 2) whether the total WMH effect on cognition is mediated by amyloid (18F-AV45-PET), glucose metabolism (18F-FDG-PET), and\\/or cortical atrophy.\\n\\nRESULTSIncreased total WMH volume was associated with poorer performance in all cognitive domains tested, with the strongest effects observed for semantic fluency. These relationships were mediated mainly through cortical atrophy, particularly in the temporal lobe, and to a lesser extent through amyloid and metabolism. WMH volumes differentially impacted cognition depending on lobar location and amyloid status.\\n\\nDISCUSSIONOur study suggests mainly an amyloid-dependent pathway in which vascular burden affects cognitive impairment through temporal lobe atrophy.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.24.21268386\",\"title\":\"PDGRFA-mutant gastrointestinal stromal tumours (GISTs) in Eastern England: clinicopathological features and outcomes of 50 patients diagnosed between 2008-2021\",\"authors\":\"Favara, D. M.; Wong, H.; Harrington, J.; Giger, O.; Bulusu, V. R.\",\"author_corresponding\":\"David M Favara\",\"author_corresponding_institution\":\"Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nd\",\"category\":\"oncology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.24.21268386.source.xml\",\"abstract\":\"BackgroundPDGRFA-mutant gastrointestinal tumours (GISTs) comprise approximately 10% of GISTs and are mostly gastric. Targeted therapies against these tumours have historically been limited by tyrosine kinase inhibitor (TKI)-resistance. We reviewed the characteristics and outcome of all PDGRFA-mutant patients seen at our centre over the last 13 years.\\n\\nMethodsAll PDGRFA-mutant patients seen at the Cambridge University Hospitals NHS Foundation Trust GIST clinic from July 2008-July 2021 were retrospectively reviewed and followed up.\\n\\nResults50 PDGRFA-mutant GIST patients were diagnosed during the 13-year period. 60% were male. Median tumour size was 5 cm and the majority were epithelioid (44%) or mixed (36%) type. Commonest primary location was the gastric body (52%). In non-metastatic patients the low-risk modified AFIP risk group was the most common (65.2%). PDGFRA exon 18 (86%) were the most common PDGFRA mutations, most being imatinib resistant. None harboured a KIT mutation. 38% of cases had high KIT expression (immunohistochemistry), whilst 48% had patchy expression and 14% were negative. Most were positive for DOG1 (94%). CD34 was highly expressed in 48% of cases. 13% developed metastases during the 13-year follow-up period: liver (80%) being the commonest site. 76% of all patients underwent radical resection. 14% received TKI therapy. After a median follow-up of 55.1 months, 82% remained alive: 6 patients died from metastatic GIST; 3 from other causes. Median time to metastatic disease was 30.1 months, and median time from metastatic diagnosis to death was 18.5 months. Patients who presented with metastatic disease had the poorest survival outcome (p=0.001)\\n\\nConclusionTo date this is the largest single-centre European PDGRFA-mutant GIST cohort. Results highlight the generally indolent nature of PDGRFA-mutant disease (contrasted to the poor outcome of those who present with metastatic disease), male and gastric preponderance (unlike KIT-mutant GISTs), and variable KIT expression.\\n\\nHighlightsO_LILargest single-centre European PDGFRA-mutant GIST series (n=50) to date\\nC_LIO_LIResults confirm the relative indolent nature of non-metastatic PDGFRA-mutant GISTs\\nC_LIO_LIPDGFRA-mutant GISTs had variable levels of KIT protein expression (immunohistochemistry) despite being KIT-wild type.\\nC_LIO_LIIn contrast to KIT-mutant GISTs, PDGFRA-mutant GISTs were more common in males and less frequent in parts of the stomach where KIT-mutant GISTS occur.\\nC_LIO_LIA minority of patients received TKI therapy. One patient with metastatic imatinib-resistant PDGFRA-mutant GIST had a 6 year response to imatinib.\\nC_LI\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.20.21268066\",\"title\":\"Persisting Chemosensory Impairments in 366 Healthcare Workers Following COVID-19: An 11-Month Follow-up.\",\"authors\":\"Bussiere, N.; Mei, J.; Levesque-Boissonneault, C.; Blais, M.; Carazo, S.; Gros-Louis, F.; Laforce, R.; DeSerres, G.; Dupre, N.; Frasnelli, J.\",\"author_corresponding\":\"Nicholas Bussiere\",\"author_corresponding_institution\":\"Universite du Quebec a Trois-Rivieres\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"otolaryngology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.20.21268066.source.xml\",\"abstract\":\"Background and ObjectivesOlfactory and gustatory dysfunctions (OD, GD) are prevalent symptoms following COVID-19 and persist in 6%-44% of individuals in the first months after the infection. As only few reports have described their prognosis more than 6 months later, the main objective of this study was to assess the prevalence of OD and GD 11 months after COVID-19. We also aimed to determine test-retest reliability of subjective chemosensory ratings for the follow-up of chemosensory sensitivity, as this measure is often used for remote follow-up.\\n\\nMethodsInclusion criteria included a PCR-confirmed SARS-CoV-2 infection; exclusion criteria were the presence of other respiratory infections and chronic sinusitis. To assess whether OD and GD had changed compared to pre-pandemic levels, we designed an observational study and distributed an online questionnaire assessing quantitative chemosensory function to healthcare workers 5 and 11 months after COVID-19. Specifically, we assessed olfaction, gustation, and trigeminal sensitivity (10-point visual analog scale) and function (4-point Likert scale) separately. We further assessed clinically relevant OD using the Chemosensory Perception Test, a psychophysical test designed to provide a reliable remote olfactory evaluation. Qualitative chemosensory dysfunction was also assessed.\\n\\nResultsWe included a total of 366 participants (mean age of 44.8 years old (SD: 11.7)). They completed the last online questionnaire 10.6 months (SD: 0.7) after the onset of COVID-19 symptoms. Of all participants, 307 (83.9%) and 301 (82.2%) individuals retrospectively reported lower olfactory or gustatory sensitivity during the acute phase of COVID-19. Eleven months later, 184 (50.3%) and 163 (44.5%) indicated reduced chemosensory sensitivity, 32.2% reported impairment of olfactory function while 24.9% exhibited clinically relevant OD. Three variables predicted OD at follow-up, namely chest pain and GD during COVID-19 and presence of phantosmia at 5 months. Olfactory sensitivity ratings had a high test-retest reliability (intraclass correlation coefficient: 0.818 (95% CI: 0.760 - 0.860))\\n\\nDiscussionThis study suggests that chemosensory dysfunctions persist in a third of COVID-19 patients 11 months after COVID-19. Subjective measures have a high test-retest reliability and thus can be used to monitor post-COVID-19 OD. OD appears to be a common long-term symptom of COVID-19 important to consider when treating patients.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.20.21268000\",\"title\":\"ESBL plasmids in Klebsiella pneumoniae: diversity, transmission, and contribution to infection burden in the hospital setting\",\"authors\":\"Hawkey, J.; Wyres, K. L.; Judd, L. M.; Harshegyi, T.; Blakeway, L.; Wick, R. R.; Jenney, A. W. J.; Holt, K. E.\",\"author_corresponding\":\"Jane Hawkey\",\"author_corresponding_institution\":\"Monash University\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by\",\"category\":\"genetic and genomic medicine\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.20.21268000.source.xml\",\"abstract\":\"BackgroundResistance to third-generation cephalosporins, often mediated by extended-spectrum beta-lactamases (ESBLs), is a considerable issue in hospital-associated infections as few drugs remain for treatment. ESBL genes are often located on large plasmids that transfer horizontally between strains and species of Enterobacteriaceae and frequently confer resistance to additional drug classes. While plasmid transmission is recognised to occur in the hospital setting, the frequency and impact of plasmid transmission on infection burden, compared to ESBL+ strain transmission, is not well understood.\\n\\nMethodsWe sequenced the genomes of clinical and carriage isolates of Klebsiella pneumoniae species complex from a year-long hospital surveillance study to investigate ESBL burden and plasmid transmission in an Australian hospital. Long-term persistence of a key transmitted ESBL+ plasmid was investigated via sequencing of ceftriaxone-resistant isolates during four years of follow-up, beginning three years after the initial study.\\n\\nResultsWe found 25 distinct ESBL plasmids. One (Plasmid A, carrying blaCTX-M-15 in an IncF backbone similar to pKPN-307) was transmitted at least four times into different Klebsiella species\\/lineages and was responsible for half of all ESBL episodes during the initial one-year study period. Three of the Plasmid A-positive strains persisted locally 3-6 years later, and Plasmid A was detected in two additional strain backgrounds. Overall Plasmid A accounted for 21% of ESBL+ infections in the follow-up period.\\n\\nConclusionsWhilst ESBL plasmid transmission events were rare in this setting, they had a significant and sustained impact on the burden of ceftriaxone-resistant and multidrug-resistant infections.\\n\\nsummaryWe detected a blaCTX-M-15 plasmid (Plasmid A) that transferred four times into different Klebsiella lineages, causing 50% of ESBL episodes during the initial study. Three Plasmid A-positive strains persisted locally 3-6 years later, accounting for 21% of ESBL+ infections.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.21.21268173\",\"title\":\"Post COVID-19 1st Dose Vaccination Common Symptoms among SE Asia College Students\",\"authors\":\"Wibowo, A.; Yostyadiananda, N. O.; Gunawan, G. R.\",\"author_corresponding\":\"Andri Wibowo\",\"author_corresponding_institution\":\"Universitas Indonesia\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"health informatics\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.21.21268173.source.xml\",\"abstract\":\"In the second year of the COVID-19 epidemic in the Southeast Asia (SE) regions, there is a plan to reopen the school, including the campus. Among students in Indonesia, college students have a population of almost 8.3 million. Considering the massive numbers of college students, school reopening should be supported by adequate COVID-19 vaccination. As a result, the first dose of the inactivated virus COVID-19 vaccine has been administered, including to college students aged over 18 years old. While COVID-19 vaccination is widely available, there is still a scarcity of information on post-vaccination symptoms. As reported from other locations, post vaccination has been reported. Then, this study aims to assess the common symptoms of COVID-19 1st dose vaccinations among the following groups: gender (male and female college students), age, body weight, and height. The observed symptoms include sore arms, fatigue, headache, fever with a body temperature above 38 {degrees}C, nausea, shivering, and muscle joint pain. Participants in this study were students at the university. They were considered eligible for this study if they were currently enrolled at university, were at least 19 years of age, and provided informed consent. The data was recorded using a standardized online questionnaire. The answers were collected in an online database. At the beginning of the questionnaire, subjects or students were informed that data would be collected anonymously. Based on the results, the symptoms were different between female and male students. In fact, female students have experienced more symptoms than male students. While male students only suffered sore arms (68%) followed by headache symptoms (32%). Similar to male students, sore arms are the most common symptom observed among female students. Among female students, from the most to the least common symptoms observed from 20 years of age in this study are sore arms at site reaction > headache > fatigue > fever > muscle joint pain > shivering > nausea. A higher risk of presenting fatigue and headache symptoms was found in those with a non-overweight status with weight ranges of 50-60 kg.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.22.21268233\",\"title\":\"The shape of cancer relapse: Topological data analysis predicts recurrence in paediatric acute lymphoblastic leukaemia\",\"authors\":\"Chulian, S.; Stolz, B. J.; Martinez-Rubio, A.; Blazquez Goni, C.; Rodriguez Gutierrez, J. F.; Caballero Velazquez, T.; Molinos Quintana, A.; Ramirez Orellana, M.; Castillo Robleda, A.; Fuster Soler, J. L.; Minguela Puras, A.; Martinez Sanchez, M. V.; Rosa, M.; Perez-Garcia, V. M.; Byrne, H.\",\"author_corresponding\":\"Salvador Chulian\",\"author_corresponding_institution\":\"Department of Mathematics, Universidad de Cadiz; Biomedical Research and Innovation Institute of Cadiz (INiBICA)\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"hematology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.22.21268233.source.xml\",\"abstract\":\"Acute Lymphoblastic Leukaemia (ALL) is the most frequent paediatric cancer. Modern therapies have improved survival rates, but approximately 15-20 % of patients relapse. At present, patients risk of relapse are assessed by projecting high-dimensional flow cytometry data onto a subset of biomarkers and manually estimating the shape of this reduced data. Here, we apply methods from topological data analysis (TDA), which quantify shape in data via features such as connected components and loops, to pre-treatment ALL datasets with known outcomes. We combine these fully unsupervised analyses with machine learning to identify features in the pre-treatment data that are prognostic for risk of relapse. We find significant topological differences between relapsing and non-relapsing patients and confirm the predictive power of CD10, CD20, CD38, and CD45. Further, we are able to use the TDA descriptors to predict patients who relapsed. We propose three prognostic pipelines that readily extend to other haematological malignancies.\\n\\nTeaserTopology reveals features in flow cytometry data which predict relapse of patients with acute lymphoblastic leukemia\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.25.21268404\",\"title\":\"Cooccurrence of N501Y, P681R and other key mutations in SARS-CoV-2 Spike\",\"authors\":\"Lee, C.; Mangalaganesh, S.; Wilson, L. O.; Kuiper, M. J.; Drew, T. W.; Vasan, S. S.\",\"author_corresponding\":\"Seshadri S Vasan\",\"author_corresponding_institution\":\"Commonwealth Scientific and Industrial Research Organisation\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.25.21268404.source.xml\",\"abstract\":\"Analysis of circa 4.2 million severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome sequences on  Global Initiative on Sharing All Influenza Data (GISAID) shows the spike mutations  N501Y (common to Alpha, Beta, Gamma, Omicron variants) and  P681R (central to Delta variants spread) have cooccurred 3,678 times between 17 October 2020 and 1 November 2021. In contrast, the N501Y+P681H combination is present in Alpha and Omicron variants and circa 1.1 million entries. Two-thirds of the 3,678 cooccurrences were in France, Turkey or US (East Coast), and the rest across 62 other countries. 55.5% and 4.6% of the cooccurrences were Alphas Q.4 and Gammas P.1.8 sub-lineages acquiring P681R; 10.7% and 3.8% were Deltas B.1.617.2 lineage and AY.33 sub-lineage acquiring N501Y; remaining 10.2% were in other variants. Despite the selective advantages individually conferred by N501Y and P681R, the N501Y+P681R combination counterintuitively didnt outcompete other variants in every instance. Although a relief to worldwide public health efforts, in vitro and in vivo studies are urgently required in the absence of a strong in silico explanation for this phenomenon. This study demonstrates a pipeline to analyse combinations of key mutations from public domain information in a systematic manner and provide early warnings of spread.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.26.21268414\",\"title\":\"Interpretable and Predictive Deep Modeling of the SARS-CoV-2 Spike Protein Sequence\",\"authors\":\"Sokhansanj, B. A.; Zhao, Z.; Rosen, G. L.\",\"author_corresponding\":\"Bahrad A Sokhansanj\",\"author_corresponding_institution\":\"Drexel University\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.26.21268414.source.xml\",\"abstract\":\"As the COVID-19 pandemic continues, the SARS-CoV-2 virus continues to rapidly mutate and change in ways that impact virulence, transmissibility, and immune evasion. Genome sequencing is a critical tool, as other biological techniques can be more costly, time-consuming, and difficult. However, the rapid and complex evolution of SARS-CoV-2 challenges conventional sequence analysis methods like phylogenetic analysis. The virus picks up and loses mutations independently in multiple subclades, often in novel or unexpected combinations, and, as for the newly emerged Omicron variant, sometimes with long explained branches. We propose interpretable deep sequence models trained by machine learning to complement conventional methods. We apply Transformer-based neural network models developed for natural language processing to analyze protein sequences. We add network layers to generate sample embeddings and sequence-wide attention to interpret models and visualize multiscale patterns. We demonstrate and validate our framework by modeling SARS-CoV-2 and coronavirus taxonomy. We then develop an interpretable predictive model of disease severity that integrates SARS-CoV-2 spike protein sequence and patient demographic variables, using publicly available data from the GISAID database. We also apply our model to Omicron. Based on knowledge prior to the availability of empirical data for Omicron, we predict: 1) reduced neutralization antibody activity (15-50 fold) greater than any previously characterized variant, varying between Omicron sublineages, and 2) reduced risk of severe disease (by 35-40%) relative to Delta. Both predictions are in accord with recent epidemiological and experimental data.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.21.21268203\",\"title\":\"Home Monitoring for Fever: An Inexpensive Screening Method to Prevent Household Spread of COVID-19\",\"authors\":\"Kim, J.; Threadcraft, M. A.; Xue, W.; Yue, S.; Wenzel, R. P.; Southwick, F. S.\",\"author_corresponding\":\"Frederick S Southwick\",\"author_corresponding_institution\":\"University of Florida College of Medicine\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.21.21268203.source.xml\",\"abstract\":\"The COVID-19 pandemic surge has exceeded testing capacities in many parts of the world. We investigated the effectiveness of home temperature monitoring for early identification of COVID-19 patients.\\n\\nStudy DesignWe compared home temperature measurements from a convenience sample of 1180 individuals who reported being test positive for SARS-CoV-2 to an age, sex, and location matched control group of 1249 individuals who had not tested positive.\\n\\nMethodsAll individuals monitored their temperature at home using an electronic smartphone thermometer that relayed temperature measurements and symptoms to a centralized cloud based, de-identified data bank.\\n\\nResultsIndividuals varied in the number of times they monitored their temperature. When temperature was monitored for over 72 hours fever (> 37.6{degrees}C or 99.7{degrees}F or a change in temperature of > 1{degrees}C or 1.8{degrees}F) was detected in 73% of test positive individuals, a sensitivity comparable to rapid SARS-CoV-2 antigen tests. When compared our control group the specificity of fever for COVID-19 was 0.70. However, when fever was combined with complaints of loss of taste and smell, difficulty breathing, fatigue, chills, diarrhea, or stuffy nose the odds ratio of having COVID-19 was sufficiently high as to obviate the need to employ RTPCR or antigen testing to screen for and isolate coronavirus infected cases.\\n\\nConclusionsOur findings suggest that home temperature monitoring could serve as an inexpensive convenient screen for the onset of COVID-19, encourage earlier isolation of potentially infected individuals, and more effectively reduce the spread of infection in closed spaces.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.21.21268209\",\"title\":\"Risk of Myopericarditis following COVID-19 mRNA vaccination in a Large Integrated Health System: A Comparison of Completeness and Timeliness of Two Methods\",\"authors\":\"Sharff, K.; Dancoes, D. M.; Longueil, J. L.; Johnson, E. S.; Lewis, P. F.\",\"author_corresponding\":\"Katie Sharff\",\"author_corresponding_institution\":\"Kaiser Permanente Northwest\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.21.21268209.source.xml\",\"abstract\":\"PurposeHow completely do hospital discharge diagnoses identify cases of myopericarditis after an mRNA vaccine?\\n\\nMethodsWe assembled a cohort 12 to 39 years old patients, insured by Kaiser Permanente Northwest, who received at least one dose of an mRNA vaccine (Pfizer-BioNTech or Moderna) between December 2020 and October 2021. We followed them for up to 30 days after their second dose of an mRNA vaccine to identify encounters for myocarditis, pericarditis or myopericarditis. We compared two identification methods: A method that searched all encounter diagnoses using a brief text description (e.g., ICD-10-CM code I40.9 is defined as  acute myocarditis, unspecified). We searched the text description of all inpatient or outpatient encounter diagnoses (in any position) for \\\"myocarditis\\\" or \\\"pericarditis.\\\" The other method was developed by the Centers for Disease Control and Preventions Vaccine Safety Datalink (VSD), which searched for emergency department visits or hospitalizations with a select set of discharge ICD-10-CM diagnosis codes. For both methods, two physicians independently reviewed the identified patient records and classified them as confirmed, probable or not cases using the CDCs case definition.\\n\\nResultsThe encounter methodology identified 14 distinct patients who met the confirmed or probable CDC case definition for acute myocarditis or pericarditis with an onset within 21 days of receipt of COVID-19 vaccination. Three of these 14 patients had an ICD-10 code of I51.4 \\\"Myocarditis, Unspecified\\\" which was overlooked by the VSD algorithm. The VSD methodology identified 11 patients who met the CDC case definition for acute myocarditis or pericarditis. Seven (64%) of the eleven patients had initial care for myopericarditis outside of a KPNW facility and their diagnosis could not be ascertained by the VSD methodology until claims were submitted (median delay of 33 days; range of 12-195 days). Among those who received a second dose of vaccine (n=146,785), we estimated a risk as 95.4 cases of myopericarditis per million second doses administered (95% CI, 52.1 to 160.0).\\n\\nConclusionWe identified additional valid cases of myopericarditis following an mRNA vaccination that would be missed by the VSDs search algorithm, which depends on select hospital discharge diagnosis codes. The true incidence of myopericarditis is markedly higher than the incidence reported to US advisory committees. The VSD should validate its search algorithm to improve its sensitivity for myopericarditis.\\n\\nKey PointsO_LIWe identified a higher estimate of myopericarditis following COVID-19 mRNA vaccine by searching encounter text description compared with the Vaccine Safety Datalink (VSD) methodology\\nC_LIO_LIAn incomplete list of ICD-10 codes and delays in hospital claims data were responsible for the difference\\nC_LIO_LIWe estimated a risk of 95.4 cases of myopericarditis per million second doses administered in patients age 12-39 which is higher than the incidence reported to US advisory committees\\nC_LIO_LIWe encourage other VSD sites to validate the case ascertainment of current VSD methodology\\nC_LI\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.21.21268157\",\"title\":\"Transmission of SARS-CoV-2 among children and staff in German daycare centers: results from the COALA study\",\"authors\":\"Loss, J.; Wurm, J.; Varnaccia, G.; Schienkiewitz, A.; Iwanowski, H.; Loer, A.-K.; Allen, J.; Wess, B.; Schaffrath Rosario, A.; Damerow, S.; Kuttig, T.; Perlitz, H.; Hornbacher, A.; Finkel, B.; Krause, C.; Wormsbaecher, J.; Sandoni, A.; Kubisch, U.; Eggers, K.; Nitsche, A.; Radonic, A.; Trappe, K.; Drechsel, O.; Klaper, K.; Franke, A.; Huether, A.; Buchholz, U.; Haas, W.; Wieler, L. H.; Jordan, S.\",\"author_corresponding\":\"Julika Loss\",\"author_corresponding_institution\":\"Department of Epidemiology and Health Monitoring, Robert Koch Institute, Berlin, Germany\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.21.21268157.source.xml\",\"abstract\":\"BackgroundWhereas the majority of children under 6 years of age attend daycare centers in Germany, evidence on the role of daycare centers in the transmission of SARS-CoV-2 is scarce.\\n\\nAimsThis study aims to investigate the transmission risk in daycare centers among children and staff and the spread of infections to associated households.\\n\\nMethods30 daycare groups with at least one recent laboratory-confirmed SARS-CoV-2 case (child or staff) were enrolled in the study (10\\/2020-06\\/2021). Close contacts within the daycare group and households were examined over a 12-day period (repeated SARS-CoV-2 PCR tests, genetic sequencing of viruses, documentation of symptoms). Households, local health authorities and daycare staff were interviewed to gain comprehensive information on each outbreak. We determined primary cases for all daycare groups.\\n\\nResultsThe number of secondary cases varied considerably between daycare groups. The pooled secondary attack rate (SAR) across all 30 daycare centers was 9.6%. The SAR tended to be higher in daycare centers in which the Alpha variant of the virus was detected (15.9% vs. 5.1% with evidence of wild type). The SAR in households was 53.3%. Exposed children were less likely to get infected with SARS-CoV-2 in daycare centers, compared to adults (7.7% vs. 15.5%).\\n\\nConclusionContainment measures in daycare programs are critical and become increasingly important with highly transmissible new variants to reduce SARS-CoV-2 transmission, especially to avoid spread to associated households. Virus variants may modify transmission dynamics in daycare programs.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.23.21268184\",\"title\":\"Controlling the worldwide chaotic spreading of COVID-19 through vaccinations\",\"authors\":\"Bonasera, A.; zheng, h.\",\"author_corresponding\":\"Aldo Bonasera\",\"author_corresponding_institution\":\"texas A&M university\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.23.21268184.source.xml\",\"abstract\":\"The striking differences and similarities between the  Spanish-flu of 1918 and the Coronavirus disease of 2019 (COVID-19) are analyzed. Progress in medicine and technology and in particular the availability of vaccines has decreased the death probability from about 2% for the Spanish-flu, to about 10-4 in the UK and 10-3 in Italy, USA, Canada, San Marino and other countries for COVID-19. The logistic map reproduces most features of the disease and may be of guidance for predictions and future steps to be taken in order to contrast the virus. We estimate 6.4 x 107 deceases worldwide without the vaccines, this value decreases to 2.4 x 107 with the current vaccination rate. In November 2021, the number of deceased worldwide was 5.1 x 106. To reduce the fatalities further, it is imperative to increase the vaccination rate worldwide to at least 120 millions\\/day and the AstraZeneca vaccine due to its efficacity and cost is a possible route to accomplish this.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.21.21268197\",\"title\":\"Antibody therapy reverses biological signatures of COVID-19 progression\",\"authors\":\"Maher, M. C.; Soriaga, L. B.; Gupta, A.; di Iulio, J.; Ledoux, S.; Smithey, M. J.; Cathcart, A. L.; McKusick, K.; Sun, D.; Aldinger, M.; Alexander, E.; Purcell, L.; Ding, X.; Peppercorn, A. F.; Austin, D. J.; Mogalian, E.; Yeh, W. W.; Shapiro, A. E.; Corti, D.; Virgin, H. W.; Pang, P. S.; Telenti, A.\",\"author_corresponding\":\"Amalio Telenti\",\"author_corresponding_institution\":\"Vir Biotechnology\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.21.21268197.source.xml\",\"abstract\":\"Understanding who is at risk of progression to severe COVID-19 is key to effective treatment. We studied correlates of disease severity in the COMET-ICE clinical trial that randomized 1:1 to placebo or to sotrovimab, a monoclonal antibody for the treatment of SARS-CoV-2 infection. Several laboratory parameters identified study participants at greater risk of severe disease, including a high neutrophil-lymphocyte ratio (NLR), a negative SARS-CoV-2 serologic test and whole blood transcriptome profiles. Sotrovimab treatment in these groups was associated with normalization of NLR and the transcriptomic profile, and with a decrease of viral RNA in nasopharyngeal samples. Transcriptomics provided the most sensitive detection of participants who would go on to be hospitalized or die. To facilitate timely measurement, we identified a 10-gene signature with similar predictive accuracy. In summary, we identified markers of risk for disease progression and demonstrated that normalization of these parameters occurs with antibody treatment of established infection.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.22.21268201\",\"title\":\"Reliably Assessing Duration of Protection for COVID-19 Vaccines\",\"authors\":\"Lin, D.; Zeng, D.; Gu, Y.; Fleming, T.; Krause, P.\",\"author_corresponding\":\"Danyu Lin\",\"author_corresponding_institution\":\"University of North Carolina\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.22.21268201.source.xml\",\"abstract\":\"Decision-making about booster dosing for COVID-19 vaccine recipients hinges on reliable methods for evaluating the longevity of vaccine protection. We show that modeling of protection as a piecewise linear function of time since vaccination for the log hazard ratio of the vaccine effect provides more reliable estimates of vaccine effectiveness at the end of an observation period and also more reliably detects plateaus in protective effectiveness as compared with the traditional method of estimating a constant vaccine effect over each time period. This approach will be useful for analyzing data pertaining to COVID-19 vaccines and other vaccines where rapid and reliable understanding of vaccine effectiveness over time is desired.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.20.21267877\",\"title\":\"Immunosequencing and epitope mapping reveal substantial preservation of the T cell immune response to Omicron generated by SARS-CoV-2 vaccines\",\"authors\":\"May, D. H.; Rubin, B. E. R.; Dalai, S. C.; Patel, K.; Shafiani, S.; Elyanow, R.; Noakes, M. T.; Snyder, T. M.; Robins, H. S.\",\"author_corresponding\":\"Harlan S. Robins\",\"author_corresponding_institution\":\"Adaptive Biotechnologies\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.20.21267877.source.xml\",\"abstract\":\"The Omicron SARS-CoV-2 variant contains 34 mutations in the spike gene likely impacting protective efficacy from vaccines. We evaluated the potential impact of these mutations on the cellular immune response. Combining epitope mapping to SARS-CoV-2 vaccines that we have determined from past experiments along with T cell receptor (TCR) repertoire sequencing from thousands of vaccinated or naturally infected individuals, we estimate the abrogation of the cellular immune response in Omicron. Although 20% of CD4+ T cell epitopes are potentially affected, the loss of immunity mediated by CD4+ T cells is estimated to be slightly above 30% as some of the affected epitopes are relatively more immunogenic. For CD8+ T cells, we estimate a loss of approximately 20%. These reductions in T cell immunity are substantially larger than observed in other widely distributed variants. Combined with the expected substantial loss of neutralization from antibodies, the overall protection provided by SARS-CoV-2 vaccines could be impacted adversely. From analysis of prior variants, the efficacy of vaccines against symptomatic infection has been largely maintained and is strongly correlated with the T cell response but not as strongly with the neutralizing antibody response. We expect the remaining 70% to 80% of on-target T cells induced by SARS-CoV-2 vaccination to reduce morbidity and mortality from infection with Omicron.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.20.21268130\",\"title\":\"High Rate of Asymptomatic Carriage Associated with Variant Strain Omicron\",\"authors\":\"Garret, N.; Tapley, A.; Andriesen, J.; Seocharan, I.; Fisher, L. H.; Bunts, L.; Espy, N.; Wallis, C.; Randhawa, A. K.; Goga, A.; Bekker, L.-G.; Gray, G. E.; Corey, L.\",\"author_corresponding\":\"Lawrence Corey\",\"author_corresponding_institution\":\"Fred Hutchinson Cancer Research Center\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.20.21268130.source.xml\",\"abstract\":\"The early widespread dissemination of Omicron indicates the urgent need to better understand the transmission dynamics of this variant, including asymptomatic spread among immunocompetent and immunosuppressed populations. In early December 2021, the Ubuntu clinical trial, designed to evaluate efficacy of the mRNA-1273 vaccine (Moderna) among persons living with HIV (PLWH), began enrolling participants. Nasal swabs are routinely obtained at the initial vaccination visit, which requires participants to be clinically well to receive their initial jab. Of the initial 230 participants enrolled between December 2 and December 17, 2021, 71 (31%) were PCR positive for SARS-CoV-2: all of whom were subsequently confirmed by S gene dropout to be Omicron; 48% of the tested samples had cycle threshold (CT) values <25 and 18% less than 20, indicative of high titers of asymptomatic shedding. Asymptomatic carriage rates were similar in SARS-CoV-2 seropositive and seronegative persons (27% respectively). These data are in stark contrast to COVID-19 vaccine studies conducted pre-Omicron, where the SARS-CoV-2 PCR positivity rate at the first vaccination visit ranged from <1%-2.4%, including a cohort of over 1,200 PLWH largely enrolled in South Africa during the Beta outbreak. We also evaluated asymptomatic carriage in a sub study of the Sisonke vaccine trial conducted in South African health care workers, which indicated 2.6% asymptomatic carriage during the Beta and Delta outbreaks and subsequently rose to 16% in both PLWH and PHLWH during the Omicron period.\\n\\nThese findings strongly suggest that Omicron has a much higher rate of asymptomatic carriage than other VOC and this high prevalence of asymptomatic infection is likely a major factor in the widespread, rapid dissemination of the variant globally, even among populations with high prior rates of SARS-COV-2 infection.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.24.21268387\",\"title\":\"The Canadian COVID-19 Experiences Survey: Study Protocol\",\"authors\":\"Hall, P.; Fong, G.; Hitchman, S.; Quah, A.; Agar, T.; Meng, G.; Sakib, M. N.; Hudson, A.; Boudreau, C.\",\"author_corresponding\":\"Peter Hall\",\"author_corresponding_institution\":\"University of Waterloo\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.24.21268387.source.xml\",\"abstract\":\"IntroductionVaccine hesitancy and inconsistent mitigation behavior performance have been significant challenges throughout the COVID-19 pandemic. In Canada, despite relatively high vaccine availability and uptake, willingness to accept booster shots and maintain mitigation behaviors in the post-acute phase of COVID-19 remain uncertain. The aim of the Canadian COVID-19 Experiences Project (CCEP) is two-fold: 1) to identify social-cognitive and neurocognitive correlates of vaccine hesitancy and mitigation behaviors, and 2) to identify optimal communication strategies to promote vaccination and mitigation behaviors into the post-acute phase of the pandemic.\\n\\nMethods and analysesThe CCEP is comprised of two components: a conventional population survey (Study 1) and a functionally interconnected laboratory study (Study 2). Study 1 will involve 3 waves of data collection. Wave 1, completed between 28 September and 21 October, 2021, recruited 1,958 vaccine-hesitant (49.8%) and fully vaccinated (50.2%) adults using quota sampling to ensure maximum statistical power. Measures included a variety of social cognitive (e.g., beliefs, intentions) and neurocognitive (e.g., delay discounting) measures, followed by an opportunity to view and rate a set of professionally produced COVID-19 public service announcement (PSA) videos for perceived efficacy. Study 2 employs the same survey items and PSAs but coupled with lab-based eye tracking and functional brain imaging to directly quantify neural indicators of attention capture and self-reflection in a smaller community sample. In the final phase of the project, subjective impressions and neural indicators of PSA efficacy will be compared and used to inform recommendations for construction of COVID-19 PSAs into the post-acute phase of the pandemic.\\n\\nEthics and disseminationThe CCEP has received ethical review and approval by the University of Waterloo Office of Research Ethics. Findings will be disseminated through peer-reviewed publications and presentations at scientific meetings.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.25.21268392\",\"title\":\"BNT162b2 boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19\\/BNT162b2 vaccination against COVID-19\",\"authors\":\"Behrens, G. M.; Barros-Martins, J.; Cossmann, A.; Morillas Ramos, G.; Stankov, M. V.; Odak, I.; Dopfer-Jablonka, A.; Hetzel, L.; Koehler, M.; Patzer, G.; Binz, C.; Ritter, C.; Friedrichsen, M.; Schultze-Florey, C. R.; Inga, R.; Willenzon, S.; Bubke, A.; Rispenpart, J.; Janssen, A.; Ssebyatika, G.; Bernhardt, G.; Hoffmann, M. R.; Poehlmann, S.; Krey, T.; Bosnjak, B.; Hammerschmidt, S. I.; Foerster, R.\",\"author_corresponding\":\"Reinhold Foerster\",\"author_corresponding_institution\":\"Hannover Medical School\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.25.21268392.source.xml\",\"abstract\":\"Reports suggest that COVID-19 vaccine effectiveness is decreasing, either due to waning immune protection, emergence of new variants of concern, or both. Heterologous prime\\/boost vaccination with a vector-based approach (ChAdOx-1nCov-19, ChAd) followed by an mRNA vaccine (e.g. BNT162b2, BNT) appeared to be superior in inducing protective immunity, and large scale second booster vaccination is ongoing. However, data comparing declining immunity after homologous and heterologous vaccination as well as effects of a third vaccine application after heterologous ChAd\\/BNT vaccination are lacking. We longitudinally monitored immunity in ChAd\\/ChAd (n=41) and ChAd\\/BNT (n=88) vaccinated individuals and assessed the impact of a second booster with BNT in both groups. The second booster greatly augmented waning anti-spike IgG but only moderately increased spike-specific CD4+ and CD8+ T cells in both groups to cell frequencies already present after the boost. More importantly, the second booster efficiently restored neutralizing antibody responses against Alpha, Beta, Gamma, and Delta, but neutralizing activity against B.1.1.529 (Omicron) stayed severely impaired. Our data suggest that inferior SARS-CoV-2 specific immune responses after homologous ChAd\\/ChAd vaccination can be cured by a heterologous BNT vaccination. However, prior heterologous ChAd\\/BNT vaccination provides no additional benefit for spike-specific T cell immunity or neutralizing Omicron after the second boost.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.25.21268336\",\"title\":\"Durability of Response to a Third BNT162b2 Vaccine in Adults >=60 Years\",\"authors\":\"Eliakim Raz, N.; Stemmer, A.; Leibovici-Weissman, Y.; Ness, A.; Awwad, M.; Ghantous, N.; Erez, N.; Bareket-Samish, A.; Levy-Barda, A.; Ben-Zvi, H.; Moskovits, N.; Bar-Haim, E.; Stemmer, S.\",\"author_corresponding\":\"Salomon Stemmer\",\"author_corresponding_institution\":\"Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.25.21268336.source.xml\",\"abstract\":\"BackgroundAge\\/frailty are strong predictors of COVID-19 mortality. After the second BNT162b2 dose, immunity wanes faster in older ([&ge;]65 years) versus younger adults. The durability of response after the third vaccine is unclear.\\n\\nMethodsThis prospective cohort study included healthcare workers\\/family members[&ge;]60 years who received a third BNT162b2 dose. Blood samples were drawn immediately before (T0), 10{square}19 (T1), and 74{square}103 (T2) days after the third dose. Anti-spike IgG titers were determined using a commercial assay, seropositivity was defined as[&ge;]50 AU\\/mL. Neutralising antibody titres were determined at T2. Adverse events, COVID-19 infections, and clinical frailty scale (CFS) levels were documented.\\n\\nFindingsThe analysis included 97 participants (median age, 70 years [IQR, 66{square}74], 58% CFS level 2). IgG titres, which increased significantly from T0 to T1 (medians, 440 AU\\/mL [IQR, 294{square}923] and 25,429 [14203{square}36114] AU\\/mL, respectively; p<0{middle dot}001), decreased significantly by T2, but all remained seropositive (median, 8306 AU\\/mL [IQR, 4595{square}14701], p<0{middle dot}001 vs T1). In a multivariable analysis, only time from the first vaccine was significantly associated with lower IgG levels at T2 (p=0{middle dot}004). At T2, 60 patients were evaluated for neutralising antibodies; all were seropositive (median, 1294 antibody titre [IQR, 848{square}2072]). Neutralising antibody and anti-spike IgG levels were correlated (R=0{middle dot}6, p<0{middle dot}001). No major adverse events or COVID-19 infections were reported.\\n\\nInterpretationAnti-spike IgG and neutralising antibody levels remain adequate 3 months after the third BNT162b2 vaccine in healthy adults[&ge;]60 years, although the decline in IgG is concerning. A third vaccine dose in this population should be top priority.\\n\\nFundingNo external funding.\\n\\nResearch in contextO_ST_ABSEvidence before this studyC_ST_ABSWe searched PubMed on Aug 1, 2021, for published research articles with no date restrictions, using the search terms of \\\"SARS-Cov-2\\\", \\\"COVID-19\\\", \\\"vaccine\\\", \\\"dose\\\", \\\"antibody response\\\", and \\\"adults\\\" with English as a filter. Several studies were identified that investigated waning of immunity in healthy adults. It is well established through epidemiology and serology studies that in healthy adults, the protection conferred by the BNT162b2 messenger RNA (mRNA) vaccine (Pfizer\\/BioNtech) wanes significantly after several months. Studies have also shown that the immune response to the vaccine varies with age, and that after the second dose of the BNT162b2 vaccine, the older adult population (65-85 years of age) typically has a lower immune response (as reflected in an analysis of anti-spike IgG antibodies and neutralising antibody titres), than younger adults (18-55 years of age), and that the immunity wanes in all age groups within several months.\\n\\nAdded value of this studyThis is, to our knowledge, the first study that examined anti-spike IgG and neutralising antibody titres three months after the third BNT162b2 vaccine dose. The study has demonstrated that three months after that dose, participants, who were healthy adults aged 60 years and older, remained anti-spike IgG seropositive, although a significant decrease in anti-spike IgG titres was observed (compared to two weeks after the third dose). In addition, a statistically significant correlation was observed between the neutralising antibody titres and the anti-spike IgG titres, and all participants were seropositive for neutralising antibodies three months after the third dose. Also, no major adverse events or COVID-19 infections were reported.\\n\\nImplications of all the available evidenceAs our data suggest that a third dose of the BNT162b2 vaccine is effective in maintaining adequate immune response against COVID-19 for at least several months in healthy adults aged 60 years and older, and as it is well established that older adults are at higher risk of severe COVID-19 disease and COVID-19 mortality, providing a third dose to this population should be a top priority. Our data also highlight that understanding the waning of the immune response in other age groups is key for making evidence-based policies regarding booster vaccinations for the population at large.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.22.21268219\",\"title\":\"Detection of the omicron variant virus with the Abbott BinaxNow SARS-CoV-2 Rapid Antigen Assay\",\"authors\":\"Regan, J.; Flynn, J.; Choudhary, M.; Uddin, R.; Lemieux, J.; Boucau, J.; Bhattacharyya, R.; Barczak, A. K.; Li, J. Z. K.; Siedner, M.\",\"author_corresponding\":\"Mark Siedner\",\"author_corresponding_institution\":\"Massachusetts General Hospital\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.22.21268219.source.xml\",\"abstract\":\"The US Centers for Disease Control and Prevention recommends rapid testing for SARS-CoV-2 infection as a key element of epidemic control. The Abbott BinaxNow is in widespread use in the United States for self-testing and as part of public health screening campaigns, but has not been evaluated for use with the omicron variant of SARS-CoV-2. We recruited individuals testing positive for COVID-19 PCR at an academic medical center. Anterior nasal swabs were stored in viral transport media and evaluated by viral load quantification and whole genome sequencing. We created serial dilutions from 2.5x103-2.5x105 viral copies\\/specimen for two delta and omicron specimens, respectively, and tested each with the BinaxNow assay per manufacturer instructions. Results were interpreted by three readers, blinded to the specimen variant and concentration. All omicron and delta specimens with concentrations of 100,000 copies\\/swab or greater were positive by the BinaxNow Assay, a concentration similar to previously reported limits of detection for this assay. Assay sensitivity diminished below that. This study demonstrates that Omicron variant SARS-CoV-2 infections are detected by the BinaxNow rapid antigen assay. Additional laboratory and clinical validation assessments are needed to better determine their limits of detection and performance in real-world settings.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.21.21268058\",\"title\":\"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil\",\"authors\":\"Cerqueira-Silva, T.; Andrews, J. R.; Boaventura, V. S.; Ranzani, O. T.; Oliveira, V. d. A.; Paixao, E. S.; Bertoldo, J.; Machado, T. M.; Hitchings, M. D. T.; Dorion, M.; Lind, M. L.; Penna, G. O.; Cummings, D. A. T.; Dean, N. E.; Werneck, G. L.; Pearce, N.; Barreto, M. L.; Ko, A. I.; Croda, J.; Barral-Netto, M.\",\"author_corresponding\":\"Julio Croda\",\"author_corresponding_institution\":\"Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil; Fiocruz Mato Grosso do Sul, Fundacao Oswaldo Cruz, Campo Grande, MS, Brazil\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.21.21268058.source.xml\",\"abstract\":\"BackgroundCOVID-19 vaccines have proven highly effective among SARS-CoV-2 naive individuals, but their effectiveness in preventing symptomatic infection and severe outcomes among individuals with prior infection is less clear.\\n\\nMethodsUtilizing national COVID-19 notification, hospitalization, and vaccination datasets from Brazil, we performed a case-control study using a test-negative design to assess the effectiveness of four vaccines (CoronaVac, ChAdOx1, Ad26.COV2.S and BNT162b2) among individuals with laboratory-confirmed prior SARS-CoV-2 infection. We matched RT-PCR positive, symptomatic COVID-19 cases with RT-PCR-negative controls presenting with symptomatic illnesses, restricting both groups to tests performed at least 90 days after an initial infection. We used multivariable conditional logistic regression to compare the odds of test positivity, and the odds of hospitalization or death due to COVID-19, according to vaccination status and time since first or second dose of vaccines.\\n\\nFindingsAmong individuals with prior SARS-CoV-2 infection, vaccine effectiveness against symptomatic infection [&ge;] 14 days from vaccine series completion was 39.4% (95% CI 36.1-42.6) for CoronaVac, 56.0% (95% CI 51.4-60.2) for ChAdOx1, 44.0% (95% CI 31.5-54.2) for Ad26.COV2.S, and 64.8% (95% CI 54.9-72.4) for BNT162b2. For the two-dose vaccine series (CoronaVac, ChAdOx1, and BNT162b2), effectiveness against symptomatic infection was significantly greater after the second dose compared with the first dose. Effectiveness against hospitalization or death [&ge;] 14 days from vaccine series completion was 81.3% (95% CI 75.3-85.8) for CoronaVac, 89.9% (95% CI 83.5-93.8) for ChAdOx1, 57.7% (95% CI -2.6-82.5) for Ad26.COV2.S, and 89.7% (95% CI 54.3-97.7) for BNT162b2.\\n\\nInterpretationAll four vaccines conferred additional protection against symptomatic infections and severe outcomes among individuals with previous SARS-CoV-2 infection. Provision of a full vaccine series to individuals following recovery from COVID-19 may reduce morbidity and mortality.\\n\\nFundingBrazilian National Research Council, Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro, Oswaldo Cruz Foundation, JBS S.A., Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, Generalitat de Catalunya.\\n\\nRESEARCH IN CONTEXTO_ST_ABSEvidence before this studyC_ST_ABSWe searched PubMed, medRxiv, and SSRN for articles published from January 1, 2020 until December 15, 2021, with no language restrictions, using the search terms \\\"vaccine effectiveness\\\" AND \\\"previous*\\\" AND (\\\"SARS-CoV-2\\\" OR \\\"COVID-19\\\"). We found several studies evaluating ChAdOx1 and BNT162b2, and one additionally reporting on mRNA-1273 and Ad26.COV2.S, which found that previously infected individuals who were vaccinated had lower risk of symptomatic SARS-CoV-2 infection. One study found that risk of hospitalization was lower for previously infected individuals after a full series of BNT162b2 or mRNA-1273. Limited evidence is available comparing effectiveness of one versus two doses among individuals with prior infection. No studies reported effectiveness of inactivated vaccines among previously infected individuals.\\n\\nAdded value of this studyWe used national databases of COVID-19 case surveillance, laboratory testing, and vaccination from Brazil to investigate effectiveness of CoronaVac, ChAdOx1, Ad26.COV2.S and BNT162b2 among individuals with a prior, laboratory-confirmed SARS-CoV-2 infection. We matched >22,000 RT-PCR-confirmed re-infections with >145,000 RT-PCR-negative controls using a test-negative design. All four vaccines were effective against symptomatic SARS-CoV-2 infections, with effectiveness from 14 days after series completion ranging from 39-65%. For vaccines with two-dose regimens, the second dose provided significantly increased effectiveness compared with one dose. Effectiveness against COVID-19-associated hospitalization or death from 14 days after series completion was >80% for CoronaVac, ChAdOx1and BNT162b2.\\n\\nImplications of all the available evidenceWe find evidence that four vaccines, using three different platforms, all provide protection to previously infected individuals against symptomatic SARS-CoV-2 infection and severe outcomes, with a second dose conferring significant additional benefits. These results support the provision of a full vaccine series among individuals with prior SARS-CoV-2 infection.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.22.21268216\",\"title\":\"Premature Ventricular Contractions During the Recovery Phase of Exercise Are Only Associated with Increased Cardiovascular Mortality when Present Together with Echocardiographic Abnormalities\",\"authors\":\"Lindow, T.; Ekstrom, M.; Brudin, L.; Hedman, K.; Ugander, M.\",\"author_corresponding\":\"Thomas Lindow\",\"author_corresponding_institution\":\"Kolling Institute, Royal North Shore Hospital, and University of Sydney, Sydney, Australia; Department of Clinical Physiology, Research and Development, Vaxjo C\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"cardiovascular medicine\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.22.21268216.source.xml\",\"abstract\":\"BackgroundPremature ventricular contractions (PVCs) during the recovery of exercise stress testing are associated with increased cardiovascular mortality, but the cause remains unknown. We aimed to evaluate the association of PVCs during recovery with abnormalities on echocardiography, and to evaluate their combined prognostic performance.\\n\\nMethodsEchocardiographic abnormalities (reduced left ventricular (LV) ejection fraction, valvular heart disease, LV dilatation, LV hypertrophy, or increased filling pressures) and the presence of PVCs during recovery ([&ge;]1\\/min) were identified among patients having undergone resting echocardiography within median [interquartile range] 0 [0-2] days of an exercise stress test. The association between such changes and cardiovascular mortality was analyzed using Cox regression adjusted for age, sex, clinical and exercise variables.\\n\\nResultsAmong included patients (n=3,106, 219 events, 7.9 [5.4-11.1] years follow-up), PVCs during recovery was found in 1,327 (43%) patients, among which prevalence of echocardiographic abnormalities was increased (58% vs. 43%, p<0.001). Overall, PVCs during recovery was associated with increased cardiovascular mortality (adjusted hazard ratio (HR) [95% confidence interval] 1.6 [1.2-2.1], p<0.001). When combined with echocardiographic abnormalities, PVCs during recovery was only associated with increased risk when such were present (adjusted HR 3.3 [2.0-5.4], p<0.001), and not when absent (adjusted HR 1.4 [0.7-2.6], p=0.26), in reference to those with neither.\\n\\nConclusionPVCs during recovery was associated with increased prevalence of echocardiographic abnormalities. Increased risk of cardiovascular mortality was observed only for subjects with PVCs if concomitant echocardiographic abnormalities were present. This provides a structural explanation for the increased long-term cardiovascular risk among patients with PVCs during recovery.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.25.21268390\",\"title\":\"Associations of mitochondrial DNA copy number with incident risks of gastrointestinal cancers: a prospective case-cohort study\",\"authors\":\"Guan, X.; Li, M.; Bai, Y.; Feng, Y.; Li, G.; Wei, W.; Fu, M.; Li, H.; Wang, C.; Jie, J.; Meng, H.; Wu, X.; Deng, Q.; Li, F.; Yang, H.; Zhang, X.; He, M.; Guo, H.\",\"author_corresponding\":\"Huan Guo\",\"author_corresponding_institution\":\"Huazhong University of Science and Technology\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"epidemiology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.25.21268390.source.xml\",\"abstract\":\"BackgroundEpidemiological investigations implied that inter-individual variations of mitochondrial DNA copy number (mtDNAcn) could trigger predisposition to multiple cancers, but evidence regarding gastrointestinal cancers (GICs) was still uncertain.\\n\\nMethodsWe conducted a case-cohort study within the prospective Dongfeng-Tongji cohort, including incident cases of colorectal cancer (CRC, n=278), gastric cancer (GC, n=138), and esophageal cancer (EC, n=72) as well as a random subcohort (n=1173), who were followed up from baseline to the end of 2018. Baseline blood mtDNAcn was determined with quantitative PCR assay, and associations of mtDNAcn with the GICs risks were estimated by using weighted Cox proportional hazards models.\\n\\nResultsSignificant U-shaped associations were observed between mtDNAcn and risks of CRC, GC, EC, and total GICs. Compared to subjects within the 2nd quartile (Q2) mtDNAcn subgroup, those within the 1st (Q1), 3rd (Q3) and 4th (Q4) quartile subgroups showed increased risks of CRC [HR(95%CI)=2.27(1.47-3.52), 1.65(1.04-2.62), and 2.81(1.85-4.28), respectively] and total GICs [HR(95%CI)=1.84(1.30-2.60), 1.47(1.03-2.10), and 2.51(1.82-3.47), respectively], and those within Q4 subgroup present elevated GC and EC risks [HR(95%CI)=2.16(1.31-3.54) and 2.38(1.13-5.02), respectively]. Similar associations of mtDNAcn with CRC and total GICs risks remained in stratified analyzes by age, gender, and smoking status. Notably, there were joint effects of age and smoking status with mtDNAcn on CRC and total GICs risks.\\n\\nConclusionsThis prospectively case-cohort study showed U-shaped associations between mtDNAcn and incident risks of GICs, but further researches are needed to confirm these results and uncover underlying biological mechanisms.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.22.21268212\",\"title\":\"Dying from COVID-19 or with COVID-19: a definitive answer through a retrospective analysis of mortality in Italy\",\"authors\":\"Rovetta, A.; Bhagavathula, A. S.\",\"author_corresponding\":\"Alessandro Rovetta\",\"author_corresponding_institution\":\"R&C Research\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by\",\"category\":\"epidemiology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.22.21268212.source.xml\",\"abstract\":\"BackgroundCOVID-19 mortality was associated with several reasons, including conspiracy theories and infodemic phenomena. However, little is known about the potential endogenous reasons for the increase in COVID-19 associated mortality in Italy.\\n\\nObjectiveThis study aimed to search the potential endogenous reasons for the increase in COVID-19 mortality recorded in Italy during the year 2020 and evaluate the statistical significance of the latter.\\n\\nMethodsWe analyzed all the trends in the timelapse 2011-2019 related to deaths by age, sex, region, and cause of death in Italy and compared them with those of 2020. Ordinary least squares (OLS) linear regressions and ARIMA (p, d, q) models were applied to investigate the predictions of death in 2020 as compared to death reported in the same year. Grubbs and Iglewicz-Hoaglin tests were used to identify the statistical differences between the predicted and observed deaths. The relationship between mortality and predictive variables was assessed using OLS multiple regression models.\\n\\nResultsBoth ARIMA and OLS linear regression models predicted the number of deaths in Italy during 2020 to be between 640,000 and 660,000 (95% confidence intervals range: 620,000 - 695,000) and these values were far from the observed deaths reported (above 750,000). Significant difference in deaths at national level (P = 0.003), and higher male mortality than women (+18% versus +14%, P < 0.001 versus P = 0.01) was observed. Finally, higher mortality was strongly and positively correlated with latitude (R = 0.82, P < 0.001).\\n\\nConclusionsOur findings support the absence of historical endogenous reasons capable of justifying the increase in deaths and mortality observed in Italy in 2020. Together with the current knowledge on the novel coronavirus 2019, these findings provide decisive evidence on the devastating impact of COVID-19 in Italy. We suggest that this research be leveraged by government, health, and information authorities to furnish proof against conspiracy hypotheses. Moreover, given the marked concordance between the predictions of the ARIMA and OLS regression models, we suggest that these models be exploited to predict mortality trends.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.21.21268143\",\"title\":\"Wastewater sequencing uncovers early, cryptic SARS-CoV-2 variant transmission\",\"authors\":\"Karthikeyan, S.; Levy, J. I.; De Hoff, P.; Humphrey, G.; Birmingham, A.; Jepsen, K.; Farmer, S.; Tubb, H. M.; Valles, T.; Tribelhorn, C. E.; Tsai, R.; Aigner, S.; Sathe, S.; Moshiri, N.; Henson, B.; Hakim, A.; Baer, N. A.; Barber, T.; Belda-Ferre, P.; Chacon, M.; Cheung, W.; Crescini, E. S.; Eisner, E. R.; Lastrella, A. L.; Lawrence, E. S.; Marotz, C. A.; Ngo, T. T.; Ostrander, T.; Plascencia, A.; Salido, R. A.; Seaver, P.; Smoot, E. W.; McDonald, D.; Neuhard, R. M.; Scioscia, A. L.; Satterlund, A. M.; Simmons, E. H.; Aceves, C. M.; Anderson, C.; Gangavarapu, K.; Hufbauer, E.; Kurzban, E.; Lee\",\"author_corresponding\":\"Rob Knight\",\"author_corresponding_institution\":\"Department of Pediatrics, University of California San Diego, La Jolla, CA, USA; Department of Bioengineering, University of California San Diego, La Jolla, CA,\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nd\",\"category\":\"epidemiology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.21.21268143.source.xml\",\"abstract\":\"As SARS-CoV-2 becomes an endemic pathogen, detecting emerging variants early is critical for public health interventions. Inferring lineage prevalence by clinical testing is infeasible at scale, especially in areas with limited resources, participation, or testing\\/sequencing capacity, which can also introduce biases. SARS-CoV-2 RNA concentration in wastewater successfully tracks regional infection dynamics and provides less biased abundance estimates than clinical testing. Tracking virus genomic sequences in wastewater would improve community prevalence estimates and detect emerging variants. However, two factors limit wastewater-based genomic surveillance: low-quality sequence data and inability to estimate relative lineage abundance in mixed samples. Here, we resolve these critical issues to perform a high-resolution, 295-day wastewater and clinical sequencing effort, in the controlled environment of a large university campus and the broader context of the surrounding county. We develop and deploy improved virus concentration protocols and deconvolution software that fully resolve multiple virus strains from wastewater. We detect emerging variants of concern up to 14 days earlier in wastewater samples, and identify multiple instances of virus spread not captured by clinical genomic surveillance. Our study provides a scalable solution for wastewater genomic surveillance that allows early detection of SARS-CoV-2 variants and identification of cryptic transmission.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.22.21268232\",\"title\":\"Understanding the impact of the COVID-19 pandemic on a socially deprived UK coastal town: a preliminary exploratory analysis of health and socioeconomic data\",\"authors\":\"French, M.; Spencer, M.; Walker, M.; Patel, A.; Clarke, N.; Hughes, R.; Taylor, C.; Orwin, M.; Elliott, A.; Worsley, K.; Casson, J.; Milan, S.; Bowen, M.; Sedda, L.\",\"author_corresponding\":\"Maddy French\",\"author_corresponding_institution\":\"Lancaster University\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"epidemiology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.22.21268232.source.xml\",\"abstract\":\"IntroductionIn addition to the direct impact of COVID-19 infections on health and mortality, a growing body of literature indicates there are wide-ranging indirect impacts of the COVID-19 pandemic and associated public health measures on population health and wellbeing. Exploring these indirect impacts in the context of a socially deprived UK coastal town will help identify priority areas to focus COVID-19 recovery efforts on.\\n\\nMethodsData on primary care diagnosis, hospital admissions, and several socioeconomic outcomes between 2016 and Spring 2021 in the UK town of Fleetwood were collected and analysed in an exploratory analysis looking at pre- and post-COVID-19 patterns in health and social outcomes. Weekly and monthly trends were plotted by time and differences between periods examined using Chi-squared and t-tests.\\n\\nResultsInitial falls in hospital admissions and diagnoses of conditions in primary care in March 2020 were followed by sustained changes to health service activity for specific diagnostic and demographic groups, including for chronic kidney disease and young people. Increases in the number of people receiving Universal Credit and children eligible for free school meals appear to be greater for those in the least deprived areas of the town.\\n\\nDiscussionThese exploratory findings provide initial evidence of the sustained impact of the pandemic across several health and social outcomes. Examining these trends in multivariate analyses will further test these associations and establish the strength of the medium term impact of the pandemic on the population of this coastal town. Advanced modelling of this data is ongoing and will be published shortly.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.26.21268434\",\"title\":\"Use of Baricitinib in Treatment of COVID-19: A Systematic Review\",\"authors\":\"Sampath, A.; Banerjee, A.; Atal, S.; Jhaj, R.\",\"author_corresponding\":\"Shubham Atal\",\"author_corresponding_institution\":\"AIIMS Bhopal\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"respiratory medicine\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.26.21268434.source.xml\",\"abstract\":\"ObjectivesTo assess the role of baricitinib alone or in combination with other therapies as a treatment for patients with COVID-19.\\n\\nMethodsSystematic literature search was conducted in the WHO COVID-19 Coronavirus disease database to find clinical studies on use of baricitinib for treatment of COVID-19 between December 1st 2019 and September 30th 2021. Two independent set of reviewers identified the eligible studies fulfilling the inclusion criteria, and relevant data was extracted and a qualitative synthesis of evidence performed. The risk of bias was evaluated with validated tools.\\n\\nResultsA total of 267 articles were found to be eligible after primary screening of title and abstracts. Following assessment of full texts, 19 studies were finally included for this systematic review, out of which 16 are observational, and 3 are interventional studies. Collating the results from these observational and interventional studies, baricitinib used as add on to standard therapy, either alone or in combination with other drugs, was found to have favourable outcomes in moderate to severe hospitalised patients with COVID-19. Furthermore, ongoing trials indicate that drug is being extensively studied across the world for its safety and efficacy in COVID-19.\\n\\nConclusionBaricitinib significantly improves clinical outcomes in hospitalized patients with COVID-19 pneumonia and further evidence may establish the drug as a standard treatment among such patients.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.21.21268110\",\"title\":\"The Health Effects of Chunga Dumpsite on surrounding communities in Lusaka, Zambia.\",\"authors\":\"Chibwe, W.; Mbewe, A.; Hazemba, A. N.\",\"author_corresponding\":\"Wilson Chibwe\",\"author_corresponding_institution\":\"The University of Zambia , School of Natural Sciences, Department of Physics, P.O. Box 32379, Lusaka , ZAMBIA.\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"occupational and environmental health\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.21.21268110.source.xml\",\"abstract\":\"BackgroundDumpsites in low and middle income countries (LMICs) are commonly used for solid waste disposal as opposed to landfills. However, these are naturally unsanitary hence provide ideal conditions for breeding of disease transmitting agents and become predisposing factors for spread of diseases and infections to surrounding communities. This study aimed at determining the Health Effects of Chunga Dumpsite on surrounding communities in Lusaka, Zambia.\\n\\nDesign and MethodsThis was a mixed method design and employed a cross sectional approach and case study conducted concurrently. Communities were stratified by distance into Stratum One (within 250 meters radius) and Two (above 250 to 500 meters). Quantitative data were collected from total 200 households thus 100 households from each stratum by using self-administered questionnaires. Qualitative data were collected from Two Key informants from the Local Authority and 15 participants using semi-structured interview guide. Both data were collected from December 22nd, 2018 to February 18th, 2019.\\n\\nResultsResults revealed that smoke and various gasses emitted from burning and decomposing waste compromised quality of air in surrounding communities. Communities were infested with flies, mosquitoes and vermin. Consequently, (73.5%) complained of persistent coughing, (65.1%) suffered from malaria, (72.6%) complained of persistent headaches and (62.2%) had frequent diarrhoea cases in stratum one. Respiratory problems were more pronounced at night possibly due to high humidity which hindered pollutants to easily escape. However, these cases reduced drastically in stratum two.\\n\\nConclusionsUnsanitary dumpsites in LMICs including Zambia are commonly used as solid waste disposal facilities as opposed to sanitary landfills and become predisposing factors for spread of diseases. Short proximities to dumpsites by unplanned human settlements cause serious environmental challenges leading to public health risks to surrounding communities.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.21.21268094\",\"title\":\"Development and validation of blood-based predictive biomarkers for response to PD-(L)-1 checkpoint inhibitors: evidence of a universal systemic core of 3D immunogenetic profiling across multiple oncological indications.\",\"authors\":\"Hunter, E.; Dizfouli, M.; Koutsothanasi, C.; Wilson, A.; Santos, F. C.; Salter, M.; Westra, J.; Powell, R.; Dring, A.; Egan, B.; Parnall, M.; Thacker, M.; Green, J.; Ramadass, A.; Ng, S.; Lim, C. R.; Keat, C. S.; Suan, A. T.; Raman, R.; Fatt, H. K.; Wei Luen, F. L.; Heaton, R.; Levine, J.; Akoulitchev, A.\",\"author_corresponding\":\"Alexandre Akoulitchev\",\"author_corresponding_institution\":\"Oxford BioDynamics Plc, Oxford, UK\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by\",\"category\":\"oncology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.21.21268094.source.xml\",\"abstract\":\"Unprecedented advantages in cancer treatment with immune checkpoint inhibitors (ICI) remain limited to a subset of patients. Systemic analyses of the regulatory 3D genome architecture linked to individual epigenetics and immunogenetic controls associated with tumour immune evasion mechanisms and immune checkpoint pathways reveals a highly prevalent patient molecular profiles predictive of response to PD-(L)1 immune checkpoint inhibitors. A clinical blood test based on the set of 8 3D genomic biomarkers has been developed and validated on several independent cancer patient cohorts to predict response to PD-(L)1 immune checkpoint inhibition. The predictive 8 biomarker set is derived from prospective observational clinical trials, representing 229 treatments with Pembrolizumab, Atezolizumab, Durvalumab, in diverse indications: melanoma, non-small cell lung, urethral, hepatocellular, bladder, prostate cancer, head and neck, vulvar, colon, breast, bone, brain, lymphoma, larynx cancer, and cervix cancers.\\n\\nThe 3D genomic 8 biomarker panel for response to immune checkpoint therapy achieved high accuracy up to 85%, sensitivity of 93% and specificity of 82%. This study demonstrates that a 3D genomic approach could be used to develop a predictive clinical assay for response to PD-(L)1 checkpoint inhibition in cancer patients.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.26.21268420\",\"title\":\"NATIONAL SCALE REAL-TIME SURVEILLANCE OF SARS-COV-2 VARIANTS DYNAMICS BY WASTEWATER MONITORING IN ISRAEL\",\"authors\":\"Bar-Or, I.; Indenbaum, V.; Weil, M.; Elul, M.; Levi, N.; Aguvaev, I.; Cohen, Z.; Levy, V.; Azar, R.; Mannasse, B.; Shirazi, R.; Buchris, E.; Zuckerman, N. S.; Sela Brown, A.; Sofer, D.; Mor, O.; Mendelson, E.; Erster, O.\",\"author_corresponding\":\"Oran Erster\",\"author_corresponding_institution\":\"Central Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Center, Ramat Gan, Israel\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.26.21268420.source.xml\",\"abstract\":\"In this report, we describe a national-scale monitoring of the SARS-COV-2 (SC-2) variant dynamics in Israel, using multiple-time sampling of twelve wastewater treatment plants. We used a combination of inclusive and selective quantitative PCR assays that specifically identify variants A19 or B.1.1.7 and tested each sample for the presence and relative viral RNA load of each variant. We show that between December-2020 and March-2021, a complete shift in the SC-2 variant circulation was observed, where the B.1.1.7 replaced the A19 in all examined test points. We further show that the normalized viral load (NVL) values and the average new cases per week reached a peak in January 2021, and then decreased gradually in almost all test points, in parallel with the progression of the national vaccination campaign, during February-March 2021. This study demonstrates the importance of monitoring SC-2 variant dynamics on a national scale through wastewater sampling. It also provides a proof-of-concept methodology for continuous surveillance by using a combination of inclusive and selective PCR tests, which is far more amendable for high throughput monitoring compared with sequencing. This approach may be useful for real-time dynamics surveillance of current and future variants, such as the Omicron (BA.1) variant.\\n\\nSynopsisThis study describes the continuous monitoring of the SARS CoV-2 variant B.1.1.7 circulation in wastewater in Israel using a positive\\/negative quantitative PCR assay.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.26.21268358\",\"title\":\"Can individuals with low antibody responses to vaccines against other viruses acquire adequate SARS-CoV-2 antibody after vaccination with the BNT162b2 mRNA vaccine?\",\"authors\":\"Ogura, W.; Ohtsuka, K.; Matsuura, S.; Okuyama, T.; Matsushima, S.; Yamasaki, S.; Miyagi, H.; Sekiguchi, K.; Ohnishi, H.; Watanabe, T.\",\"author_corresponding\":\"Kouki Ohtsuka\",\"author_corresponding_institution\":\"Department of Laboratory Medicine, Kyorin University School of Medicine\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nd\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.26.21268358.source.xml\",\"abstract\":\"ObjectiveIn Japan, healthcare workers (HCWs) are vaccinated against coronavirus disease (COVID-19) and other contagious viruses (measles, rubella, chickenpox, mumps, and hepatitis B) to prevent nosocomial infection. However, some do not produce sufficient antibodies after vaccination (low responders). This study investigated changes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody levels among HCWs after SARS-CoV-2 vaccination and assessed whether low responders produced adequate SARS-CoV-2 anti-spike and neutralizing antibodies.\\n\\nMethodsWe conducted a prospective cohort study of HCWs before and after vaccination with the BNT162b2 mRNA vaccine in a hospital in Tokyo, Japan. The HCWs received two doses of BNT162b2 vaccine, 3 weeks apart. Those whose antibody levels against previous antiviral vaccines did not reach protective antibody levels after receiving two doses were defined as low responders, whereas those who produced adequate antibodies were defined as normal responders. SARS-CoV-2 anti-spike antibodies were measured 11 times from before the first BNT162b2 vaccination to 5 months after the second vaccination. SARS-CoV-2 neutralizing antibody activity was measured twice in low responders, 1 week to 1 month and 5 months after the second vaccination.\\n\\nResultsFifty HCWs were included in the analytic cohort. After vaccination, SARS-CoV-2 anti-spike antibody was detectable in the samples from both responders at each timepoint, but the level was lower at 5 months than at 1 week after the second vaccination. Low responders had SARS-CoV-2 neutralizing antibody activity 1 week to 1 month after the second vaccination, which exceeded the positive threshold after 5 months.\\n\\nConclusionAfter BNT162b2 vaccination, low responders acquired adequate SARS-CoV-2 anti-spike and SARS-CoV-2 neutralizing antibodies to prevent SARS-CoV-2. However, SARS-CoV-2 anti-spike antibody levels were lower at 5 months than at 1 week after the second dose of BNT162b2 vaccine in low and normal responders. Therefore, low responders should also receive a third dose of BNT162b2 vaccine.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.23.21268040\",\"title\":\"Disease severity related to VOC dominance in unvaccinated SARS-CoV-2 positive adults without risk factors in Sweden\",\"authors\":\"Wahlstrom, E.; Bruce, D.; Bennet-Bark, A. M.; Walther, S.; Hanberger, H.; Stralin, K.\",\"author_corresponding\":\"Hakan Hanberger\",\"author_corresponding_institution\":\"Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linkoping University, Linkoping\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.23.21268040.source.xml\",\"abstract\":\"Although the emerging SARS-CoV-2 variants of concern (VOC) have shown increasing transmissibility, their role for causing severe disease has not been fully clarified. Here, we studied changes in rates of hospitalisation and severe illness (subjection to high-flow nasal oxygen or admission to an intensive care unit during hospital stay) among all (n=685 891) unvaccinated SARS-CoV-2 positive adults without risk factors in Sweden from November 2020 to September 2021.\\n\\nAfter adjustment for age, sex, and socio-economic factors, and with November 2020 (non-VOC period) as reference, the odds ratios (OR) for hospitalisation were 1.6-1.7 in March-May 2021 (Alpha VOC dominance) and 2.4-3.0 in June-September 2021 (Delta VOC dominance), and the ORs for severe illness were 1.8-2.1 in March-May 2021 and 3.1-4.7 in June-September 2021. This study shows that unvaccinated adults without risk factors, have had a gradually increased risk for hospital admission and severe illness when infected with the Alpha and Delta VOCs, respectively.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.27.21268278\",\"title\":\"SARS-CoV-2 Omicron VOC Transmission in Danish Households\",\"authors\":\"Lyngse, F. P.; Mortensen, L. H.; Denwood, M. J.; Christiansen, L. E.; Moller, C. H.; Skov, R. L.; Spiess, K.; Fomsgaard, A.; Lassauniere, R.; Rasmussen, M.; Stegger, M.; Nielsen, C.; Sieber, R. N.; Cohen, A. S.; Moller, F. T.; Overvad, M.; Molbak, K.; Krause, T. G.; Kirkeby, C. T.\",\"author_corresponding\":\"Frederik Plesner Lyngse\",\"author_corresponding_institution\":\"University of Copenhagen\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.27.21268278.source.xml\",\"abstract\":\"1The Omicron variant of concern (VOC) is a rapidly spreading variant of SARS-CoV-2 that is likely to overtake the previously dominant Delta VOC in many countries by the end of 2021.\\n\\nWe estimated the transmission dynamics following the spread of Omicron VOC within Danish households during December 2021. We used data from Danish registers to estimate the household secondary attack rate (SAR).\\n\\nAmong 11,937 households (2,225 with the Omicron VOC), we identified 6,397 secondary infections during a 1-7 day follow-up period. The SAR was 31% and 21% in households with the Omicron and Delta VOC, respectively. We found an increased transmission for unvaccinated individuals, and a reduced transmission for booster-vaccinated individuals, compared to fully vaccinated individuals. Comparing households infected with the Omicron to Delta VOC, we found an 1.17 (95%-CI: 0.99-1.38) times higher SAR for unvaccinated, 2.61 times (95%-CI: 2.34-2.90) higher for fully vaccinated and 3.66 (95%-CI: 2.65-5.05) times higher for booster-vaccinated individuals, demonstrating strong evidence of immune evasiveness of the Omicron VOC.\\n\\nOur findings confirm that the rapid spread of the Omicron VOC primarily can be ascribed to the immune evasiveness rather than an inherent increase in the basic transmissibility.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.21.21268202\",\"title\":\"The changing epidemiology of human monkeypox - a potential threat? A systematic review\",\"authors\":\"Bunge, E.; Hoet, B.; Chen, L.; Lienert, F.; Weidenthaler, H.; Baer, L.; Steffen, R.\",\"author_corresponding\":\"Bernard Hoet\",\"author_corresponding_institution\":\"Bavarian Nordic AG,  Zug, Switzerland\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nd\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.21.21268202.source.xml\",\"abstract\":\"Monkeypox, a zoonotic disease caused by an orthopoxvirus, results in a smallpox-like disease in humans. Since monkeypox in humans was initially diagnosed in 1970 in the Democratic Republic of the Congo (DRC), it has spread to other regions of Africa (primarily West and Central), and cases outside Africa have emerged in recent years. We conducted a systematic review of peer-reviewed and grey literature on how monkeypox epidemiology has evolved, with particular emphasis on the number of confirmed, probable, and\\/or possible cases, age at presentation, mortality, and geographical spread. The review is registered with PROSPERO (CRD42020208269). We identified 48 peer-reviewed articles and 18 grey literature sources for data extraction. The number of human monkeypox cases has been on the rise since the 1970s, with the most dramatic increases occurring in the DRC. The median age at presentation has increased from 4 (1970s) to 21 years (2010-2019). There was an overall case fatality rate of 8.7%, with a significant difference between clades -- Central African 10.6% (95% CI: 8.4% - 13.3%) vs. West African 3.6% (95% CI: 1.7% - 6.8%). Since 2003, import- and travel-related spread outside of Africa has occasionally resulted in outbreaks. Interactions\\/activities with infected animals or individuals are risk behaviors associated with acquiring monkeypox. Our review shows an escalation of monkeypox cases, especially in the highly endemic DRC, a spread to other countries, and a growing median age from young children to young adults. These findings may be related to the cessation of smallpox vaccination, which provided some cross-protection against monkeypox, leading to increased human-to-human transmission. The appearance of outbreaks beyond Africa highlights the global relevance of the disease. Increased surveillance and detection of monkeypox cases are essential tools for understanding the continuously changing epidemiology of this resurging disease.\\n\\nAuthor SummaryMonkeypox, a zoonotic disease caused by an orthopoxvirus, results in a smallpox-like disease in humans. We conducted a systematic review to assess how monkeypox epidemiology has evolved since it was first diagnosed in 1970 in the Democratic Republic of the Congo. In total, human monkeypox has now appeared in 10 African countries and 4 countries elsewhere. Examples include Nigeria, where the disease re-emerged in the last decade after a 40-year hiatus, and the United States, where an outbreak occurred in 2003. The number of cases has increased at a minimum of 10-fold and median age at presentation has evolved from young children (4 years old) in the 1970s to young adults (21 years old) in 2010-2019. This may be related to the cessation of smallpox vaccinations, which provided some cross-protection against monkeypox. The case fatality rate for the Central African clade was 10.6% versus 3.6% for the West African clade. Overall, monkeypox is gradually evolving to become of global relevance. Surveillance and detection programs are essential tools for understanding the continuously changing epidemiology of this resurging disease.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.26.21268426\",\"title\":\"Pandemic-related decline in injuries related to women wearing high-heeled shoes: Analysis of U.S. data for 2016-2020\",\"authors\":\"Cohen, P. N.\",\"author_corresponding\":\"Philip N. Cohen\",\"author_corresponding_institution\":\"University of Maryland\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by\",\"category\":\"public and global health\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.26.21268426.source.xml\",\"abstract\":\"BackgroundWearing high-heeled shoes is associated with injury risk. During the COVID-19 pandemic, changes in work and social behavior may have reduced womens use of such footwear.\\n\\nMethodsThis study assessed the trend in high-heel related injuries among U.S. women, using 2016-2020 data from the U.S. Consumer Product Safety Commissions National Electronic Injury Surveillance System (NEISS).\\n\\nResultsIn 2020 there were an estimated 6,290 high-heel related emergency department visits involving women ages 15-69, down from 16,000 per year in 2016-2019. The 2020 decline began after the start of the COVID-19 shutdowns on March 15. There was no significant change in the percentage of fractures or hospital admissions.\\n\\nConclusionsThe COVID-19 pandemic was associated with a decline in reported injuries related to high-heeled shoes among US women. If this resulted from fewer women wearing such shoes, and such habits influence future behavior, the result may be fewer injuries in the future.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.22.21268287\",\"title\":\"Direct, Indirect and Mixed Methods of Health Education By Nurse and Its Impact on Type 2 Diabetes Patients: A Literature review\",\"authors\":\"Akoit, E. E.; Pandin, M. G. R.\",\"author_corresponding\":\"Emilia Erningwati Akoit Sr.\",\"author_corresponding_institution\":\"University of Airlangga\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"public and global health\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.22.21268287.source.xml\",\"abstract\":\"BackgroundDiabetes Mellitus (DM) is one of the chronic non-communicable diseases that has currently been very common, in particular Diabetes Mellitus type 2 that threatens public health. It has been included in the category of the six biggest causes of worldwide death, but self-control of treatment and obedience to self-care is still low. One of the influencing factors is related to the lack of knowledge. Providing ongoing health education is one of the solutions or efforts to strengthen knowledge in type 2 diabetes. The aim was to identify the various health education methods currently used by nurses and their impacts on type 2 DM. The method used is a literature review. The literature was searched on data based on Scopus, Web of Science, SAGE, CINAHL with the keywords \\\"methods\\\" or \\\"interventions\\\", \\\"education\\\", \\\"health\\\", \\\"nursing\\\", and \\\"type 2 diabetes melitus. Fifteen (15) pieces of literature were considered to meet the criteria inclusion.\\n\\nResultsThree (3) types of health education methods used by nurses were identified: 1). Direct health education refers to providing education by nurses to patients through training, coaching, interviews, Focus Group Discussion (FGD) and home visits; 2). Indirect Health Education - using mobile phones; 3). The mixed of direct health education and the use of mobile phone-based applications is carried out with the application of mobile health technology and nurse health coaching. The impact of providing health education by nurses to type 2 diabetic patients: increasing of knowledge, behavioral change on preventing diabetes complications, increasing self-efficacy, increasing self-care activities (diet management, physical activity, monitoring blood sugar levels, and foot care).\\n\\nConclusionvarious methods of health education carried out by nurses currently have a positive impact on improving and increasing self-care management and efforts to prevent complications in type 2 diabetes.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.27.21268439\",\"title\":\"Omicron infection enhances neutralizing immunity against the Delta variant\",\"authors\":\"Khan, K.; Karim, F.; Cele, S.; Tegally, H.; San, J. E.; Lustig, G.; Bernstein, M.; Ganga, Y.; Jule, Z.; Reedoy, K.; Ngcobo, N.; Miya, Y.; Mazibuko, M.; Mthabela, N.; Mhlane, Z.; Mbatha, N.; Giandhari, J.; Ramphal, Y.; Naidoo, T.; Manickchund, N.; Magula, N.; Karim, S. A.; Gray, G.; Hanekom, W.; von Gottberg, A.; Gosnell, B.; Lessells, R.; de Oliveira, T.; Moore, P.; Moosa, Y. S.; Sigal, A.\",\"author_corresponding\":\"Alex Sigal\",\"author_corresponding_institution\":\"Africa Health Research Institute\",\"date\":\"2021-12-27\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nd\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/27\\/2021.12.27.21268439.source.xml\",\"abstract\":\"Omicron has been shown to be highly transmissible and have extensive evasion of neutralizing antibody immunity elicited by vaccination and previous SARS-CoV-2 infection. Omicron infections are rapidly expanding worldwide often in the face of high levels of Delta infections. Here we characterized developing immunity to Omicron and investigated whether neutralizing immunity elicited by Omicron also enhances neutralizing immunity of the Delta variant. We enrolled both previously vaccinated and unvaccinated individuals who were infected with SARS-CoV-2 in the Omicron infection wave in South Africa soon after symptom onset. We then measured their ability to neutralize both Omicron and Delta virus at enrollment versus a median of 14 days after enrollment. Neutralization of Omicron increased 14-fold over this time, showing a developing antibody response to the variant. Importantly, there was an enhancement of Delta virus neutralization, which increased 4.4-fold. The increase in Delta variant neutralization in individuals infected with Omicron may result in decreased ability of Delta to re-infect those individuals. Along with emerging data indicating that Omicron, at this time in the pandemic, is less pathogenic than Delta, such an outcome may have positive implications in terms of decreasing the Covid-19 burden of severe disease.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.26.21268380\",\"title\":\"SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against Omicron\",\"authors\":\"Keeton, R.; Tincho, M. B.; Ngomti, A.; Baguma, R.; Benede, N.; Suzuki, A.; Khan, K.; Cele, S.; Bernstein, M.; Karim, F.; Madzorera, S. V.; Moyo-Gwete, T.; Mennen, M.; Skelem, S.; Adriaanse, M.; Mutithu, D.; Aremu, O.; Stek, C.; du Bruyn, E.; Van Der Mescht, M.; de Beer, Z.; de Villiers, T. R.; Bodenstein, A.; van den Berg, G.; Mendes, A.; Strydom, A.; Venter, M.; Grifoni, A.; Weiskopf, D.; Sette, A.; Wilkinson, R. J.; Bekker, L.-G.; Gray, G.; Ueckermann, V.; Rossouw, T.; Boswell, M. T.; Bihman, J.; Moore, P.; Sigal, A.; Ntusi, N. A. B.; Burgers, W. A.; Riou, C.\",\"author_corresponding\":\"Catherine Riou\",\"author_corresponding_institution\":\"Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa;  Division of Medical Virology, Department of Patholo\",\"date\":\"2021-12-28\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/28\\/2021.12.26.21268380.source.xml\",\"abstract\":\"The SARS-CoV-2 Omicron variant has multiple Spike (S) protein mutations that contribute to escape from the neutralizing antibody responses, and reducing vaccine protection from infection. The extent to which other components of the adaptive response such as T cells may still target Omicron and contribute to protection from severe outcomes is unknown. We assessed the ability of T cells to react with Omicron spike in participants who were vaccinated with Ad26.CoV2.S or BNT162b2, and in unvaccinated convalescent COVID-19 patients (n = 70). We found that 70-80% of the CD4 and CD8 T cell response to spike was maintained across study groups. Moreover, the magnitude of Omicron cross-reactive T cells was similar to that of the Beta and Delta variants, despite Omicron harbouring considerably more mutations. Additionally, in Omicron-infected hospitalized patients (n = 19), there were comparable T cell responses to ancestral spike, nucleocapsid and membrane proteins to those found in patients hospitalized in previous waves dominated by the ancestral, Beta or Delta variants (n = 49). These results demonstrate that despite Omicrons extensive mutations and reduced susceptibility to neutralizing antibodies, the majority of T cell response, induced by vaccination or natural infection, cross-recognises the variant. Well-preserved T cell immunity to Omicron is likely to contribute to protection from severe COVID-19, supporting early clinical observations from South Africa.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.28.21268477\",\"title\":\"Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in Japanese patients after allogeneic stem cell transplantation.\",\"authors\":\"Watanabe, M.; Yakushijin, K.; Funakoshi, Y.; Ohji, G.; Sakai, H.; Hojo, W.; Saeki, M.; Hirakawa, Y.; Matsumoto, S.; Sakai, R.; Nagao, S.; Kitao, A.; Miyata, Y.; Koyama, T.; Saito, Y.; Kawamoto, S.; Ito, M.; Murayama, T.; Matsuoka, H.; Minami, H.\",\"author_corresponding\":\"Kimikazu Yakushijin\",\"author_corresponding_institution\":\"Division of Medical Oncology\\/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan\",\"date\":\"2021-12-29\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"hematology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/29\\/2021.12.28.21268477.source.xml\",\"abstract\":\"Patients who have undergone hematopoietic stem cell transplantation (HSCT) for hematological disease experience high mortality when infected by coronavirus disease 2019 (COVID-19). However, the safety and efficacy of COVID-19 vaccine in HSCT patients remains to be investigated. We prospectively evaluated the safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine (Pfizer BioNTech) in 25 Japanese allogeneic HSCT patients in comparison with 19 healthy volunteers. While anti-S1 antibody titers in almost all healthy volunteers after the second dose were higher than the cut-off value reported previously, levels in HSCT patients after the second dose were diverse. Nineteen patients (76%) got seroconversion of anti-S1 IgG. Median optical density of antibody levels in HSCT patients with low IgG levels (< 600 mg\\/dL), steroid treatment, or low lymphocytes (< 1000 \\/L) was significantly lower than that in the other HSCT patients. There were no serious adverse events (> Grade 3), no new development or exacerbation of graft-versus-host disease after vaccination. We concluded BNT162b2 mRNA vaccine is safe and effective in Japanese allogeneic HSCT patients.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.27.21268431\",\"title\":\"SARS-CoV-2 Omicron variant: healthcare workers' perceptions and beliefs of vaccine effectiveness and advocacy: a national survey during the first week of the World Health Organization variant alert\",\"authors\":\"Temsah, M.-H.; Aljamaan, F.; Alenezi, S.; Alhasan, K.; Alrabiaah, A.; Assiri, R.; Bassrawi, R.; Alhaboob, A.; Alshahrani, F.; Al-Arabi, M.; Alaraj, A.; Alharbi, N. S.; Halwani, R.; Jamal, A.; Al-Eyadhy, A.; Abdulmajeed, N.; Alfarra, L.; Almashdali, W.; AlZamil, F.; Barry, M.; Memish, Z. A.; Al-Tawfiq, J. A.; Al-Subaie, S.\",\"author_corresponding\":\"Mohamad-Hani Temsah\",\"author_corresponding_institution\":\"King Saud University\",\"date\":\"2021-12-29\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/29\\/2021.12.27.21268431.source.xml\",\"abstract\":\"BackgroundAs COVID-19 Omicron variant spread in several countries, healthcare workers (HCWs) perceptions of vaccine effectiveness, booster and worries warrant reassessment.\\n\\nMethodsOnline questionnaire among HCWs in Saudi Arabia (KSA) was collected between Dec 1-6, 2021, aiming to assess their Omicron variants perceptions, worries, and booster-vaccine advocacy.\\n\\nResultsAmong the 1285 HCWs participants in the study, two-thirds were females, 41% were nurses,46.4% were physicians, and 50% worked in tertiary care hospitals. Vaccination was perceived to be the most effective way to prevent the spread of Omicron variant and future variants by 66.9%. The respondents perceived social distancing (78%), universal masking (77.8%), and avoiding unnecessary travel (71.4%), slightly superior to vaccination to prevent COVID-19 variants spread. Of the respondents, 99.5% received two doses of COVID-19 vaccine. Regarding the booster dose, 96% either received it or planned to receive it once they are eligible. 57.7% of the respondents agreed that Omicron could cause a new COVID-19 wave worldwide, 45.9% agreed it may cause another COVID-19 wave in Saudi Arabia and 46.1% indicated the possibility of another lockdown. Overall, the HCWs worry level of the Omicron variant correlated significantly and strongly with their perception of the effectiveness of vaccination and preventive measures. Male HCWs had a significant agreement with mandatory vaccination of all eligible adult populations while HCWs who are unwilling to receive the vaccine had a strong disagreement with mandatory vaccination.\\n\\nConclusionsThe current study was conducted in the first week of Omicron variant discovery in KSA and only two-thirds of HCWs felt that vaccination is the best option to prevent the variant spread, indicating the need to further motivation campaigns for vaccination and booster doses education among HCWs. HCWs had a strong belief in non-pharmacologic interventions that should be encouraged and augmented. It is important to further study and enhance coping strategies for HCWs as we move through the third year of the pandemic with more potential variants, to protect HCWs from fatigue and burnout.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.26.21268412\",\"title\":\"Effects of statin therapy on coronary plaque volume by decreasing CRP\\/hsCRP levels: A meta-regression of randomized controlled trials\",\"authors\":\"Gao, D.; Hua, R.; Jiesisibieke, D.; Ma, Y.; Li, C.; Wu, S.; Ma, Q.; Xie, W.\",\"author_corresponding\":\"Wuxiang Xie\",\"author_corresponding_institution\":\"Peking University Clinical Research Institute, Peking University First Hospital\",\"date\":\"2021-12-29\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"cardiovascular medicine\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/29\\/2021.12.26.21268412.source.xml\",\"abstract\":\"Background and aimsSeveral clinical trials have indicated that statins stabilize and reverse atherosclerotic plaque. However, different studies have provided inconsistent findings regarding mechanisms and influencing factors of plaque regression under statin therapy. In this study, meta-analysis and meta-regression were used to determine the effect of statin medication on coronary plaque volume as determined by intravenous ultrasound. Meanwhile, the impact of statins on CRP\\/hsCRP reduction on plaque regression was discussed.\\n\\nMethodsUp to May 28, 2021, a systematic PubMed, EMBASE, and Cochrane search was performed for randomized controlled trials that assessed treatment effect using total atheroma volume (TAV), percent atheroma volume (PAV), or plaque volume (PV). Only CRP\\/hsCRP and LDL-C values reported before and after treatment were considered.\\n\\nResults12 studies fulfilled the inclusion criteria and were included in the systematic review. Compared with control groups, meta-analysis of 15 statin-treated arms reported change of TAV\\/PV showed standardized mean difference (SMD) at -0.27 (95% confidence intervals [CI]: -0.42, -0.12). Meta-analysis of 7 studies reported change of PAV revealed SMD at -0.16 (95% CI: -0.29, -0.03). Meta-regression analysis revealed percent change of CRP\\/hsCRP statistically influences SMD in change of TAV\\/PVafter adjusting for percent change of LDL-C, age and gender. Meta-regression analysis showed that percent change of CRP\\/hsCRP statistically influences SMD in change of PAV.\\n\\nConclusionIn conclusion, statin therapy is beneficial for plaque regression. Statins promote plaque regression through their anti-inflammatory ability while lowering LDL-C is unaffected.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.27.21268448\",\"title\":\"Risk of Cardiovascular Events after Covid-19: a double-cohort study\",\"authors\":\"Tereshchenko, L. G.; Bishop, A.; Fisher-Campbell, N.; Levene, J.; Morris, C.; Patel, H.; Beeson, E.; Blank, J.; Bradner, J. G.; Coblens, M.; Corpron, J.; Davison, J.; Denny, K.; Earp, M.; Florea, S.; Freeman, H.; Fuson, O.; Guillot, F.; Haq, K.; Hyde, J.; Khader, A.; Kolseth, C.; Kim, M.; Krol, O.; Lin, L.; Litwin, L.; Malik, A.; Mitchell, E.; Mohapatra, A.; Mullen, C.; Nix, C.; Oyeyemi, A.; Rutlen, C.; Corley-Stampke, L.; Tam, A.; Van Buren, I.; Wallace, J.; Khan, A.\",\"author_corresponding\":\"Larisa G Tereshchenko\",\"author_corresponding_institution\":\"Cleveland Clinic Lerner Research Institute\",\"date\":\"2021-12-29\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"cardiovascular medicine\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/29\\/2021.12.27.21268448.source.xml\",\"abstract\":\"ObjectiveTo determine absolute and relative risks of either symptomatic or asymptomatic SARS-CoV-2 infection for late cardiovascular events and all-cause mortality.\\n\\nMethodsWe conducted a retrospective double-cohort study of patients with either symptomatic or asymptomatic SARS-CoV-2 infection [COVID-19(+) cohort] and its documented absence [COVID-19(-) cohort]. The study investigators drew a simple random sample of records from all Oregon Health & Science University (OHSU) Healthcare patients (N=65,585) with available COVID-19 test results, performed 03.01.2020 - 09.13.2020. Exclusion criteria were age < 18y and no established OHSU care. The primary outcome was a composite of cardiovascular morbidity and mortality. All-cause mortality was the secondary outcome.\\n\\nResultsThe study population included 1355 patients (mean age 48.7{+\\/-}20.5 y; 770(57%) female, 977(72%) white non-Hispanic; 1072(79%) insured; 563(42%) with cardiovascular disease (CVD) history). During a median 6 months at risk, the primary composite outcome was observed in 38\\/319 (12%) COVID-19(+) and 65\\/1036 (6%) COVID-19(-) patients (p=0.001). In Cox regression adjusted for demographics, health insurance, and reason for COVID-19 testing, SARS-CoV-2 infection was associated with the risk of the primary composite outcome (HR 1.71; 95%CI 1.06-2.78; p=0.029). Inverse-probability-weighted estimation, conditioned for 31 covariates, showed that for every COVID-19(+) patient, the average time to all-cause death was 65.5 days less than when all these patients were COVID-19(-): average treatment effect on the treated -65.5 (95%CI -125.4 to -5.61) days; p=0.032.\\n\\nConclusionsEither symptomatic or asymptomatic SARS-CoV-2 infection is associated with increased risk of late cardiovascular outcomes and has causal effect on all-cause mortality in a late post-COVID-19 period.\\n\\nClinicalTrials.gov Identifier: NCT04555187\\n\\nKey messagesO_ST_ABSWhat is already known about this subjectC_ST_ABSO_LIAcute, symptomatic COVID-19 can cause acute cardiovascular manifestations.\\nC_LIO_LIPost-acute or \\\"long\\\" COVID-19 can be a debilitating disease following acute infection with a heterogenous presentation.\\nC_LI\\n\\nWhat might this study add?O_LIEither symptomatic or asymptomatic SARS-CoV-2 infection is associated with increased risk of late cardiovascular outcomes.\\nC_LIO_LIEither symptomatic or asymptomatic SARS-CoV-2 infection has causal effect on all-cause mortality in a late post-COVID-19 period.\\nC_LI\\n\\nHow might this impact on clinical practice?O_LIAs we begin to care for more survivors of COVID-19, we will need to better understand not only how to care for their acute symptoms and complications following infection, but also recognize future cardiovascular risk and mitigate such risk with appropriate screening and preventative measures.\\nC_LI\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.24.21267822\",\"title\":\"Trends and country-level variation in age at first sex in sub-Saharan Africa among birth cohorts entering adulthood between 1985 and 2020\",\"authors\":\"Nguyen, V. K.; Eaton, J. W.\",\"author_corresponding\":\"Van Kinh Nguyen\",\"author_corresponding_institution\":\"Imperial College London\",\"date\":\"2021-12-29\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by\",\"category\":\"public and global health\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/29\\/2021.12.24.21267822.source.xml\",\"abstract\":\"BackgroundDebuting sexual intercourse is a life course event marking exposure to pregnancy or fatherhood, and sexually transmitted infections (STIs), including HIV. We systematically analysed the timing, distribution, and trends in age at first sex (AFS) in 42 sub-Saharan Africa (SSA) countries.\\n\\nMethodsWe collated individual-level AFS data from nationally representative household surveys across SSA. We used a log-skew-logistic distribution to model the distribution of AFS in a Bayesian spatio-temporal hierarchical random-effect model to estimate national trends of AFS over time and space, adjusting for age at report biases.\\n\\nResultsSmall changes in AFS are observed between the birth cohorts entering adulthood between 1985 and 2020, ranging 0,79 years [-0,01-1,51] and 0,48 [-0,03-1,92] for female and male, respectively. Northern SSA countries show appreciable increase in AFS but its gender gap remains the widest compared with minimal gender gap in the southern countries. The gender gap shows little evidence of change over time in most of the countries. Females AFS approach to a similar age across SSA while males AFS varies between regions. Proportion ever had sex under fifteen and eighteen are as high 34% and 83%, respectively. AFS distribution is typically asymmetric with most of sexual debut events occur in a span of 3,9 [3,4-5,0] years. Female teen often reports higher AFS compared to their late twenties while male teen report lower AFS; both sexes tend to recall a higher AFS in older ages compared to their thirties.\\n\\nConclusionsWomen debut sexually earlier and in a shorter span of age than men. Northern and southern SSA gender gap are distinctively different. Since the ratifying of HIV\\/AIDS intervention programs in SSA, a stagnant trend in AFS had remained in the countries most affected by the epidemic.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.22.21268176\",\"title\":\"A preliminary study of commercially available general-purpose chest radiography artificial intelligence-based software for detecting airspace opacity lesions in COVID-19 patients\",\"authors\":\"Suzuki, M.; Niimura, A.; Nakamura, Y.; Otsuka, Y.\",\"author_corresponding\":\"Munemura Suzuki\",\"author_corresponding_institution\":\"Plusman LLC\",\"date\":\"2021-12-29\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by\",\"category\":\"radiology and imaging\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/29\\/2021.12.22.21268176.source.xml\",\"abstract\":\"PurposeTo validate commercially available general-purpose artificial intelligence (AI)-based software for detecting airspace opacity in chest radiographs (CXRs) of COVID-19 patients.\\n\\nMaterials and MethodsWe used the ieee8023-covid-chestxray-dataset to validate commercial AI software capable of detecting \\\"Nodule\\/Mass\\\" and \\\"Airspace opacity\\\" as regions of interest with probability scores. From this dataset, we excluded computed tomography images and CXR images taken using an anteroposterior spine view and analyzed CXR images tagged with \\\"Pneumonia\\/Viral\\/COVID-19\\\" and \\\"no findings.\\\" A radiologist then reviewed the images and rated them on a 3-point opacity score for the presence of airspace opacity. The maximum probability score of airspace opacity for each image was calculated using this software. The difference in each maximum probability for each opacity score was evaluated using Wilcoxons rank sum test. The threshold of the probability score was determined by receiver operator characteristic curve analysis for the presence or absence of COVID-19, and the true positive rate (TPR) and false positive rate (FPR) were determined for the individual and overall opacity scores.\\n\\nResultsImages from 342 patients with COVID-19 and 15 normal images were included. Opacity scores of 1, 2, and 3 were observed in 44, 70, and 243 images, respectively, of which 33 (75%), 66 (94.2%), and 243 (100%), respectively, were from COVID-19 patients. The overall TPR and FPR were 0.82 and 0.13, respectively, at an area under the curve of 0.88 and a threshold of 0.06, while the FPR for opacity score 1 was 0.18 and the TPR for score 3 was 0.97.\\n\\nConclusionUsing a public database containing CXR images of COVID-19 patients, commercial AI software was shown to be able to detect airspace opacity in severe pneumonia.\\n\\nSummaryCommercially available AI software was capable of detecting airspace opacity in CXR images of COVID-19 patients in a public database.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.26.21268422\",\"title\":\"Vitamin D Status & Latitude Predict Brain Lesions in Adrenoleukodystrophy\",\"authors\":\"Van Haren, K.; Wilkes, J.; Moser, A. B.; Raymond, G. V.; Richardson, T.; Aubourg, P.; Collins, T. W.; Mowry, E.; Bonkowsky, J. L.\",\"author_corresponding\":\"Keith Van Haren\",\"author_corresponding_institution\":\"Department of Neurology, Stanford University, Palo Alto, California\",\"date\":\"2021-12-29\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"neurology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/29\\/2021.12.26.21268422.source.xml\",\"abstract\":\"A subset of boys with X-linked adrenoleukodystrophy (ALD) develop inflammatory demyelinating brain lesions. Risk factors are largely undefined. We used two independent cohorts to assess whether low vitamin D status predicts lesion development. In our first cohort, we measured 25-hydroxyvitamin D in 53 plasma samples from 20 pre-lesional ALD boys followed at two centers; half subsequently developed lesions. In our second cohort, we measured latitude (using home ZIP code) among 230 ALD boys in a database of 51 US pediatric hospitals; over half developed lesions. In regression models, low plasma vitamin D and northerly latitudes independently predicted ALD brain lesions.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.27.21268455\",\"title\":\"Effects of COVID-19 on the human central olfactory system: a natural pre-post experiment\",\"authors\":\"Thunell, E.; Peter, M. G.; Lenoir, V.; Andersson, P.; Landis, B. N.; Becker, M.; Lundstrom, J. N.\",\"author_corresponding\":\"Johan N Lundstrom\",\"author_corresponding_institution\":\"Karolinska Institutet\",\"date\":\"2021-12-29\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"neurology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/29\\/2021.12.27.21268455.source.xml\",\"abstract\":\"Reduced olfactory function is the symptom with the highest prevalence in COVID-19 with nearly 70% of individuals with COVID-19 experiencing partial or total loss of their sense of smell at some point during the disease. The exact cause is not known but beyond peripheral damage, studies have demonstrated insults to both the olfactory bulb and central olfactory brain areas. However, these studies often lack both baseline pre-COVID-19 assessments and a control group and could therefore simply reflect preexisting risk factors. Right before the COVID-19 outbreak, we completed an olfactory focused study including structural MR brain images and a full clinical olfactory test. Opportunistically, we invited participants back one year later, including 9 participants who had experienced mild to medium COVID-19 (C19+) and 12 that had not (C19-), thereby creating a pre-post controlled natural experiment with a control group. Despite C19+ participants reporting subjective olfactory dysfunction, few showed signs of objectively altered function one year later. Critically, all but one individual in the C19+ group had reduced olfactory bulb volume with an average volume reduction of 14.3%, but this did not amount to a significant between group difference compared to the control group (2.3% reduction) using inference statistics. No morphological differences in cerebral olfactory areas were found but we found stronger functional connectivity between olfactory brain areas in the C19+ croup at the post measure. Taken together, these data suggest that COVID-19 might cause a long-term reduction in olfactory bulb volume but with no discernible differences in cerebral olfactory regions.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.23.21268152\",\"title\":\"A Pilot Basket Study to Evaluate Multi-Analyte Liquid Biopsies for Personalized Treatments in Advanced Refractory Cancers\",\"authors\":\"Nagarkar, R.; Crook, T.; Plowman, N.; Gaya, A.; Patil, D.; Akolkar, D.; Palwe, V.; Pandit, P.; Kate, S.; Roy, S.; Srivastava, N.; Datta, V.; Bose, C.; Patil, S.; Apurwa, S.; Srinivasan, A.; Datar, R.\",\"author_corresponding\":\"Ajay Srinivasan\",\"author_corresponding_institution\":\"Datar Cancer Genetics, Nasik, India\",\"date\":\"2021-12-29\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by\",\"category\":\"oncology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/29\\/2021.12.23.21268152.source.xml\",\"abstract\":\"AbstarctPrior attempts at personalizing anticancer treatments based on univariate tumor profiling ( single gene variant) for selection of monotherapy with targeted agents ( single drug) have generally yielded poor response rates. We report findings from the LIQUID IMPACT pilot trial where Multi-analyte Liquid Biopsy (MLB) profiling of circulating tumor analytes in peripheral blood was used to inform selection of personalized combination regimens in advanced refractory cancers. Among the 43 patients evaluable as per study protocol, 34 had targetable pathway activations. Partial Response (PR) was observed in 14 (41.1%) of the 34 patients with signaling pathway activation, including 5 (50%) of 10 cases with mTOR activation, 8 (44.4%) of 18 cases with activation of angiogenesis and 4 (50.0%) of 8 cases with EGFR \\/ ERBB2 activation. PR was not reported among the 9 cases with no detectable pathway activation. Toxicities were manageable and there were no treatment related deaths. The study findings suggest that MLB may be able to inform safe and efficacious combination regimens in patients with advanced refractory cancers.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.27.21268450\",\"title\":\"Validation of a Pancreatic Cancer Detection Test in New-Onset Diabetes Using Cell-Free DNA 5-Hydroxymethylation Signatures\",\"authors\":\"Haan, D.; Bergamaschi, A.; Guler, G.; Friedl, V.; Ning, Y.; Reggiardo, R.; Kesling, M.; Collins, M.; Gibb, W.; Pitea, A.; Hazen, K.; Bates, S.; Antoine, M.; Fraire, C.; Lopez, V.; Malta, R.; Nabiyouni, M.; Nguyen, A.; Phillips, T.; Riviere, M.; Scott, A.; Nilson, E.; Sheard, J.; Peters, M.; Chowdhury, S.; Volkmuth, W.; Levy, S.\",\"author_corresponding\":\"Samuel Levy\",\"author_corresponding_institution\":\"Bluestar Genomics, 10578 Science Center Drive, Suite 210, San Diego, California 92121\",\"date\":\"2021-12-29\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"genetic and genomic medicine\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/29\\/2021.12.27.21268450.source.xml\",\"abstract\":\"BACKGROUNDPancreatic cancer (PaC) has poor (10%) 5-year overall survival, largely due to predominant late-stage diagnosis. Patients with new-onset diabetes (NOD) are at a six-to eightfold increased risk for PaC. We developed a pancreatic cancer detection test for the use in a clinical setting that employs a logistic regression model based on 5-hydroxymethylcytosine (5hmC) profiling of cell-free DNA (cfDNA).\\n\\nMETHODScfDNA was isolated from plasma from 89 subjects with PaC and 596 case-control non-cancer subjects, and 5hmC libraries were generated and sequenced. These data coupled with machine-learning, were used to generate a predictive model for PaC detection, which was independently validated on 79 subjects with PaC, 163 non-cancer subjects, and 506 patients with non-PaC cancers.\\n\\nRESULTSThe area under the receiver operating characteristic curve for PaC classification was 0.93 across the training data. Training sensitivity was 58.4% (95% confidence interval [CI]: 47.5- 68.6) after setting a classification probability threshold that resulted in 98% (95% CI: 96.5-99) specificity. The independent validation dataset sensitivity and specificity were 51.9% (95% CI: 40.4-63.3) and 100.0% (95% CI: 97.8-100.0), respectively. Early-stage (stage 1 and 2) PaC detection was 47.6% (95% CI: 23%-58%) and 39.4% (95% CI: 32%-64%) in the training and independent validation datasets, respectively. Sensitivity and specificity in NOD patients were 55.2% [95% CI: 35.7-73.6] and 98.4% [95% CI: 91.3-100.0], respectively. The PaC signal was identified in intraductal papillary mucinous neoplasm (64%), pancreatitis (56%), and non-PaC cancers (17%).\\n\\nCONCLUSIONSThe pancreatic cancer detection assay showed robust performance in the tested cohorts and carries the promise of becoming an essential clinical tool to enable early detection in high-risk NOD patients.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.27.21268309\",\"title\":\"Replacement of the Gamma by the Delta variant in Brazil: impact of lineage displacement on the ongoing pandemic\",\"authors\":\"Giovanetti, M.; Fonseca, V.; Wilkinson, E.; Tegally, H.; San, E. J.; Althaus, C. L.; Xavier, J.; Nanev Slavov, S.; Viala, V. L.; Ranieri Jeronimo Lima, A.; Ribeiro, G.; Souza-Neto, J. A.; Fukumasu, H.; Lehmann Coutinho, L.; Venancio da Cunha, R.; Freitas, C.; Campelo de A e Melo, C. F.; Navegantes, W.; do Carmo Said, R. F.; Almiron, M.; de Oliveira, T.; Sampaio, S. C.; Elias, M. C.; Tadeu Covas, D.; Holmes, E. C.; Lourenco, J.; Kashima, S.; Alcantara, L. C. J.\",\"author_corresponding\":\"Luiz Carlos Junior Alcantara\",\"author_corresponding_institution\":\"Oswaldo Cruz Foundation\",\"date\":\"2021-12-29\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/29\\/2021.12.27.21268309.source.xml\",\"abstract\":\"The COVID-19 epidemic in Brazil was driven mainly by the spread of Gamma (P.1), a locally emerged Variant of Concern (VOC) that was first detected in early January 2021. This variant was estimated to be responsible for more than 96% of cases reported between January and June 2021, being associated with increased transmissibility and disease severity, a reduction in neutralization antibodies and effectiveness of treatments or vaccines, as well as diagnostic detection failure. Here we show that, following several importations predominantly from the USA, the Delta variant rapidly replaced Gamma after July 2021. However, in contrast to what was seen in other countries, the rapid spread of Delta did not lead to a large increase in the number of cases and deaths reported in Brazil. We suggest that this was likely due to the relatively successful early vaccination campaign coupled with natural immunity acquired following prior infection with Gamma. Our data reinforces reports of the increased transmissibility of the Delta variant and, considering the increasing concern due to the recently identified Omicron variant, argues for the necessity to strengthen genomic monitoring on a national level to quickly detect and curb the emergence and spread of other VOCs that might threaten global health.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.26.21268421\",\"title\":\"Relationship between temperature and relative humidity on the initial spread of COVID-19 cases and deaths in Brazil\",\"authors\":\"Olinto, M. T. A.; Garcez, A.; Brunelli, G.; Olinto, F. A.; Fanton, M.; Canuto, R.\",\"author_corresponding\":\"Maria Teresa Anselmo Olinto\",\"author_corresponding_institution\":\"University of Vale do Rio dos Sinos, UNISINOS\",\"date\":\"2021-12-29\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/29\\/2021.12.26.21268421.source.xml\",\"abstract\":\"IntroductionClimate conditions may have influence on the transmission of COVID-19. Thus, this study aims to evaluate the impact of temperature and relative humidity on COVID-19 cases and deaths during the initial phase of the epidemic in Brazil.\\n\\nMethodologyThis is an ecological study based on secondary data. Daily data on new COVID-19 cases and deaths and on climate indicators was collected from February 20th to April 18th, 2020 (n=59 days), for all state capital cities in Brazil and the Federal District (Brasilia). The studied climate indicators included mean temperature, temperature amplitude, mean relative humidity, relative humidity amplitude, and percentage of days with mean relative humidity less than or equal to 65%. Correlation and multiple linear regression analysis were performed for all cities and was also stratified by quintiles of the COVID-19 incidence rate.\\n\\nResultsMean daily temperature was positively correlated with the number of days until the first COVID-19 case was reported. A lower mean relative humidity was correlated with lower number of cases and deaths in Brazil, especially when the relative humidity was less than or equal to 65%. Higher temperatures and humidity amplitudes were correlated with lower COVID-19 mortality. Additionally, after controlling for humidity, cumulative cases of COVID-19 were inversely associated with temperature in cities with mean temperatures less than 25.8 {degrees}C.\\n\\nConclusionsOur findings indicate that variations in temperature and humidity across the Brazilian territory may have influenced the spread of the novel coronavirus during the initial phase of the epidemic in the country.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.27.21268312\",\"title\":\"Mechanically ventilated patients shed high titre live SARS-CoV2 for extended periods from both the upper and lower respiratory tract\",\"authors\":\"Saud, Z.; PONSFORD, M. J.; Bentley, K.; Cole, J.; Pandey, M.; Jolles, S.; Fegan, C.; Humphreys, I.; Wise, M.; Stanton, R. J.\",\"author_corresponding\":\"Richard James Stanton\",\"author_corresponding_institution\":\"Cardiff University\",\"date\":\"2021-12-29\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by_nc_nd\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/29\\/2021.12.27.21268312.source.xml\",\"abstract\":\"BackgroundSARS-CoV-2 infection can lead to severe acute respiratory distress syndrome needing intensive care admission and may lead to death. As a virus that transmits by respiratory droplets and aerosols, determining the duration of viable virus shedding from the respiratory tract is critical for patient prognosis, and informs infection control measures both within healthcare settings and the public domain.\\n\\nMethodsWe examined upper and lower airway respiratory secretions for both viral RNA and infectious virions in mechanically ventilated patients admitted to the intensive care unit of the University Hospital of Wales. Samples were taken from the oral cavity (saliva), oropharynx (sub-glottic aspirate), or lower respiratory tract (non-directed bronchoalveolar lavage (NBL) or bronchoalveolar lavage (BAL)) and analyzed by both qPCR and plaque assay.\\n\\nResults117 samples were obtained from 25 patients. qPCR showed extremely high rates of positivity across all sample types, however live virus was far more common in saliva (68%) than in BAL\\/NBAL (32%). Average titres of live virus were higher in subglottic aspirates (4.5x107) than in saliva (2.2x106) or BAL\\/NBAL (8.5x106), and reached >108 PFU\\/ml in some samples. The longest duration of shedding was 98 days, while the majority of patients (14\\/25) shed live virus for 20 days or longer.\\n\\nConclusionsIntensive care unit patients infected with SARS-CoV-2 can shed high titres of virus both in the upper and lower respiratory tract, and tend to be prolonged shedders. This information is important for decision making around cohorting patients, de-escalation of PPE, and undertaking potential aerosol generating procedures.\\n\\nSummaryPatients on intensive therapy infected with SARS-CoV-2 tend to be prolonged shedders, excreting virus for far beyond the time periods specified in current guidelines, and live virus titres can be extremely high in both the upper and lower respiratory tracts.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.25.21268206\",\"title\":\"Topological data analysis identifies distinct biomarker phenotypes during the inflammatory phase of COVID-19\",\"authors\":\"Blair, P. W.; Brandsma, J.; Chenoweth, J. G.; Richard, S. A.; Epsi, N. J.; Mehta, R.; Striegel, D. A.; Clemens, E. G.; Lindholm, D. A.; Maves, R. C.; Larson, D. T.; Mende, K.; Colombo, R. E.; Ganesan, A.; Lalani, T.; Colombo, C. J.; Malloy, A. A.; Snow, A. L.; Schully, K. L.; Lanteri, C.; Simons, M. P.; Dumler, J. S.; Tribble, D.; Burgess, T.; Pollett, S.; Agan, B. K.; Clark, D. V.; EPICC COVID-19 Cohort Study Group,  \",\"author_corresponding\":\"Paul W Blair\",\"author_corresponding_institution\":\"The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD\",\"date\":\"2021-12-29\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc0\",\"category\":\"infectious diseases\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/29\\/2021.12.25.21268206.source.xml\",\"abstract\":\"OBJECTIVESThe relationships between baseline clinical phenotypes and the cytokine milieu of the peak  inflammatory phase of coronavirus 2019 (COVID-19) are not yet well understood. We used Topological Data Analysis (TDA), a dimensionality reduction technique to identify patterns of inflammation associated with COVID-19 severity and clinical characteristics.\\n\\nDESIGNExploratory analysis from a multi-center prospective cohort study.\\n\\nSETTINGEight military hospitals across the United States between April 2020 and January 2021.\\n\\nPATIENTSAdult ([&ge;]18 years of age) SARS-CoV-2 positive inpatient and outpatient participants were enrolled with plasma samples selected from the putative  inflammatory phase of COVID-19, defined as 15-28 days post symptom onset.\\n\\nINTERVENTIONSNone.\\n\\nMEASUREMENTS AND MAIN RESULTSConcentrations of 12 inflammatory protein biomarkers were measured using a broad dynamic range immunoassay. TDA identified 3 distinct inflammatory protein expression clusters. Peak severity (outpatient, hospitalized, ICU admission or death), Charlson Comorbidity Index (CCI), and body mass index (BMI) were evaluated with logistic regression for associations with each cluster. The study population (n=129, 33.3% female, median 41.3 years of age) included 77 outpatient, 31 inpatient, 16 ICU-level, and 5 fatal cases. Three distinct clusters were found that differed by peak disease severity (p <0.001), age (p <0.001), BMI (p<0.001), and CCI (p=0.001).\\n\\nCONCLUSIONSExploratory clustering methods can stratify heterogeneous patient populations and identify distinct inflammation patterns associated with comorbid disease, obesity, and severe illness due to COVID-19.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.26.21268418\",\"title\":\"Prediction of SARS-CoV-2 Omicron Variant Immunogenicity, Immune Escape and Pathogenicity, through Analysis of Spike Protein-specific Core Unique Peptides\",\"authors\":\"Pierros, V.; KONTOPODIS, E.; STRAVOPODIS, D. J.; TSANGARIS, G. T.\",\"author_corresponding\":\"GEORGE TH. TSANGARIS\",\"author_corresponding_institution\":\"BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS\",\"date\":\"2021-12-29\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"allergy and immunology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/29\\/2021.12.26.21268418.source.xml\",\"abstract\":\"The recently discovered Omicron variant of the SARS-CoV-2 corona virus has raised a new, global, awareness, since it is considered as a new variant of concern from all major health organizations, including WHO and ECDC. Omicron variant is characterized by 30 amino acid changes, three small deletions and one small insertion in the Spike protein. In this study, we have identified the Core Unique Peptides (CrUPs) that reside exclusively in the Omicron variant of Spike protein and are absent from the human proteome, thus creating a new dataset of peptides named as C\\/H-CrUPs. Furthermore, we have analyzed their protein locations and compared them with the respective ones of Alpha and Delta SARS-CoV-2 variants. In Omicron, 115 C\\/H-CrUPs were generated and 119 C\\/H-CrUPs were lost, almost four times as many compared to the other two variants. From position 440 to position 508, at the Receptor Binding Motif (RBM), 8 mutations were detected, resulting in the construction of 28 novel C\\/H-CrUPs. Most importantly, in Omicron variant, new C\\/H-CrUPs carrying two or three mutant amino acids were produced, as a consequence of the accumulation of multiple mutations in the RBM. Remarkably, these Omicron-derived C\\/H-CrUPs that bear several mutated amino acids could not be recognized in any other viral Spike variant. We suggest that virus binding to the ACE2 receptor is facilitated by the herein identified C\\/H-CrUPs in contact point mutations and Spike-cleavage sites, while the immunoregulatory NF9 peptide is not detectably affected. Taken together, our findings indicate that Omicron variant contains intrinsic abilities to escape immune-system attack, while its mutations can mediate strong viral binding to the ACE2 receptor, leading to highly efficient fusion of the virus to the target cell. However, the intact NF9 peptide suggests that Omicron exhibits reduced pathogenicity compared to Delta variant.\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.22.21268006\",\"title\":\"Mechanism of bisphosphonate-related osteonecrosis of the jaw (BRONJ) revealed by targeted removal of legacy bisphosphonate from jawbone using equilibrium competing inert hydroxymethylene diphosphonate\",\"authors\":\"Okawa, H.; Kondo, T.; Hokugo, A.; Cherian, P.; Campagna, J. J.; Lentini, N.; Sung, S.; Sung, E. C.; Chiang, S. H.; Lin, Y.-L.; Ebetino, F. H.; John, V.; McKenna, C. E.; Nishimura, I.\",\"author_corresponding\":\"Ichiro Nishimura\",\"author_corresponding_institution\":\"UCLA School of Dentistry\",\"date\":\"2021-12-29\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_no\",\"category\":\"dentistry and oral medicine\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/29\\/2021.12.22.21268006.source.xml\",\"abstract\":\"Bisphosphonate-related osteonecrosis of the jaw (BRONJ) presents as a morbid jawbone lesion in patients exposed to a nitrogen-containing bisphosphonate (N-BP). Although it is rare, BRONJ has caused apprehension among patients and healthcare providers and decreased acceptance of this anti-resorptive drug class to treat osteoporosis and metastatic osteolysis. We report here a novel method to elucidate the pathological mechanism of BRONJ by the selective removal of legacy N-BP from the jawbone using an intra-oral application of hydroxymethylene diphosphonate (HMDP) formulated in deformable nanoscale vesicles (DNV). After maxillary tooth extraction, zoledronate-treated mice developed delayed gingival wound closure, delayed tooth extraction socket healing and increased jawbone osteonecrosis consistent with human BRONJ lesion. Single cell RNA sequencing of mouse gingival cells revealed oral barrier immune dysregulation and unresolved pro-inflammatory reaction. HMDP-DNV topical applications to nascent mouse BRONJ lesions resulted in accelerated gingival wound closure and bone socket healing as well as attenuation of osteonecrosis development. The gingival single cell RNA sequencing demonstrated resolution of chronic inflammation by increased anti-inflammatory signature gene expression of lymphocytes and myeloid-derived suppressor cells. This study suggests that BRONJ pathology was predominantly induced by the oral N-BP and demonstrates the potential of HMDP-DNV as an effective BRONJ therapy.\\n\\nBrief SummaryThe targeted removal of legacy bisphosphonate from the jawbone by competitive equilibrium therapy elucidated the pathological mechanism of aberrant oral barrier immunity and bisphosphonate-related osteonecrosis of the jaw (BRONJ)\",\"published\":\"NA\",\"server\":\"medrxiv\"},{\"doi\":\"10.1101\\/2021.12.27.21268464\",\"title\":\"Control Strategies for the Third wave of COVID-19 infection in India: A Mathematical Model Incorporating Vaccine Effectiveness\",\"authors\":\"A Sivadas, N.; Mahajan, A.; Panda, P.\",\"author_corresponding\":\"Namitha A Sivadas\",\"author_corresponding_institution\":\"Vellore Institute of Technology\",\"date\":\"2021-12-29\",\"version\":\"1\",\"type\":\"PUBLISHAHEADOFPRINT\",\"license\":\"cc_by\",\"category\":\"epidemiology\",\"jatsxml\":\"https:\\/\\/www.medrxiv.org\\/content\\/early\\/2021\\/12\\/29\\/2021.12.27.21268464.source.xml\",\"abstract\":\"The waning effectiveness of the COVID-19 vaccines and the emergence of a new variant Omicron has given rise to the possibility of another outbreak of the infection in India. COVID-19 has caused more than 34 million reported cases and 475 thousand deaths in India so far, and it has affected the country at the root level, socially as well as economically. After going through different control measures, mass vaccination has been achieved to a large extent for the highly populous country, and currently under progress. India has already been hit by a massive second wave of infection in April-June, 2021 mainly due to the delta variant, and might see a third wave in the near future that needs to be controlled with effective control strategies. In this paper, we present a compartmental epidemiological model with vaccinations incorporating the dose-dependent effectiveness. We study a possible sudden outbreak of SARS-CoV2 variants in the future, and bring out the associated predictions for various vaccination rates and point out optimum control measures. Our results show that for transmission rate 30% higher than the current rate due to emergence of new variant or relaxation of social distancing conditions, daily new cases can peak to 250k in March 2022, taking the second dose effectiveness dropping to 50% in the future. Combination of vaccination and controlled lockdown or social distancing is the key to tackling the current situation and for the coming few months. Our simulation results show that social distancing measures show better control over the disease spread than the higher vaccination rates.\",\"published\":\"NA\",\"server\":\"medrxiv\"}]}\r\n",
            "\r\n",
            "\r\n",
            "\r\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "print(test.json()['collection'][0].keys())"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "7XWqSvzxS3kw",
        "outputId": "e666c2c5-a3df-4cb5-960d-67da852d76ea"
      },
      "execution_count": 71,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "dict_keys(['doi', 'title', 'authors', 'author_corresponding', 'author_corresponding_institution', 'date', 'version', 'type', 'license', 'category', 'jatsxml', 'abstract', 'published', 'server'])\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "S = test\n",
        "D = S.json()\n",
        "F = D['collection']\n",
        "All_data_bio = pd.DataFrame(F)\n",
        "for i in range(1,3):\n",
        "  j = i*100\n",
        "  location = 'https://api.medrxiv.org/details/medrxiv/2019-07-19/2021-12-29/35500' + str(j)\n",
        "  test = requests.get(location)  \n",
        "  temp = test.json()\n",
        "  temp2 = temp['collection']\n",
        "  df = pd.DataFrame(temp2)\n",
        "  All_data_bio = pd.concat([All_data_bio, df], axis=0)\n",
        "\n",
        "initialCleanedData = All_data_bio.drop(labels = ['abstract','author_corresponding_institution','author_corresponding','jatsxml','server'], axis =1)\n",
        "\n",
        "print(initialCleanedData.doi) #hi guys"
      ],
      "metadata": {
        "id": "L-CEMRVwS91p",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "1379e15d-3841-4ef4-ec06-b4a90b55c5bc"
      },
      "execution_count": 83,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "0     10.1101/2021.12.24.21268317\n",
            "1     10.1101/2021.12.23.21268338\n",
            "2     10.1101/2021.12.23.21268305\n",
            "3     10.1101/2021.12.24.21268367\n",
            "4     10.1101/2021.12.24.21268373\n",
            "                 ...             \n",
            "95    10.1101/2021.12.27.21268312\n",
            "96    10.1101/2021.12.25.21268206\n",
            "97    10.1101/2021.12.26.21268418\n",
            "98    10.1101/2021.12.22.21268006\n",
            "99    10.1101/2021.12.27.21268464\n",
            "Name: doi, Length: 100, dtype: object\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "temp_g = initialCleanedData.doi"
      ],
      "metadata": {
        "id": "yfUZi6CykN0l"
      },
      "execution_count": 84,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "print(temp_g)"
      ],
      "metadata": {
        "id": "YOW_F0Q6kOFX",
        "outputId": "2b65266e-1767-4163-d566-cdbd1faa70d7",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "execution_count": 85,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "0     10.1101/2021.12.24.21268317\n",
            "1     10.1101/2021.12.23.21268338\n",
            "2     10.1101/2021.12.23.21268305\n",
            "3     10.1101/2021.12.24.21268367\n",
            "4     10.1101/2021.12.24.21268373\n",
            "                 ...             \n",
            "95    10.1101/2021.12.27.21268312\n",
            "96    10.1101/2021.12.25.21268206\n",
            "97    10.1101/2021.12.26.21268418\n",
            "98    10.1101/2021.12.22.21268006\n",
            "99    10.1101/2021.12.27.21268464\n",
            "Name: doi, Length: 100, dtype: object\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        ""
      ],
      "metadata": {
        "id": "gOxgO_1ckYpl"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        ""
      ],
      "metadata": {
        "id": "InhMcbvjkYq7"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        ""
      ],
      "metadata": {
        "id": "lbhYZaNnkYt3"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "initialCleanedData"
      ],
      "metadata": {
        "id": "Zti67yLnkYvI",
        "outputId": "865847fd-f490-4106-8937-d32683e7f922",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 424
        }
      },
      "execution_count": 86,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/html": [
              "\n",
              "  <div id=\"df-6267dab1-797e-44ce-9246-1cfad34974be\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>doi</th>\n",
              "      <th>title</th>\n",
              "      <th>authors</th>\n",
              "      <th>date</th>\n",
              "      <th>version</th>\n",
              "      <th>type</th>\n",
              "      <th>license</th>\n",
              "      <th>category</th>\n",
              "      <th>published</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>10.1101/2021.12.24.21268317</td>\n",
              "      <td>COMPARATIVE ANALYSIS OF ANTIBODY RESPONSES FRO...</td>\n",
              "      <td>Focosi, D.; Franchini, M.; Joyner, M. J.; Casa...</td>\n",
              "      <td>2021-12-26</td>\n",
              "      <td>2</td>\n",
              "      <td>PUBLISHAHEADOFPRINT</td>\n",
              "      <td>cc_no</td>\n",
              "      <td>infectious diseases</td>\n",
              "      <td>NA</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>10.1101/2021.12.23.21268338</td>\n",
              "      <td>Unsuspected clonal spread of Methicillin-resis...</td>\n",
              "      <td>Talbot, B. M.; Jacko, N. F.; Petit, R. A.; Peg...</td>\n",
              "      <td>2021-12-25</td>\n",
              "      <td>1</td>\n",
              "      <td>PUBLISHAHEADOFPRINT</td>\n",
              "      <td>cc_by_nc_nd</td>\n",
              "      <td>infectious diseases</td>\n",
              "      <td>NA</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>10.1101/2021.12.23.21268305</td>\n",
              "      <td>The HUNT Study: a population-based cohort for ...</td>\n",
              "      <td>Brumpton, B. M.; Graham, S.; Surakka, I.; Skog...</td>\n",
              "      <td>2021-12-25</td>\n",
              "      <td>1</td>\n",
              "      <td>PUBLISHAHEADOFPRINT</td>\n",
              "      <td>cc_no</td>\n",
              "      <td>epidemiology</td>\n",
              "      <td>NA</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>10.1101/2021.12.24.21268367</td>\n",
              "      <td>Genomic surveillance reveals the emergence of ...</td>\n",
              "      <td>Umair, M.; Ikram, A.; Rehman, Z.; Haider, S. A...</td>\n",
              "      <td>2021-12-25</td>\n",
              "      <td>1</td>\n",
              "      <td>PUBLISHAHEADOFPRINT</td>\n",
              "      <td>cc_by_nd</td>\n",
              "      <td>epidemiology</td>\n",
              "      <td>NA</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>10.1101/2021.12.24.21268373</td>\n",
              "      <td>Are COVID-19 data reliable? The case of the Eu...</td>\n",
              "      <td>Kolias, P.</td>\n",
              "      <td>2021-12-25</td>\n",
              "      <td>1</td>\n",
              "      <td>PUBLISHAHEADOFPRINT</td>\n",
              "      <td>cc_by</td>\n",
              "      <td>public and global health</td>\n",
              "      <td>NA</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>95</th>\n",
              "      <td>10.1101/2021.12.27.21268312</td>\n",
              "      <td>Mechanically ventilated patients shed high tit...</td>\n",
              "      <td>Saud, Z.; PONSFORD, M. J.; Bentley, K.; Cole, ...</td>\n",
              "      <td>2021-12-29</td>\n",
              "      <td>1</td>\n",
              "      <td>PUBLISHAHEADOFPRINT</td>\n",
              "      <td>cc_by_nc_nd</td>\n",
              "      <td>infectious diseases</td>\n",
              "      <td>NA</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>96</th>\n",
              "      <td>10.1101/2021.12.25.21268206</td>\n",
              "      <td>Topological data analysis identifies distinct ...</td>\n",
              "      <td>Blair, P. W.; Brandsma, J.; Chenoweth, J. G.; ...</td>\n",
              "      <td>2021-12-29</td>\n",
              "      <td>1</td>\n",
              "      <td>PUBLISHAHEADOFPRINT</td>\n",
              "      <td>cc0</td>\n",
              "      <td>infectious diseases</td>\n",
              "      <td>NA</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>97</th>\n",
              "      <td>10.1101/2021.12.26.21268418</td>\n",
              "      <td>Prediction of SARS-CoV-2 Omicron Variant Immun...</td>\n",
              "      <td>Pierros, V.; KONTOPODIS, E.; STRAVOPODIS, D. J...</td>\n",
              "      <td>2021-12-29</td>\n",
              "      <td>1</td>\n",
              "      <td>PUBLISHAHEADOFPRINT</td>\n",
              "      <td>cc_no</td>\n",
              "      <td>allergy and immunology</td>\n",
              "      <td>NA</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>98</th>\n",
              "      <td>10.1101/2021.12.22.21268006</td>\n",
              "      <td>Mechanism of bisphosphonate-related osteonecro...</td>\n",
              "      <td>Okawa, H.; Kondo, T.; Hokugo, A.; Cherian, P.;...</td>\n",
              "      <td>2021-12-29</td>\n",
              "      <td>1</td>\n",
              "      <td>PUBLISHAHEADOFPRINT</td>\n",
              "      <td>cc_no</td>\n",
              "      <td>dentistry and oral medicine</td>\n",
              "      <td>NA</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>99</th>\n",
              "      <td>10.1101/2021.12.27.21268464</td>\n",
              "      <td>Control Strategies for the Third wave of COVID...</td>\n",
              "      <td>A Sivadas, N.; Mahajan, A.; Panda, P.</td>\n",
              "      <td>2021-12-29</td>\n",
              "      <td>1</td>\n",
              "      <td>PUBLISHAHEADOFPRINT</td>\n",
              "      <td>cc_by</td>\n",
              "      <td>epidemiology</td>\n",
              "      <td>NA</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>100 rows  9 columns</p>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-6267dab1-797e-44ce-9246-1cfad34974be')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-6267dab1-797e-44ce-9246-1cfad34974be button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-6267dab1-797e-44ce-9246-1cfad34974be');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ],
            "text/plain": [
              "                            doi  ... published\n",
              "0   10.1101/2021.12.24.21268317  ...        NA\n",
              "1   10.1101/2021.12.23.21268338  ...        NA\n",
              "2   10.1101/2021.12.23.21268305  ...        NA\n",
              "3   10.1101/2021.12.24.21268367  ...        NA\n",
              "4   10.1101/2021.12.24.21268373  ...        NA\n",
              "..                          ...  ...       ...\n",
              "95  10.1101/2021.12.27.21268312  ...        NA\n",
              "96  10.1101/2021.12.25.21268206  ...        NA\n",
              "97  10.1101/2021.12.26.21268418  ...        NA\n",
              "98  10.1101/2021.12.22.21268006  ...        NA\n",
              "99  10.1101/2021.12.27.21268464  ...        NA\n",
              "\n",
              "[100 rows x 9 columns]"
            ]
          },
          "metadata": {},
          "execution_count": 86
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "All_data_bio"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "y9FhjclfG27_",
        "outputId": "6e526f8d-a420-4694-9639-4e34b22dc962"
      },
      "execution_count": 78,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/html": [
              "\n",
              "  <div id=\"df-3f2a2c83-f0b3-4368-85b6-ba0a624fc854\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>doi</th>\n",
              "      <th>title</th>\n",
              "      <th>authors</th>\n",
              "      <th>author_corresponding</th>\n",
              "      <th>author_corresponding_institution</th>\n",
              "      <th>date</th>\n",
              "      <th>version</th>\n",
              "      <th>type</th>\n",
              "      <th>license</th>\n",
              "      <th>category</th>\n",
              "      <th>jatsxml</th>\n",
              "      <th>abstract</th>\n",
              "      <th>published</th>\n",
              "      <th>server</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>10.1101/2021.12.24.21268317</td>\n",
              "      <td>COMPARATIVE ANALYSIS OF ANTIBODY RESPONSES FRO...</td>\n",
              "      <td>Focosi, D.; Franchini, M.; Joyner, M. J.; Casa...</td>\n",
              "      <td>Daniele Franchini Focosi</td>\n",
              "      <td>Pisa University Hospital</td>\n",
              "      <td>2021-12-26</td>\n",
              "      <td>2</td>\n",
              "      <td>PUBLISHAHEADOFPRINT</td>\n",
              "      <td>cc_no</td>\n",
              "      <td>infectious diseases</td>\n",
              "      <td>https://www.medrxiv.org/content/early/2021/12/...</td>\n",
              "      <td>The novel SARS-CoV-2 Omicron variant of concer...</td>\n",
              "      <td>NA</td>\n",
              "      <td>medrxiv</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>10.1101/2021.12.23.21268338</td>\n",
              "      <td>Unsuspected clonal spread of Methicillin-resis...</td>\n",
              "      <td>Talbot, B. M.; Jacko, N. F.; Petit, R. A.; Peg...</td>\n",
              "      <td>Michael Z David</td>\n",
              "      <td>Division of Infectious Diseases, Department of...</td>\n",
              "      <td>2021-12-25</td>\n",
              "      <td>1</td>\n",
              "      <td>PUBLISHAHEADOFPRINT</td>\n",
              "      <td>cc_by_nc_nd</td>\n",
              "      <td>infectious diseases</td>\n",
              "      <td>https://www.medrxiv.org/content/early/2021/12/...</td>\n",
              "      <td>BackgroundThough detection of transmission clu...</td>\n",
              "      <td>NA</td>\n",
              "      <td>medrxiv</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>10.1101/2021.12.23.21268305</td>\n",
              "      <td>The HUNT Study: a population-based cohort for ...</td>\n",
              "      <td>Brumpton, B. M.; Graham, S.; Surakka, I.; Skog...</td>\n",
              "      <td>Ben M. Brumpton</td>\n",
              "      <td>Norwegian University of Science and Technology</td>\n",
              "      <td>2021-12-25</td>\n",
              "      <td>1</td>\n",
              "      <td>PUBLISHAHEADOFPRINT</td>\n",
              "      <td>cc_no</td>\n",
              "      <td>epidemiology</td>\n",
              "      <td>https://www.medrxiv.org/content/early/2021/12/...</td>\n",
              "      <td>The Trondelag Health Study (HUNT) is a populat...</td>\n",
              "      <td>NA</td>\n",
              "      <td>medrxiv</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>10.1101/2021.12.24.21268367</td>\n",
              "      <td>Genomic surveillance reveals the emergence of ...</td>\n",
              "      <td>Umair, M.; Ikram, A.; Rehman, Z.; Haider, S. A...</td>\n",
              "      <td>Massab Umair</td>\n",
              "      <td>National Institute of Health</td>\n",
              "      <td>2021-12-25</td>\n",
              "      <td>1</td>\n",
              "      <td>PUBLISHAHEADOFPRINT</td>\n",
              "      <td>cc_by_nd</td>\n",
              "      <td>epidemiology</td>\n",
              "      <td>https://www.medrxiv.org/content/early/2021/12/...</td>\n",
              "      <td>The lineage A of SARS-CoV-2 has been around th...</td>\n",
              "      <td>NA</td>\n",
              "      <td>medrxiv</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>10.1101/2021.12.24.21268373</td>\n",
              "      <td>Are COVID-19 data reliable? The case of the Eu...</td>\n",
              "      <td>Kolias, P.</td>\n",
              "      <td>Pavlos Kolias</td>\n",
              "      <td>Aristotle University of Thessaloniki</td>\n",
              "      <td>2021-12-25</td>\n",
              "      <td>1</td>\n",
              "      <td>PUBLISHAHEADOFPRINT</td>\n",
              "      <td>cc_by</td>\n",
              "      <td>public and global health</td>\n",
              "      <td>https://www.medrxiv.org/content/early/2021/12/...</td>\n",
              "      <td>Previous studies have used Benfords distributi...</td>\n",
              "      <td>NA</td>\n",
              "      <td>medrxiv</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>95</th>\n",
              "      <td>10.1101/2021.12.27.21268312</td>\n",
              "      <td>Mechanically ventilated patients shed high tit...</td>\n",
              "      <td>Saud, Z.; PONSFORD, M. J.; Bentley, K.; Cole, ...</td>\n",
              "      <td>Richard James Stanton</td>\n",
              "      <td>Cardiff University</td>\n",
              "      <td>2021-12-29</td>\n",
              "      <td>1</td>\n",
              "      <td>PUBLISHAHEADOFPRINT</td>\n",
              "      <td>cc_by_nc_nd</td>\n",
              "      <td>infectious diseases</td>\n",
              "      <td>https://www.medrxiv.org/content/early/2021/12/...</td>\n",
              "      <td>BackgroundSARS-CoV-2 infection can lead to sev...</td>\n",
              "      <td>NA</td>\n",
              "      <td>medrxiv</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>96</th>\n",
              "      <td>10.1101/2021.12.25.21268206</td>\n",
              "      <td>Topological data analysis identifies distinct ...</td>\n",
              "      <td>Blair, P. W.; Brandsma, J.; Chenoweth, J. G.; ...</td>\n",
              "      <td>Paul W Blair</td>\n",
              "      <td>The Henry M. Jackson Foundation for the Advanc...</td>\n",
              "      <td>2021-12-29</td>\n",
              "      <td>1</td>\n",
              "      <td>PUBLISHAHEADOFPRINT</td>\n",
              "      <td>cc0</td>\n",
              "      <td>infectious diseases</td>\n",
              "      <td>https://www.medrxiv.org/content/early/2021/12/...</td>\n",
              "      <td>OBJECTIVESThe relationships between baseline c...</td>\n",
              "      <td>NA</td>\n",
              "      <td>medrxiv</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>97</th>\n",
              "      <td>10.1101/2021.12.26.21268418</td>\n",
              "      <td>Prediction of SARS-CoV-2 Omicron Variant Immun...</td>\n",
              "      <td>Pierros, V.; KONTOPODIS, E.; STRAVOPODIS, D. J...</td>\n",
              "      <td>GEORGE TH. TSANGARIS</td>\n",
              "      <td>BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY ...</td>\n",
              "      <td>2021-12-29</td>\n",
              "      <td>1</td>\n",
              "      <td>PUBLISHAHEADOFPRINT</td>\n",
              "      <td>cc_no</td>\n",
              "      <td>allergy and immunology</td>\n",
              "      <td>https://www.medrxiv.org/content/early/2021/12/...</td>\n",
              "      <td>The recently discovered Omicron variant of the...</td>\n",
              "      <td>NA</td>\n",
              "      <td>medrxiv</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>98</th>\n",
              "      <td>10.1101/2021.12.22.21268006</td>\n",
              "      <td>Mechanism of bisphosphonate-related osteonecro...</td>\n",
              "      <td>Okawa, H.; Kondo, T.; Hokugo, A.; Cherian, P.;...</td>\n",
              "      <td>Ichiro Nishimura</td>\n",
              "      <td>UCLA School of Dentistry</td>\n",
              "      <td>2021-12-29</td>\n",
              "      <td>1</td>\n",
              "      <td>PUBLISHAHEADOFPRINT</td>\n",
              "      <td>cc_no</td>\n",
              "      <td>dentistry and oral medicine</td>\n",
              "      <td>https://www.medrxiv.org/content/early/2021/12/...</td>\n",
              "      <td>Bisphosphonate-related osteonecrosis of the ja...</td>\n",
              "      <td>NA</td>\n",
              "      <td>medrxiv</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>99</th>\n",
              "      <td>10.1101/2021.12.27.21268464</td>\n",
              "      <td>Control Strategies for the Third wave of COVID...</td>\n",
              "      <td>A Sivadas, N.; Mahajan, A.; Panda, P.</td>\n",
              "      <td>Namitha A Sivadas</td>\n",
              "      <td>Vellore Institute of Technology</td>\n",
              "      <td>2021-12-29</td>\n",
              "      <td>1</td>\n",
              "      <td>PUBLISHAHEADOFPRINT</td>\n",
              "      <td>cc_by</td>\n",
              "      <td>epidemiology</td>\n",
              "      <td>https://www.medrxiv.org/content/early/2021/12/...</td>\n",
              "      <td>The waning effectiveness of the COVID-19 vacci...</td>\n",
              "      <td>NA</td>\n",
              "      <td>medrxiv</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>100 rows  14 columns</p>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-3f2a2c83-f0b3-4368-85b6-ba0a624fc854')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-3f2a2c83-f0b3-4368-85b6-ba0a624fc854 button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-3f2a2c83-f0b3-4368-85b6-ba0a624fc854');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ],
            "text/plain": [
              "                            doi  ...   server\n",
              "0   10.1101/2021.12.24.21268317  ...  medrxiv\n",
              "1   10.1101/2021.12.23.21268338  ...  medrxiv\n",
              "2   10.1101/2021.12.23.21268305  ...  medrxiv\n",
              "3   10.1101/2021.12.24.21268367  ...  medrxiv\n",
              "4   10.1101/2021.12.24.21268373  ...  medrxiv\n",
              "..                          ...  ...      ...\n",
              "95  10.1101/2021.12.27.21268312  ...  medrxiv\n",
              "96  10.1101/2021.12.25.21268206  ...  medrxiv\n",
              "97  10.1101/2021.12.26.21268418  ...  medrxiv\n",
              "98  10.1101/2021.12.22.21268006  ...  medrxiv\n",
              "99  10.1101/2021.12.27.21268464  ...  medrxiv\n",
              "\n",
              "[100 rows x 14 columns]"
            ]
          },
          "metadata": {},
          "execution_count": 78
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "S = requests.get('https://api.medrxiv.org/details/biorxiv/2013-11-15/2021-12-29/200')\n",
        "D = S.json()\n",
        "F = D['collection']\n",
        "All_data_bio = pd.DataFrame(F)"
      ],
      "metadata": {
        "id": "8tQprikCJudB"
      },
      "execution_count": 23,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "All_data_bio"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 956
        },
        "id": "njJOUtP2Jukw",
        "outputId": "02c838ba-d59e-4cb6-cf4d-7b1728d64bd2"
      },
      "execution_count": 18,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/html": [
              "\n",
              "  <div id=\"df-d141624c-0875-46b4-9339-f55231000a1a\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>doi</th>\n",
              "      <th>title</th>\n",
              "      <th>authors</th>\n",
              "      <th>author_corresponding</th>\n",
              "      <th>author_corresponding_institution</th>\n",
              "      <th>date</th>\n",
              "      <th>version</th>\n",
              "      <th>type</th>\n",
              "      <th>license</th>\n",
              "      <th>category</th>\n",
              "      <th>jatsxml</th>\n",
              "      <th>abstract</th>\n",
              "      <th>published</th>\n",
              "      <th>server</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>10.1101/000604</td>\n",
              "      <td>A, tau, -synuclein, huntingtin, TDP-43, PrP ...</td>\n",
              "      <td>Claudiu I Bandea;</td>\n",
              "      <td>Claudiu I Bandea</td>\n",
              "      <td>Centers for Disease Control and Prevention</td>\n",
              "      <td>2013-11-18</td>\n",
              "      <td>1</td>\n",
              "      <td>Contradictory Results</td>\n",
              "      <td>cc_by_nc</td>\n",
              "      <td>Immunology</td>\n",
              "      <td>https://www.biorxiv.org/content/early/2013/11/...</td>\n",
              "      <td>Despite decades of research, thousands of stud...</td>\n",
              "      <td>NA</td>\n",
              "      <td>biorxiv</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>10.1101/000513</td>\n",
              "      <td>Lack of evidence for the presence of an interf...</td>\n",
              "      <td>Pei-Hui Wang;</td>\n",
              "      <td>Pei-Hui Wang</td>\n",
              "      <td>The University of Hong Kong</td>\n",
              "      <td>2013-11-16</td>\n",
              "      <td>1</td>\n",
              "      <td>New Results</td>\n",
              "      <td>cc_no</td>\n",
              "      <td>Immunology</td>\n",
              "      <td>https://www.biorxiv.org/content/early/2013/11/...</td>\n",
              "      <td>In vertebrates, the interferon (IFN) response ...</td>\n",
              "      <td>NA</td>\n",
              "      <td>biorxiv</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>10.1101/001362</td>\n",
              "      <td>Extensive Phenotypic Changes Associated with L...</td>\n",
              "      <td>Kevin Dougherty;Brian A Smith;Autum F Moore;Sh...</td>\n",
              "      <td>David A Baltrus</td>\n",
              "      <td>University of Arizona</td>\n",
              "      <td>2013-12-12</td>\n",
              "      <td>1</td>\n",
              "      <td>New Results</td>\n",
              "      <td>cc_by_nc_nd</td>\n",
              "      <td>Microbiology</td>\n",
              "      <td>https://www.biorxiv.org/content/early/2013/12/...</td>\n",
              "      <td>Horizontal gene transfer often leads to phenot...</td>\n",
              "      <td>10.1371/journal.pone.0102170</td>\n",
              "      <td>biorxiv</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>10.1101/000869</td>\n",
              "      <td>Virulence in a Pseudomonas syringae Strain wit...</td>\n",
              "      <td>Kevin L Hockett;Marc T Nishimura;Erick Karlsru...</td>\n",
              "      <td>David A Baltrus</td>\n",
              "      <td>University of Arizona</td>\n",
              "      <td>2013-11-23</td>\n",
              "      <td>1</td>\n",
              "      <td>New Results</td>\n",
              "      <td>cc_no</td>\n",
              "      <td>Microbiology</td>\n",
              "      <td>https://www.biorxiv.org/content/early/2013/11/...</td>\n",
              "      <td>Both type III effector proteins and non-riboso...</td>\n",
              "      <td>NA</td>\n",
              "      <td>biorxiv</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>10.1101/000869</td>\n",
              "      <td>Virulence in a Pseudomonas syringae Strain wit...</td>\n",
              "      <td>Kevin L Hockett;Marc T Nishimura;Erick Karlsru...</td>\n",
              "      <td>David A Baltrus</td>\n",
              "      <td>University of Arizona</td>\n",
              "      <td>2014-04-21</td>\n",
              "      <td>2</td>\n",
              "      <td>New Results</td>\n",
              "      <td>cc_no</td>\n",
              "      <td>Microbiology</td>\n",
              "      <td>https://www.biorxiv.org/content/early/2014/04/...</td>\n",
              "      <td>Both type III effector proteins and non-riboso...</td>\n",
              "      <td>NA</td>\n",
              "      <td>biorxiv</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>95</th>\n",
              "      <td>10.1101/001776</td>\n",
              "      <td>Chromothripsis-like patterns are recurring but...</td>\n",
              "      <td>Haoyang Cai;Nitin Kumar;Homayoun C Bagheri;Chr...</td>\n",
              "      <td>Michael Baudis</td>\n",
              "      <td>University of Zurich</td>\n",
              "      <td>2014-01-13</td>\n",
              "      <td>2</td>\n",
              "      <td>New Results</td>\n",
              "      <td>cc_by_nc</td>\n",
              "      <td>Genomics</td>\n",
              "      <td>https://www.biorxiv.org/content/early/2014/01/...</td>\n",
              "      <td>BackgroundChromothripsis is a recently discove...</td>\n",
              "      <td>10.1186/1471-2164-15-82</td>\n",
              "      <td>biorxiv</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>96</th>\n",
              "      <td>10.1101/001800</td>\n",
              "      <td>The Toxoplasma Acto-MyoA Motor Complex Is Impo...</td>\n",
              "      <td>Saskia Egarter;Nicole Andenmatten;Allison J Ja...</td>\n",
              "      <td>Markus Meissner</td>\n",
              "      <td>University of Glasgow</td>\n",
              "      <td>2014-01-15</td>\n",
              "      <td>1</td>\n",
              "      <td>New Results</td>\n",
              "      <td>cc_by_nc_nd</td>\n",
              "      <td>Cell Biology</td>\n",
              "      <td>https://www.biorxiv.org/content/early/2014/01/...</td>\n",
              "      <td>Apicomplexan parasites are thought to actively...</td>\n",
              "      <td>10.1371/journal.pone.0091819</td>\n",
              "      <td>biorxiv</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>97</th>\n",
              "      <td>10.1101/001800</td>\n",
              "      <td>The Toxoplasma Acto-MyoA Motor Complex Is Impo...</td>\n",
              "      <td>Saskia Egarter;Nicole Andenmatten;Allison J Ja...</td>\n",
              "      <td>Markus Meissner</td>\n",
              "      <td>University of Glasgow</td>\n",
              "      <td>2014-02-12</td>\n",
              "      <td>2</td>\n",
              "      <td>New Results</td>\n",
              "      <td>cc_by_nc_nd</td>\n",
              "      <td>Cell Biology</td>\n",
              "      <td>https://www.biorxiv.org/content/early/2014/02/...</td>\n",
              "      <td>Apicomplexan parasites are thought to actively...</td>\n",
              "      <td>10.1371/journal.pone.0091819</td>\n",
              "      <td>biorxiv</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>98</th>\n",
              "      <td>10.1101/001800</td>\n",
              "      <td>The Toxoplasma Acto-MyoA Motor Complex Is Impo...</td>\n",
              "      <td>Saskia Egarter;Nicole Andenmatten;Allison J Ja...</td>\n",
              "      <td>Markus Meissner</td>\n",
              "      <td>University of Glasgow</td>\n",
              "      <td>2014-03-18</td>\n",
              "      <td>3</td>\n",
              "      <td>New Results</td>\n",
              "      <td>cc_by_nc_nd</td>\n",
              "      <td>Cell Biology</td>\n",
              "      <td>https://www.biorxiv.org/content/early/2014/03/...</td>\n",
              "      <td>Apicomplexan parasites are thought to actively...</td>\n",
              "      <td>10.1371/journal.pone.0091819</td>\n",
              "      <td>biorxiv</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>99</th>\n",
              "      <td>10.1101/001842</td>\n",
              "      <td>Theemergenceoftherescueeffectfromexplic...</td>\n",
              "      <td>Anders Eriksson;Federico Elas-Wolff;Bernhard ...</td>\n",
              "      <td>Anders Eriksson</td>\n",
              "      <td>University of Cambridge</td>\n",
              "      <td>2014-01-15</td>\n",
              "      <td>1</td>\n",
              "      <td>New Results</td>\n",
              "      <td>cc_by_nc_nd</td>\n",
              "      <td>Ecology</td>\n",
              "      <td>https://www.biorxiv.org/content/early/2014/01/...</td>\n",
              "      <td>Immigration can rescue local populations from ...</td>\n",
              "      <td>10.1098/rspb.2013.3127</td>\n",
              "      <td>biorxiv</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>100 rows  14 columns</p>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-d141624c-0875-46b4-9339-f55231000a1a')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-d141624c-0875-46b4-9339-f55231000a1a button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-d141624c-0875-46b4-9339-f55231000a1a');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ],
            "text/plain": [
              "               doi  ...   server\n",
              "0   10.1101/000604  ...  biorxiv\n",
              "1   10.1101/000513  ...  biorxiv\n",
              "2   10.1101/001362  ...  biorxiv\n",
              "3   10.1101/000869  ...  biorxiv\n",
              "4   10.1101/000869  ...  biorxiv\n",
              "..             ...  ...      ...\n",
              "95  10.1101/001776  ...  biorxiv\n",
              "96  10.1101/001800  ...  biorxiv\n",
              "97  10.1101/001800  ...  biorxiv\n",
              "98  10.1101/001800  ...  biorxiv\n",
              "99  10.1101/001842  ...  biorxiv\n",
              "\n",
              "[100 rows x 14 columns]"
            ]
          },
          "metadata": {},
          "execution_count": 18
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "tempA = test.json()\n",
        "tempB = tempA['collection']\n",
        "print(tempB[0])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "O_YoNFRuEnCi",
        "outputId": "dff42787-a8e9-4165-a14f-18d8b7b03098"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "{'doi': '10.1101/001842', 'title': 'The\\xa0emergence\\xa0of\\xa0the\\xa0rescue\\xa0effect\\xa0from\\xa0explicit\\xa0within- and\\xa0between-patch\\xa0dynamics\\xa0in\\xa0a metapopulation', 'authors': 'Anders Eriksson;Federico Elas-Wolff;Bernhard Mehlig;Andrea Manica;', 'author_corresponding': 'Anders Eriksson', 'author_corresponding_institution': 'University of Cambridge', 'date': '2014-03-05', 'version': '2', 'type': 'New Results', 'license': 'cc_by_nc_nd', 'category': 'Ecology ', 'jatsxml': 'https://www.biorxiv.org/content/early/2014/03/05/001842.source.xml', 'abstract': 'Immigration can rescue local populations from extinction, helping to stabilise a metapopulation. Local population dynamics is important for determining the strength of this rescue effect, but the mechanistic link between local demographic parameters and the rescue effect at the metapopulation level has received very little attention by modellers. We develop an analytical framework that allows us to describe the emergence of the rescue effect from interacting local stochastic dynamics. We show this framework to be applicable to a wide range of spatial scales, providing a powerful and convenient alternative to individual-based models for making predictions concerning the fate of metapopulations. We show that the rescue effect plays an important role in minimising the increase in local extinction probability associated with high demographic stochasticity, but its role is more limited in the case of high local environmental stochasticity of recruitment or survival. While most models postulate the rescue effect, our framework provides an explicit mechanistic link between local dynamics and the emergence of the rescue effect, and more generally the stability of the whole metapopulation.', 'published': '10.1098/rspb.2013.3127', 'server': 'biorxiv'}\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Save a CSV to the drive of all the Biorxiv data\n",
        "initialCleanedData.to_csv('/content/drive/MyDrive/Colab Notebooks/Preprint_server_data_biorxiv.csv',na_rep='Unkown') \n",
        "# Save a CSV to the drive of all the Medrxiv data\n",
        "#initialCleanedData2.to_csv('/content/drive/MyDrive/Colab Notebooks/Preprint_server_data_medrxiv.csv',na_rep='Unkown') "
      ],
      "metadata": {
        "id": "aRGZgj5bEnAT"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        ""
      ],
      "metadata": {
        "id": "uq32hC0aEnE_"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        ""
      ],
      "metadata": {
        "id": "BaCU0JkSEnN1"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        ""
      ],
      "metadata": {
        "id": "wTD8sxj6EnQU"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "temp3 = temp2[0]\n",
        "temp3['date']\n",
        "print(temp3.keys())\n",
        "print(temp3['doi'])\n",
        "print(temp2[0]['doi'])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "nhYYEfGBUKRC",
        "outputId": "ae9b9a66-5a43-46d2-97e4-e7e8fa51d47d"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "dict_keys(['doi', 'title', 'authors', 'author_corresponding', 'author_corresponding_institution', 'date', 'version', 'type', 'license', 'category', 'jatsxml', 'abstract', 'published', 'server'])\n",
            "10.1101/000547\n",
            "10.1101/000547\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "initialCleanedData = df.drop(labels = ['abstract','author_corresponding_institution','author_corresponding','jatsxml','server'], axis =1)"
      ],
      "metadata": {
        "id": "fCyK_HmHL6dJ"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "print(initialCleanedData)"
      ],
      "metadata": {
        "id": "JDSKDlGKL6p4"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "initialCleanedData.to_csv('/content/drive/MyDrive/Colab Notebooks/Preprint_server_data.csv',na_rep='Unkown') # missing value save as Unknown"
      ],
      "metadata": {
        "id": "DWv1RJPVOt2n"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "for i in temp2:\n",
        "  print(i['doi'])"
      ],
      "metadata": {
        "id": "uj-YASLLLao8"
      },
      "execution_count": null,
      "outputs": []
    }
  ]
}